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This report presents statistics on the National Bowel Cancer 
screening Program for Australians invited to take part 
between July 2013 and June 2014. Thirty six per cent (about 
510,000) of those who were invited went on to participate 
in screening, of whom 7.5% (37,700) were found to require 
further assessment. one out of every 11 assessments 
detected an advanced adenoma (pre-cancerous lesion), 
and a bowel cancer was detected in 1 out of every 25 
assessments.
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Summary 
The National Bowel Cancer Screening Program (NBCSP) aims to reduce the morbidity and 
mortality from bowel cancer by actively recruiting and screening the target population for 
early detection or prevention of the disease. 
The NBCSP has been running since August 2006, and this report focuses on measures of 
program performance for people invited to participate in screening between July 2013 and 
June 2014 (those turning 50, 55, 60 or 65).  
Program participation has increased 
Of the 1.4 million people invited between July 2013 and June 2014, 36.0% returned a 
completed bowel cancer screening kit for analysis. This overall participation rate was higher 
than the participation rate of 33.4% in 2012–13 (Table 1). The increase was mainly due to the 
start of the second round of invitations to 55 and 60 year olds, who had higher rates of  
re-participation. For those receiving their second invitation after participating 5 years earlier, 
the re-participation rate was more than 70%. 
How many positive screening results were there? 
Of those participants who returned a valid screening test, about 37,700 (7.5%) had a positive 
screening result. These people were encouraged to follow up this result by visiting their 
primary health-care practitioner (PHCP) for referral to further investigative testing 
(colonoscopy). Sixty-eight per cent of those with a positive screening result were recorded as 
having had a follow-up colonoscopy at the time of this report. 
The positivity rate (percentage of positive faecal occult test results) for those participating for 
the second time (6.3%) was lower than for initial screens (8.2%). 
How many bowel cancers and adenomas were detected? 
One participant in every 25 who underwent a colonoscopy to follow up a positive screening 
result was diagnosed with a confirmed or suspected cancer (149 and 599 participants 
respectively), while advanced adenomas were found in a further 1,691 participants (1 in 11 
colonoscopies assessed). Adenomas are benign growths that have the potential to become 
cancerous, and their removal is likely to lower the risk of future bowel cancers in these 
patients.  
Were there differences between subgroups participating in the 
NBCSP? 
Women were more likely to participate in screening than men; conversely, men had higher 
rates of screen-detected bowel cancers, overall bowel cancer incidence and mortality. 
Aboriginal and Torres Strait Islander participants, participants who lived in Regional and 
remote regions, and participants who lived in areas of lower socioeconomic status, continue 
to have higher rates of positive screening results, yet lower rates of follow-up colonoscopies 
than other participants. 
  vii 
2013–14 NBCSP data at a glance 
Table 1 compares 2013–14 key performance measures for the NBCSP for the target ages of 50, 
55, 60 and 65 with those from the previous monitoring report (2012–13 invitees). 
Table 1: Performance measures for the NBCSP, people aged 50, 55, 60 and 65, 2012–13 and 2013–14  
 2012–13(a)  2013–14  
Performance measure Percentage of those invited to participate 
Overall participation rate 33.4  36.0 
 50 years 27.4  27.4 
 55 years 33.2  35.9 
 60 years . .(b)  42.7 
 65 years 41.6  40.6 
 Percentage of those who screened 
Faecal occult blood test (FOBT) positivity rate 7.5  7.5 
 Percentage of those with a positive screen 
Primary health-care practitioner (PHCP) follow-up rate 58.0  61.5 
Colonoscopy follow-up rate 70.4  67.6 
 Percentage of colonoscopy outcomes 
Suspected/confirmed cancers 3.2  4.0 
Advanced adenomas 5.7  9.1 
Small or diminutive adenomas 3.9  8.4 
Polyps awaiting histopathology 41.2  31.2 
No abnormality 46.0  47.3 
(a) 2012–13 data relate to those presented in the previous monitoring report for those eligible for invitation between 1 July 2012 and 
30 June 2013 (AIHW 2014e). See Table A6.1 in Appendix A for final data for those invited in 2012–13. 
(b) Invitations to those aged 60 commenced in 2013–14. See Table S1.3. 
Note: Definitions for these performance measures are in Section 2. 
Source: National Bowel Cancer Screening Program Register. 
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Section 1 Introduction 
Structure of this report 
This report provides the most up-to-date national data available for the National Bowel 
Cancer Screening Program (NBCSP). 
The first section presents an overview of bowel cancer in Australia, outlines the process of 
bowel cancer screening, and describes the development and management of the NBCSP. It 
also provides a brief overview of technical issues that should be considered when 
interpreting the information in this report. 
The second section presents national data for the NBCSP from 1 July 2013 to 30 June 2014. 
Data are presented against a series of performance measures. A summary of each 
performance measure — including definition, rationale, information on data quality and a 
guide for interpretation — form the start of each chapter. This is followed by 
measure-specific background information and detailed analyses. 
Additional data tables for some sections of this report are presented on the Australian 
Institute of Health and Welfare (AIHW) webpage for National Bowel Cancer Screening Program 
monitoring report: 2013–14 supplementary tables.  
Changes in this latest report 
Because some 2013–14 invitees are now starting their second invitation round (that is, those 
aged 55 and 60 in 2013–14 who were originally invited as 50 and 55 year olds in 2008–09), 
this report also includes participation and faecal occult blood test analyses by invitation 
round. 
Additionally, summary data on NBCSP expenditure have been included in Chapter 8 of 
Section 2.  
Overview of bowel cancer and bowel screening 
What is bowel cancer? 
Cancer is a group of several hundred diseases in which abnormal cells are not destroyed by 
normal processes within the body, but multiply and spread out of control. Cancers are 
distinguished from each other by the specific type of cell involved and the place in the body 
in which the disease began.  
Bowel cancer refers specifically to cancer of the large intestine (that is, the colon or rectum). 
It is also known as colorectal cancer.  
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Generally, bowel cancer 
involves a multistage process 
in which a series of cellular 
mutations occur over time in 
epithelial cells (the protective 
layer of surface tissue on 
exposed bodily surfaces, which 
also forms the lining of some 
internal cavities, such as the 
large intestine). Early stages of 
these mutations result in 
benign polyps that are 
relatively common in old age. 
However, a polyp may then undergo additional mutations and become a benign adenoma 
and, ultimately, a malignant bowel cancer that can invade into deeper layers of bowel tissue 
and then spread to other sites in the body (Figure S1.1).  
These mutations occur relatively slowly, making early detection and removal of small 
cancers—and adenomas and polyps that may become cancerous—effective in preventing ill 
health (morbidity) or death from bowel cancer.  
How common is bowel cancer? 
Bowel cancer is a disease predominantly 
seen in developed and affluent countries, 
with the highest rates occurring in Australia, 
New Zealand and Western Europe. It has 
been estimated that there were about 
1.4 million new cases of bowel cancer 
diagnosed worldwide in 2012 (10% of 
worldwide cancer diagnoses), and 694,000 
deaths attributed (8% of all worldwide 
cancer deaths). Worldwide, males have 
bowel cancer incidence rates that are 1.4 times higher than females (Ferlay et al. 2013).  
In Australia, the incidence of bowel cancer has been increasing since 1982 (the year national 
cancer data were first collected), with 15,151 new cases diagnosed in 2011 (13% of all 
cancers). The risk of being diagnosed by the age of 85 was 1 in 10 for males and 1 in 15 for 
females in 2011, with the risk increasing sharply from the age of 45. Bowel cancer accounts 
for over 9% of all deaths from invasive cancers in Australia, with 3,980 deaths in 2012, 
making it the second most common cause of cancer-related death after lung cancer 
(ABS 2014; AIHW 2014b). 
What causes bowel cancer? 
A proportion of bowel cancers (about 20%) are thought to be due to a hereditary component 
(Weitz et al. 2005). However, a larger proportion can be attributed to known and unknown 
environmental and lifestyle factors (WCRF & AICR 2011).  
An evaluation of the evidence by the World Cancer Research Fund found there was 
sufficient evidence that tobacco smoking, obesity and the consumption of alcohol and red 
 
© Cancer Council Victoria 2013.  
Source: Cancer Council Victoria (2013). 
Reproduced with permission of the copyright owner. 
Figure S1.1: The beginnings of bowel cancer 
Terminology 
Incidence: the number of new cases of bowel 
cancer diagnosed in a year. 
Morbidity: ill health. 
Mortality: the number of deaths from bowel 
cancer in a year. 
Prognosis: the likely outcome of an illness. 
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and processed meats were risk factors for bowel cancer, while consumption of foods 
containing dietary fibre and higher levels of physical activity provided a protective effect 
from bowel cancer (WCRF & AICR 2011).  
The incidence rate of bowel cancer is also known to increase with age—about 93% of people 
diagnosed in Australia in 2011 were 50 or older (see ‘Section 2, Chapter 6 Incidence of bowel 
cancer’). This is likely to be due to the accumulation of cellular mutations with increasing 
age. 
How is bowel cancer treated? 
Treatment for bowel cancer commonly involves surgery to remove the cancer, with or 
without additional chemotherapy or radiation therapy. Prognosis depends mainly on what 
stage of development the cancer has reached, with smaller, less-developed cancers having 
much better prognoses than advanced cancers (Table S1.1). Bowel cancer stages are generally 
defined using the Australian clinicopathological stage (ACPS) classification system shown in 
Table S1.1 (ACN 2005). 
Table S1.1: Defined Australian clinicopathological stages of bowel cancer 
Australian 
clinicopathological 
stage Description Survival estimates(a) 
A Submucosa or ‘into-but-not-through’ muscularis 
propria 
  (cancer contained within superficial layers of bowel) 
Bowel cancers diagnosed at this stage 
showed a 93% 5-year survival rate. 
B Through muscularis propria 
  (deep invasion into bowel tissue) 
Bowel cancers diagnosed at this stage 
showed an 82% 5-year survival rate. 
C Spread of cancer to lymph nodes 
  (invasion through bowel tissue, and cancer found in  
  lymph nodes) 
Bowel cancers diagnosed at this stage 
showed a 59% 5-year survival rate. 
D Metastatic disease 
  (cancer also discovered at other sites in the body) 
Bowel cancers diagnosed at this stage 
showed an 8% 5-year survival rate. Palliative 
care is commonly used at this stage. 
(a) Survival estimates were sourced from an American study by O’Connell et al. (2004) which used a comparable classification system. Similar 
rates have been shown in Australia (Morris et al. 2007). 
Improving treatment outcomes 
Early diagnosis of bowel cancer can improve treatment outcomes and survival. Removal of 
non-benign polyps (polypectomy) and adenomas during a colonoscopy reduces the risk of 
them developing into bowel cancer. Studies have shown that 14% of patients who refuse 
polypectomy for adenomas will develop bowel cancer within 10 years (Stryker et al. 1987). 
The excision of adenomatous polyps, and regular surveillance thereafter, has been found to 
reduce bowel cancer risk by about 76–90% (Winawer et al. 1993).  
A bowel cancer screening program that can highlight individuals with signs of a potential 
bowel abnormality, allowing earlier investigation by colonoscopy, can therefore reduce 
bowel cancer morbidity and mortality (AIHW 2014a). 
How do we screen for bowel cancer? 
Bowel cancer may be present for many years before showing symptoms such as visible rectal 
bleeding, change in bowel habits, bowel obstruction or anaemia. Often, symptoms such as 
 4 National Bowel Cancer Screening Program: monitoring report 2013–14 
these are not exhibited until the cancer has reached a relatively advanced stage. However, 
non-visible bleeding of the bowel may have been occurring in the precancerous stages for 
some time. The relatively slow development of bowel cancer makes it a valid candidate for 
population screening (APHDPCSS 2008). 
Screening tools and target populations for screening for bowel cancer vary around the world 
(Table S1.2). Evidence from clinical trials has shown that regular (biennial) screening using 
faecal occult blood testing—which can detect evidence of blood in the stool (faeces) not 
visible to the naked eye—can reduce mortality from bowel cancer by 15–33% (DoHA 2005).  
A faecal occult blood test (FOBT) is a non-invasive test that detects microscopic amounts of 
blood in the bowel motion—a common sign of a bowel abnormality such as an adenoma or 
cancer. FOBTs are accepted as the primary screening tool for bowel cancer by a large number 
of countries, and some supplement the FOBT with flexible sigmoidoscopy (a thin flexible 
tube that is inserted into the rectum and guided around the lower part of the bowel where 
most bowel cancers develop) or colonoscopy (a thin flexible tube that is inserted into the 
rectum and guided around the entire length of the bowel). Table S1.2 summarises screening 
tools and target populations of screening programs for selected countries.  
Table S1.2: Selected international bowel cancer screening programs—tools and target populations 
Country 
Primary 
screening tool Frequency Start year 
Target population 
(age in years) Notes 
Australia FOBT 5-yearly, 
see notes 
2006 50–74 People turning the target ages are 
sent an FOBT kit. As noted in 
Table S1.3, the NBCSP is being 
expanded from 2015 to implement a 
biennial screening interval for those 
aged 50–74 by 2020. 
Canada FOBT Varies 
between 
provinces 
See notes 50–74 Ten provinces had started programs 
or pilots by 2010. FOBT is the 
primary screening tool; however, 
provinces are free to adopt other 
primary screening tools. 
England FOBT Biennial 2006 60–69 FOBTs are supplemented by one-off 
flexible sigmoidoscopy in individuals 
aged 55–64. 
Finland(a) FOBT Biennial 2004 60–67 Currently in a RCT ‘implementation’ 
phase, with screening and control 
arms. The control group will be 
offered screening when the 
implementation phase is complete. 
France FOBT Biennial 2002 50–74  
Germany FOBT Annual 1971 50–54  Followed by 
FOBT Biennial  55 and over Or 
Colonoscopy 10-yearly  55 and over  
Italy FOBT Biennial See notes 50–69, see notes Regionally based programs began 
between 1982 and 2006. The target 
age ranges from 44 to 75, with all 
programs screening those aged 50 
to 69. 
Ireland(b) FOBT Biennial 2012 60–69  The program is being expanded over 
time until the full 55–74 age group is 
reached.  
(continued) 
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Table S1.2 (continued): Selected international bowel cancer screening programs—tools and target 
populations 
Country 
Primary 
screening tool Frequency Start year 
Target population 
(age in years) Notes 
Israel FOBT Annual 1993 50–74  
Japan FOBT Annual 1992 40 and over   
New 
Zealand(c) 
FOBT Biennial 2011 50–74  Four-year pilot program scheduled to 
start in late 2011 for residents of the 
Waitemata District. 
Poland Endoscopy 10-yearly 2000 40–46  
Scotland FOBT Biennial 2006 50–74   
South Korea(a) FOBT Annual 2004 50 and over  
United 
States 
FOBT, 
sigmoidoscopy 
and 
colonoscopy 
See notes  50–75  While no national organised program 
exists, screening with FOBT 
(annually), sigmoidoscopy (5-yearly) 
and colonoscopy (10-yearly), 
depending on individual risk factors 
are promoted through guideline 
dissemination and media campaigns. 
(a) Bulliard et al. (2014). 
(b) National Cancer Screening Service (2013). 
(c) New Zealand Ministry of Health (2013). 
Source: Benson et al. (2012) except where otherwise noted. 
How is bowel cancer screening managed in Australia? 
Population-based bowel cancer screening involves testing for signs of bowel cancer in people 
who do not have any obvious symptoms of the disease. People who do have symptoms, or a 
significant family history, are encouraged to discuss these with their primary health-care 
practitioner (PHCP). In accordance with the Clinical practice guidelines for the prevention, early 
detection and management of colorectal cancer, approved by the National Health and Medical 
Research Council (ACN 2005), these people should be referred directly for diagnostic 
assessment (generally colonoscopy). However, it is recognised that some people at increased 
risk may not seek the assistance of a medical professional (for example, those who are 
symptomatic but reluctant to act on their symptoms). As a result, all people of the target ages 
are currently invited to screen, regardless of evidence of previous symptoms or significant 
family history.  
These current guidelines, which will be revised by 2017, recommend organised screening 
with an FOBT, performed at least once every 2 years, for the Australian population aged 50 
or over.  
A variety of FOBT kits to aid the early detection of bowel cancer are available in Australia 
over the counter from pharmacies, through medical practitioners and through the following 
programs: 
• BowelScreen Australia®—a pharmacy-based bowel cancer awareness, education and 
screening initiative for the Australian community, which advocates annual screening for 
all non-symptomatic Australians aged 50 and over 
(see <www.bowelscreenaustralia.org>). 
• BowelScan—this is a community service project run by a number of Rotary clubs and 
districts in Australia. It has been operating since 1982, advocating annual screening for 
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men and women over the age of 40. It seeks to increase community knowledge of bowel 
cancer and its symptoms, and distributes subsidised FOBT kits to facilitate early 
diagnosis. About 150,000 kits are distributed annually across Australia 
(see <www.nationalbowelscan.org.au>).  
The NBCSP is the national screening program implemented in 2006 by the Australian 
Government in partnership with the state and territory governments (see 
<www.cancerscreening.gov.au>). This report is based on data collected through the NBCSP.  
The National Bowel Cancer Screening Program 
Initial pilot 
In 1996, the Australian Health Technology Advisory Committee systematically reviewed the 
literature on screening for bowel cancer against the World Health Organization principles for 
the assessment of a screening program. The committee concluded that, if the results of pilot 
testing were encouraging, the Australian Government should develop a bowel cancer 
screening program for the at-risk population—the ‘well population aged over 50’ (AHTAC 
1997). The Bowel Cancer Screening Pilot Program was conducted from November 2002 to 
June 2004 to test the feasibility, acceptability and cost-effectiveness of bowel cancer screening 
in the Australian community.  
The National Bowel Cancer Screening Program 
After the success of this pilot, the Australian Government implemented Phase 1 of the 
NBCSP in late 2006 (Table S1.3). In July 2008, Phase 2 of the NBCSP began. Phase 2 was 
originally scheduled to end on 30 June 2011 (with most invitations ceasing on 
31 December 2010); however, Phase 2 was continued from July 2011. The program was 
expanded from July 2013 to also invite participation by Australians turning 60. The rollout of 
biennial screening for those aged 50–74 began in 2015.  
Table S1.3: NBCSP phases and target populations 
Phase Start date End date Target ages 
1 7 August 2006 30 June 2008 55 and 65 
2 1 July 2008 30 June 2011(a) 50, 55 and 65 
2(b) 1 July 2011 30 June 2013 50, 55 and 65 
3 1 July 2013 Ongoing 50, 55, 60 and 65 
4 1 January 2015  50, 55, 60, 65, 70 and 74 
4 1 January 2016  50, 55, 60, 64, 65, 70, 72 and 74 
4 1 January 2017  50, 54, 55, 58, 60, 64, 68, 70, 72 and 74 
4 1 January 2018  50, 54, 58, 60, 62, 64, 66, 68, 70, 72 and 74 
4 1 January 2019  50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72 and 74 
(a) Eligible birthdates, and thus invitations, ended on 31 December 2010. 
(b) Ongoing NBCSP funding commenced. 
Note: The eligible population for all Phase 2 and 3 start dates incorporates all those turning the target ages from 1 January of  
that year, onwards. 
The goal of the NBCSP is to reduce the morbidity and mortality from bowel cancer by 
actively recruiting and screening the target population for early detection or prevention of 
the disease. 
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The NBCSP has been phased in gradually to help ensure that health services, such as 
colonoscopy and treatment options, are able to meet any increased demand. This is 
consistent with the introduction of other screening programs, such as the National Cervical 
Screening Program, which was also phased in over several years.  
The National Bowel Cancer Screening Program Register, currently maintained by the 
Department of Human Services (DHS), is responsible for inviting people to participate in 
screening using an FOBT supplied with the invitation pack. To avoid the possibility of 
samples deteriorating due to exposure to heat and delays in processing (Grazzini et al. 2010; 
van Rossum et al. 2009), participants living in ‘hot zone’ postcodes are not sent kits during 
months where the average temperature has historically been greater than 30.5 degrees 
Celsius. They are sent their kit either before or after those hotter months. 
Once an eligible person has received and completed their FOBT, they are asked to post it to a 
central pathology laboratory for analysis. Results are sent to the participant, to the 
participant’s nominated PHCP and to the NBCSP Register. Participants with a positive 
result, indicating blood in their stool, are advised to consult their PHCP to discuss further 
diagnostic testing—in most cases, this will be a colonoscopy.  
Responses to invitations, and the outcomes for participants who complete the screening test, 
are monitored to the point of definite diagnosis for those who are found to have bowel 
cancer (Health 2015b). Refer to Appendix B, Figure B.1 for a complete representation of the 
current screening pathway from invitation to diagnosis. 
How is the National Bowel Cancer Screening Program monitored? 
The AIHW produces these NBCSP monitoring reports for the Department of Health. These 
reports analyse data extracted from the NBCSP Register and provide an overview of 
screening participation and outcomes.  
This current report presents statistics on the progression of eligible participants, invited 
between 1 July 2013 and 30 June 2014, through the screening pathway. It covers measures of 
participation, FOBT results, and follow-up investigations and outcomes. Analyses are 
presented by age, sex, state and territory, geographical region, socioeconomic status, 
Indigenous status, language spoken at home, and disability status. 
In addition, the most recent incidence and mortality data for bowel cancer are presented as 
an indication of the current status of bowel cancer in Australia. As the NBCSP only began in 
late 2006 and currently targets a relatively small population, any influence NBCSP screening 
has on incidence and mortality rates may not be apparent for several years. 
This is the last monitoring report in this format. Future NBCSP monitoring reports will be 
based on the newly approved NBCSP performance indicators (AIHW 2014d). 
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Terminology and concepts used in this report 
Eligible population 
The eligible population list is compiled from those registered as an Australian citizen or 
migrant in the Medicare enrolment file, or registered with a Department of Veterans’ Affairs 
(DVA) gold card. Due to some variability between actual NBCSP invitation dates and invitee 
target-age birthdays, those who were the following ages when invited (from 1 January 2013 
to 30 June 2014) were included in the target-age cohorts in this report: 
• 50 year olds: those aged 49–52 when invited 
• 55 year olds: those aged 54–57 when invited 
• 60 year olds: those aged 59–62 when invited 
• 65 year olds: those aged 64–67 when invited. 
While all kits returned are analysed and processed by the NBCSP, invitees who were outside 
the target ages or did not live in Australia at the time of invitation were excluded from 
analyses in this report. There were 910 invitees excluded from the eligible population in 
2013–14 (see Table A1.1). These people were mainly participants outside the target ages who 
independently requested a kit, or were involved in jurisdictional pilot projects (such as those 
aimed at improving Aboriginal and Torres Strait Islander participation). 
Those people in the eligible population who had opted off the NBCSP (due to reasons such 
as already having regular colonoscopies), or who had suspended their participation as at 
31 December 2014, were included in analyses, because many had progressed through the 
screening pathway before opting off or suspending their participation.  
Participation 
The term ‘participation’ is used to refer to participation in the screening program. Hence, the 
‘participation rate’ is the proportion of the eligible population who were invited and who 
returned a completed FOBT.  
FOBT positivity rate 
The FOBT positivity rate refers to the proportion of participants with positive FOBT results 
out of all participants who returned a valid FOBT kit; participants who returned inconclusive 
kits were excluded from this rate. 
Primary health-care practitioner and colonoscopy follow-up rates 
The proportion of participants with a positive FOBT result who subsequently visited a PHCP 
is referred to as the ‘primary health-care practitioner follow-up rate’. PHCPs are classified by 
DHS as a general practitioner or other primary health-care provider. This may include 
remote health clinics or specialists providing general practitioner services. 
The proportion of participants with a positive FOBT, and who subsequently had a 
colonoscopy, is referred to as the ‘colonoscopy follow-up rate’.  
 National Bowel Cancer Screening Program: monitoring report 2013–14 9 
‘Crude’ versus estimated rates 
Due to inherent time lag between invitation and completion of an FOBT, calculation of a 
crude participation rate for a period can result in an underestimate of the true (final) 
participation rate, especially if sufficient time to allow all invitees to participate has not 
passed when calculating the crude rate. To adjust for the time lag in participation, this report 
includes data up to 6 months after the invitation period being reported.  
However, for later stages in the NBCSP pathway, such as PHCP and colonoscopy follow-up, 
modelled rates—based on the time it took each individual with a positive FOBT result to 
respond—were also calculated. The modelled response rates were calculated using the 
Kaplan–Meier method and provide a rate that adjusts for time lag in those who were invited 
later in the reported period and may not have yet had sufficient time to have a follow-up 
colonoscopy, for example. This method can only minimise the effect of the time lag—it 
cannot account for non-return of NBCSP forms (see ‘NBCSP data collection’ below). Details 
of the Kaplan–Meier method can be found in Appendix D. An additional update to the crude 
rates for the previous monitoring report (with an additional year of follow up time) is also 
included in Appendix A. 
Data considerations 
The analyses in this report are based on data recorded in the NBCSP Register for the eligible 
population invited between 1 July 2013 and 30 June 2014, and includes participation and 
follow-up activity until 31 December 2014.  
NBCSP data collection 
Data are collected about participants and their screening outcomes from a variety of sources 
throughout the screening pathway. The data are collected on forms completed by 
participants, PHCPs, colonoscopists, pathologists, nurses, medical administrative staff 
and/or other specialists, and are ultimately returned and stored in the NBCSP Register. 
Completion of NBCSP forms by practitioners is not mandatory, and there is the possibility 
of inconsistent reporting. For example, assessment, colonoscopy and histopathology report 
forms are received from different sources and may be entered into the register in any 
sequence; however, each must have a positive FOBT result to be included. This means that 
there may be data for colonoscopies without an associated PHCP assessment form, and data 
for histopathology results without a completed colonoscopy report form. When 
inconsistencies occur, these are noted to provide an indication of the reliability of the data. 
Additionally, specific histopathology data collection projects have been undertaken in some 
states and territories that may distort comparisons of histopathologically confirmed 
outcomes between jurisdictions. 
Because of time lags in reporting by clinicians, data on PHCP consultations, colonoscopies 
and histopathological outcomes in this report may understate the true performance of the 
NBCSP in this period and should be interpreted with caution. 
Self-reported population subgroup identification 
Information in the NBCSP Register on the Indigenous status of invitees may have been 
populated from data in other Medicare programs for which the invitee has provided this 
information; however, in practice, this information for invitees overall is considered to be of 
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low quality. Therefore, identification of participants as ‘Aboriginal and Torres Strait 
Islander’, having a disability, or speaking a language other than English at home is by 
self-identification through their return of a completed participant details form along with 
their FOBT for analysis. As membership of these subgroups is only known for invitees who 
participate, it is not possible to accurately determine NBCSP participation rates for these 
subgroups. Instead, the percentage of participants who identified as members of these 
subgroups is shown, and compared with the corresponding percentage of the population 
aged 50, 55, 60 and 65 who identified themselves as members of these subgroups in the 2011 
Australian Census of Population and Housing. This allows an estimation of under-reporting 
or under-participation for these subgroups to be made.  
Postcode-based subgroup identification 
Subgroup analyses based on remoteness area and socioeconomic status (Index of Relative 
Socioeconomic Disadvantage) area are based on an invitee’s postcode at the time of 
invitation. The correspondences (previously known as concordances) used in this report are 
based on 2011 postal area boundaries and classifications, which are defined only in census 
years. (See Appendix C for further details.) 
The need to apply correspondences to determine subgroup identification introduces an 
unavoidable level of inaccuracy. For example, many postcodes may not have valid 
socioeconomic status or remoteness correspondence data available (such as for 
non-residential postcodes, or newly created postcodes), and some areas may have changed 
classification group since the time of the last census, either due to boundaries being 
redefined by Australia Post, or subsequent population changes. The Australian Bureau of 
Statistics advises that caution should always be taken when analysing the results of data that 
have been converted using correspondences, and the potential limitations of the data taken 
into account. 
Colonoscopy follow-up 
Theoretically, the denominator for the colonoscopy follow-up rate should be all positive 
FOBTs that were referred for colonoscopy by a PHCP. However, due to the time lag in 
visiting PHCPs and the low rate of PHCP assessment form return, this cannot be accurately 
estimated. Instead, the total number of positive FOBTs recorded in the NBCSP Register was 
used as the denominator.  
As not all participants with a positive FOBT will be referred for a colonoscopy (see 
tables A3.9 and A3.11 for examples), this method may result in an underestimation of the 
true colonoscopy follow-up rate. The use of positive FOBTs as the denominator may also 
influence the rates shown in unexpected ways. For example, differences in age and sex 
population subgroups may be masked by differing referral rates—as tables A2.2 and A3.9 
show, the rate of positive FOBTs (used as the denominator for colonoscopy follow-up) 
generally increases with age, yet referrals for colonoscopy do not. 
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Section 2 Performance measures 
Structure of this section 
The Population based screening framework (APHDPCSS 2008) uses 5 incremental stages to 
describe a screening pathway. Figure S2.1 shows these stages and details how the NBCSP 
performance measures shown in the following chapters relate. The 2 remaining chapters in 
this section (‘Chapter 6 Incidence of bowel cancer’, and ‘Chapter 7 Mortality from bowel 
cancer’) provide additional context about bowel cancer in Australia. 
Recruitment
Targeted population encouraged 
to participate in screening
(Chapter 1)
Screening
Targeted population who participate in 
screening
(Chapter 1)
Assessment
Screened population who 
require further assessment
(Chapter 2)
Diagnosis
(Chapter 3)
Outcomes
(Chapters 4 and 5)
 
Source: APHDPCSS (2008). 
Figure S2.1: The 5 population-based screening framework stages 
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1 Participation 
What do we mean by ‘participation’? 
Definition: The proportion of the eligible population invited who returned a completed 
FOBT kit for analysis.  
Rationale: Through increased participation in bowel cancer screening, abnormalities that 
could otherwise develop into bowel cancer can be detected and treated. High participation 
is required for the NBCSP to achieve its major objectives of reducing bowel cancer 
incidence, morbidity and mortality. 
Data source: National Bowel Cancer Screening Program Register 
Data quality: As the number of invitations issued and FOBT kits returned is known, there 
are limited data quality issues. (See ‘Section 1 Data considerations’ for further details.) 
Guide to interpretation: Participation data are based on the eligible population invited to 
screen from 1 July 2013 to 30 June 2014, as recorded in the register. Persons are counted only 
once in the reporting period, even if they were invited or screened more than once. (See 
‘Section 1 Eligible population’ for further information.) 
Participation rate calculations should, in principle, exclude people from the denominator 
who are unlikely to require screening, such as those who have a previous diagnosis of 
bowel cancer, those who have had a colonoscopy in the past 5 years, or those who have 
completed any FOBT kit within the past 2 years. In practice, none of these groups can be 
reliably identified, and so all invitees are included in the denominator, and in the 
numerator if applicable. Similarly, those who had opted off or suspended their participation 
are included in this chapter; this may cause a slight underestimation of the participation 
rate, but increases outcomes data for later chapters. 
Kaplan–Meier rates (see Box 1.1) are presented to visually depict participation rates in terms 
of time (in weeks) since invitation. 
Key results 
• Of the 1,415,555 eligible people invited into the NBCSP in 2013–14, 509,736 (36.0%) had 
participated by 31 December 2014.  
• Participation rates differed between the 4 target ages. The highest rate of participation 
was for people aged 60 (42.7%), followed by those aged 65 (40.6%). Those aged 55 had a 
participation rate of 35.9%, while 50 year olds had the lowest rate (27.4%). The start of 
the second screening invitation round for those aged 55 and 60 (after originally being 
invited 5 years earlier in 2008–09) increased the overall participation rates for these ages. 
This was mainly due to their re-participation rate being more than 70%.  
• There was also a difference in participation between the sexes; the participation rate for 
women (38.5%) was higher than that for men (33.6%). 
• Those people invited in Remote and (particularly) Very Remote regions had lower levels of 
participation than people invited from all other regions. 
• People living in areas with the lowest socioeconomic status had the lowest level of 
participation. 
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Detailed analyses of 2013–14 invitee response 
From 1 July 2013 to 30 June 2014, a total of 1,416,465 FOBT invitations were sent out 
(Table A1.1). Of these, 910 were sent to people outside the target ages, or to addresses that 
were not in Australia, and were considered not part of the eligible NBCSP population. To 
confirm that the NBCSP Register provided adequate invitation coverage of the target ages, 
the Australian Bureau of Statistics Estimated Resident Populations for those aged 50, 55, 60 
and 65 in 2013 were compared with invitations where the eligible birthday occurred in 2013. 
Based on this comparison, invitation coverage for the eligible population was considered to 
be complete. 
Of the 1,415,555 invitation kits issued to the eligible population, 509,736 people participated 
by returning a completed FOBT for analysis. This gave an overall Australia-wide crude 
participation rate of 36.0% (Table A1.2). A further 63,380 people did not return a kit but 
responded by opting off or suspending participation. This meant 573,116 people (40.5% of 
eligible invitees) responded in some form.  
The 36.0% participation rate recorded in this report was higher than that reported in the 
previous monitoring report (33.4%), with all jurisdictions, both sexes, and all remoteness and 
socioeconomic status areas recording an increase. The main reason for these increases was 
the start of re-invitations for those aged 55 (who were previously invited as 50 year olds in 
2008) and those aged 60 (who were previously invited as 55 year olds in 2008).  
The effect of second-screen invitations 
While the overall participation rate was 36.0%, for those receiving their second invitation the 
participation rate was 40.1%. For those receiving their first invitation (the majority of which 
were to 50 year olds), the rate was 32.9% (Figure 1.1). 
 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure 1.1: Crude participation, by invitation round, 2013–14  
Further analyses of participation by invitation round (that is, first or second invitation 
round) are presented in Table A1.8.  
These data show that the participation rate for those receiving their first invitation was 
similar to the rate in the last monitoring report (which was 33.4%); however, the initiation of 
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rescreening (second invitations sent to people 5 years after their first invitation in 2008–09) 
increased the overall 2013–14 participation rate to 36.0%. Also, those who did participate in 
their first invitation round had a much higher re-participation rate (73.5%) than those who 
didn’t participate in the first round (17.7% participated at their second invitation).  
Participation trends by time since invitation 
This report allowed a 6-month window, between the period being reported and the cut-off 
for data analysis, to allow sufficient time for almost all invitees who are likely to participate 
to do so. Previous monitoring reports have determined that 6 months is sufficient for crude 
participation rates to be valid (AIHW 2013). However, Kaplan–Meier estimates are provided 
in addition to visually show the response time between invitation and participation. 
The effect of invitation reminders 8 weeks after the original invitation can be seen (in figures 
A1.1, A1.2 and A1.3) as a second steep rise in participation between weeks 10 and 14. 
Participation rates generally plateaued 16 weeks after invitation. 
Box 1.1: What are Kaplan–Meier estimates? 
Kaplan–Meier estimates are statistical methods that calculate a modelled rate based on the 
time it takes each individual invited for screening to move between points on the screening 
pathway. For example, participation is calculated by following each invited person and, for 
those who respond (by returning a completed FOBT kit), recording the time (in weeks) it 
took them to do so. This allows the calculation of an overall response rate over time from 
the date of invitation, calculated as if all invitations sent throughout the particular period 
reported were sent on the same date. 
Participation by population subgroups 
Analysing the participation of subgroups in the eligible population can help us identify 
where additional initiatives may be of benefit. Kaplan–Meier estimates are provided for 
some subgroup analyses to show differences in participation over time since invitation.  
Participation by state and territory 
Participation rates varied by state and territory. Northern Territory (26.7% crude 
participation), New South Wales (33.2%) and Queensland (35.5%) had lower participation 
rates than other jurisdictions (Table A1.2). For all other jurisdictions, participation rates were 
higher than the overall Australian rate. These jurisdictional participation results showed the 
same general pattern as results in the previous annual monitoring report.  
The reasons why invitees in particular jurisdictions participate more or less than in others are 
unknown; however, further analysis of jurisdictional participation by socioeconomic status 
and remoteness areas shows that participation in New South Wales and Queensland was 
generally lower across all subgroups (including Major cities, and Inner and outer regional 
areas) than the other jurisdictions. Therefore, lower participation appears to be an overall 
trend in these jurisdictions. As New South Wales and Queensland are 2 of the larger 
jurisdictions, their rates have a greater effect on the Australian participation rate.  
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Participation by age and sex 
Participation rates were higher for women than men and generally increased with increasing 
age, though this age-related increase was influenced by rescreening invitations issued to  
55 and 60 year olds (figures 1.2, A1.2 and A1.3).  
The start of a second invitation round for those initially invited in 2008 has resulted in an 
increase in the overall participation rates for those aged 55 and 60, with 60 year olds having a 
higher rate than 65 year olds (Table A1.8). In previous reports, the participation rate had 
always increased with invitation age. 
Women were 1.1 times more likely than men to participate in bowel screening (38.5% for 
women compared with 33.6% for men) (Table A1.2 and Figure A1.3).  
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure 1.2: Crude participation, by age and sex, 2013–14  
Participation by remoteness area and socioeconomic status area 
More than 66% of all participants came from Major cities (with a 35.2% crude participation 
rate). The proportion participating in screening was highest in Inner regional (38.8%) and 
Outer regional (37.5%) areas and lowest in Remote and Very remote areas (Table A1.3 and 
figures 1.3 and 1.4). Jurisdiction-specific figures (figures A1.4a–A1.4h) are provided in 
Appendix A. 
Analysis of invitees grouped into population-based socioeconomic status quintiles showed 
invitees from within the lowest socioeconomic areas (the areas with the most disadvantage) 
had lower participation than for those living in all other socioeconomic areas (Table A1.4 and 
Figure 1.3). Only the 2 highest socioeconomic status quintiles had average participation 
above the national average.  
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Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure 1.3: Crude participation, by remoteness area and by socioeconomic status area, 2013–14 
 
 
Notes 
1. Rate per remoteness area is an average of participation across that remoteness area. 
2. Participation rates rounded to integers. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure 1.4: Crude participation, by remoteness area, 2013–14 
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Participation by Aboriginal and Torres Strait Islander status, language spoken at home 
and disability subgroups 
As discussed in Section 1 (‘Data considerations’), identification of invitees by Aboriginal and 
Torres Strait Islander status, language spoken at home and disability subgroups is only 
obtained once an invitee completes the relevant section of their participant details form. 
Therefore, it is not possible to accurately determine participation rates for these subgroups. 
Instead, the proportion of participants who reported their status within these subgroups is 
shown, along with the corresponding population proportions derived from the 2011 
Australian Bureau of Statistics (ABS) Census of Population and Housing (tables A1.5–A1.7). 
While these are not ideal comparisons, they do allow some understanding of people in these 
3 subgroups, and whether they are participating in the NBCSP in similar proportions to their 
levels within the Australian population (as recorded at the 2011 Census). For example, if 
1.5% of the Australian population in the target ages identified as Aboriginal and/or Torres 
Strait Islander at the 2011 Census, did the same proportion of people who participated in the 
NBCSP identify as Aboriginal and/or Torres Strait Islander? If the proportion participating 
is below 1.5%, it may indicate under-participation by this population subgroup. 
The following comparisons should be interpreted with caution as the eligible NBCSP 
population (which includes only those in the target ages, living in Australia, who are 
registered as Australian citizens or migrants in the Medicare enrolment file, or are registered 
with a DVA gold card) may differ somewhat from the population recorded in those target 
ages at the 2011 Census (which did not have the same eligibility criteria, such as Medicare or 
DVA gold card registration). Further, there were slight differences between the NBCSP and 
2011 Census data in the proportion of people who did not identify (that is, who did not 
answer these questions) (tables A1.5 and A1.7); this may affect comparisons shown below.  
The proportion of participants who identified as Aboriginal and/or Torres Strait Islander in 
the NBCSP was lower across all ages—especially 50 and 55 year olds—and sex groups, 
compared with those who identified as Aboriginal and/or Torres Strait Islander in the 2011 
Census (Table A1.5). This may have been due to the eligible population who were Aboriginal 
and Torres Strait Islander having participated at a lower rate than would be expected (that is, 
0.9% of the eligible population who participated identified as Indigenous, compared with 
1.5% of the target ages identifying as Indigenous at the time of the 2011 Census). 
The NBCSP Register assumes all people who do not answer the question about language 
spoken at home speak English, so it was not possible to compare the ‘Not stated’ percentage 
with the percentage from the 2011 Census (Table A1.6). Therefore, no interpretation about 
participation rates by people who speak a language other than English at home should be 
made, though Table A1.6 is provided for completeness.  
As the proportion of participants who identified as having a severe or profound activity 
limitation (5.0%) was slightly greater than the proportion identified in the 2011 Census 
(4.6%), it is likely that participation among invitees in this subgroup was no lower than for 
those invitees without a severe or profound activity limitation (Table A1.7).  
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2 Faecal occult blood test outcomes 
What do we mean by FOBT outcomes? 
Definition: The proportion of the eligible population invited who returned a positive 
(abnormal) result from a correctly completed FOBT kit. 
Rationale: Monitoring of FOBT outcomes, including for various subgroups, is important to 
ensure the quality of the screening test results and participant safety. 
Data source: National Bowel Cancer Screening Program Register 
Data quality: All FOBT kits returned are analysed for outcome, with the result reliably 
stored in the register. There are no quality issues with this measure. (See ‘Section 1 Data 
considerations’ for further details.) 
Guide to interpretation: FOBT result data are based on data recorded in the register to 
31 December 2014 for persons invited between 1 July 2013 and 30 June 2014. 
Persons are counted only once in the reporting period, even if they completed more than 
1 FOBT during this period. For participants who returned more than 1 FOBT kit, the results 
were analysed according to the following order of precedence: a positive result was selected 
over any other result, and a negative result was selected over an inconclusive result. 
Key results 
• Of the 509,736 participants who had completed an FOBT kit, 501,382 (98.4%) had done so 
correctly, allowing for analysis by the pathology laboratory. However, 93 were 
inconclusive when analysed and those participants were still to complete and return a 
replacement FOBT. 
• Out of the 501,289 valid FOBT kits analysed, 37,744 returned a positive result, giving an 
overall positivity rate of 7.5%.  
• The positivity rate for men (8.3%) was 1.2 times that for women (6.9%). 
• First-round FOBT positivity rates for both sexes increased with age, consistent with the 
known rise in polyp, adenoma and bowel cancer incidence rates with increasing age. 
• Second-round rescreening positivity rates for 55 and 60 year olds were both noticeably 
lower than the first-round rates for those ages. 
• Positivity rates generally increased with increasing geographical remoteness. Rates for 
participants in Very remote (9.6%), Outer regional (8.3%) and Remote (8.2%) areas were 
higher than those in Inner regional (7.7%) areas and Major cities (7.4%). 
• Positivity rates were higher for participants living in areas with higher socioeconomic 
disadvantage—from 6.5% for participants living in areas with the least disadvantage to 
8.7% for participants living in areas with the most disadvantage. 
• Participants who self-identified as Aboriginal and/or Torres Strait Islander had a higher 
positivity rate (12.1%) than those who reported as non-Indigenous (7.4%) or those who 
did not state their Indigenous status (9.7%). 
• The positivity rate for participants with a severe or profound activity limitation (12.0%) 
was higher than for participants without those limitations (7.4%). 
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Background information 
Each invitee in the NBCSP is initially sent 1 FOBT kit containing 2 sample tubes to be 
completed, from 2 separate bowel motions, and returned to the pathology laboratory 
together for analysis.  
Completed and returned kits are categorised by pathologists into 3 groups: correctly 
completed, incorrectly completed or unsatisfactory. A kit may be incorrectly completed or 
unsatisfactory (and thus ineligible for analysis) due to: 
• the participant not completing the test correctly 
• the completed kit having expired 
• the kit having taken more than 14 days between the date of the first sample and analysis 
by the pathology laboratory. 
Participants who return FOBTs that were incorrectly completed are asked to complete 
another FOBT. (See Figure B.1, Appendix B, for details of the screening pathway.) 
Results of correctly completed FOBT kits are classified by pathologists as either positive 
(abnormal—blood detected in either sample), negative (blood not detected in either sample) 
or inconclusive (only 1 sample was taken, and it was negative). Valid kits are considered to 
be those from which it is possible to determine a positive or negative outcome. 
Participants with a positive FOBT are encouraged to visit their PHCP to follow up this 
finding. Those with an inconclusive kit are requested to complete another FOBT kit, while 
those with a negative result are reminded that it is recommended they rescreen every 2 years 
with an FOBT. Participants are advised to discuss continuing screening options with their 
PHCP.  
Detailed faecal occult blood test outcome analyses 
Between 1 July 2013 and 30 June 2014, 1,415,555 eligible people were invited to screen, and 
by 31 December 2014, 509,736 participants had returned at least 1 completed FOBT kit. Of 
these, 501,382 (98.4%) had a correctly completed FOBT kit tested by the pathology laboratory 
(Table A2.1); the remaining kits had been incorrectly completed. Of the correctly completed 
kits, some were deemed inconclusive when tested. Those participants who returned an 
incorrectly completed or inconclusive FOBT kit were requested to complete another FOBT; 
however, by 31 December 2014, 8,354 participants had not returned a replacement kit, and 93 
had returned kits with an inconclusive result. These were excluded from the positivity 
analyses. 
Of the 501,289 valid FOBT kits analysed, 37,744 (7.5%) returned a positive FOBT result 
(Table A2.2). These participants were advised to consult their PHCP to discuss this result 
and to seek further diagnostic testing (see ‘Section 2, Chapter 3 Follow-up of positive FOBT 
results’).  
Faecal occult blood test outcomes by population subgroups 
Faecal occult blood test outcomes by state and territory 
The positivity rates for South Australia (8.0%), Tasmania (8.0%) and the Northern Territory 
(7.8%) were higher than the overall Australian rate of 7.5% (Table A2.3). 
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Faecal occult blood test outcomes by age and sex 
The first-screen FOBT positivity rate increased with increasing age. This was true for both 
men and women (Figure 2.1 and Table A2.2). These findings are consistent with the increase 
in prevalence of polyps and adenomas with age (Winawer et al. 1997). 
The second-screen positivity rates for 55 and 60 year olds were lower than the first-screen 
rates for those ages. Overall, this contributed to the 55-year-old positivity rate being lower 
than that for 50 year olds. The overall 60-year-old positivity rate was affected by a lower 
positivity rate for second screens (compared to initial screens) in this age cohort. This 
suggests that the overall program positivity rate may be lower once biennial screening is 
fully implemented. 
The overall men’s positivity rate (8.3%) was 1.2 times the rate for women (6.9%), indicating 
both age and sex affect the FOBT positivity rate (Table A2.2).  
 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure 2.1: FOBT positivity, by age and sex, 2013–14 
Faecal occult blood test outcomes by remoteness area and socioeconomic status area 
Analysis of the positivity rate by area (Table A2.4) showed generally increasing positivity 
with increasing remoteness. Outer regional, Remote and Very remote areas had positivity rates 
1.1, 1.1 and 1.3 times the positivity rate of Major cities, respectively. This was a similar result 
to previous reports. Positivity rates by remoteness area and jurisdiction are shown in 
Figure 2.2. Jurisdiction-specific figures (figures A2.1a–A2.1h) are provided in Appendix A. 
FOBT positivity rates also increased for people living in areas of increasing disadvantage 
(Table A2.5). The positivity rate for participants living in areas with the lowest 
socioeconomic status (8.7%) was 1.3 times that of participants living in areas with the highest 
socioeconomic status (6.5%). Socioeconomic status analyses for the participation measure 
(see ‘Section 2, Chapter 1 Participation’) and the FOBT analyses in this chapter show that 
those living in areas of lower socioeconomic status participate less in the NBCSP 
(Table A1.4); yet those who do participate return a higher proportion of positive FOBT 
results (Table A2.5). 
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Notes 
1. Remoteness areas left unshaded contain data that are not publishable due to small numbers, confidentiality or other concerns.  
2. Rate per remoteness area is an average of positivity across that remoteness area. 
3. Positivity rates rounded to 1 decimal place. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure 2.2: FOBT positivity, by remoteness area, 2013–14 
Faecal occult blood test outcomes by Aboriginal and Torres Strait Islander status, 
language spoken at home and disability subgroups 
Aboriginal and Torres Strait Islander participants had a higher positivity rate (12.1%) than 
non-Indigenous participants (7.4%) (Table A2.6).  
The positivity rate of those who spoke a language other than English at home (7.9%) was 
higher than participants who spoke English at home (7.5%) (Table A2.7); however, as those 
who do not report their language spoken at home are assumed to speak English, the 
interpretability of this result is limited. 
People with a severe or profound activity limitation recorded a higher positivity rate (12.0%) 
than people without such limitations (7.4%) (Table A2.8). Reasons for this difference are 
speculative, but may include a lower level of physical activity (Wolin et al. 2011), or 
comorbidities and medications that increase the likelihood of a positive FOBT screening 
result in people with a severe or profound activity limitation.  
FOBT positivity (per cent)
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3 Follow-up of positive FOBT results 
What do we mean by FOBT follow-up? 
Definition: The proportion of the eligible population invited to participate who returned a 
positive (abnormal) result from a correctly completed FOBT kit and received follow-up care 
by a PHCP and colonoscopist. 
Rationale: Not all positive screening results will be due to a bowel cancer. Polyps, 
adenomas and other conditions can also cause a positive screening result. Monitoring of 
follow-up care for participants with a positive FOBT is important to ensure they have 
followed up their screening result with medical specialists to determine the cause. 
Data source: National Bowel Cancer Screening Program Register. 
Data quality: All positive FOBT results are recorded in the register; however, reporting of 
follow-up care by PHCPs, colonoscopists, surgeons and pathologists is not mandatory, so 
follow-up rates may be underestimated. (See ‘Section 1 Data considerations’ for further 
details.) 
Guide to interpretation: This chapter discusses the follow-up procedures, including PHCP 
visits, colonoscopy procedures and histopathology diagnoses for those participants who 
were invited between 1 July 2013 and 30 June 2014. Persons are counted only once in the 
reporting period, even if they attended more than 1 follow-up consultation during this 
period. For participants who attended more than 1 follow-up consultation, the first 
consultation after the positive result was used to establish time to follow-up, while the most 
serious follow-up result was used for outcomes. 
Kaplan–Meier rates (see ‘Section 1 Crude versus estimated rates’) are used to take into 
account potential time lag between a positive FOBT result and both PHCP and colonoscopy 
follow-up dates. 
The rates of colonoscopy follow-up are discussed in this chapter, while the actual outcomes 
of colonoscopic investigation are discussed in ‘Section 2, Chapter 4 Bowel abnormality 
detection’. 
Key results 
• Using Kaplan–Meier estimates, of the 37,744 participants who had a positive FOBT, 
62.5% had a follow-up PHCP visit and 71.2% had a follow-up colonoscopy within 1 year 
of their screening result; because the number of participants reported as proceeding to 
colonoscopy exceeds the number reported as making a PHCP visit, the PHCP visits may 
be under-reported (see Box 3.1). 
• PHCP follow-up was highest for participants living in Inner regional and Outer regional 
areas. 
• Of the 23,215 participants who had reported a PHCP consultation, 82.3% reported 
experiencing no symptoms before their positive FOBT result and 92.2% were referred for 
a colonoscopy. 
• Aboriginal and Torres Strait Islander participants, participants who spoke a language 
other than English at home, and those with a severe or profound activity limitation had a 
lower rate of colonoscopy follow-up than other participants. 
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Background information 
The NBCSP uses an FOBT as the screening tool to screen for microscopic blood loss from the 
bowel—a sign of potential bowel problems that require further investigation, including 
bowel cancer and adenomas. A procedure such as a colonoscopy is required to actually 
diagnose a bowel condition after a positive screening test.  
Participants who receive a positive FOBT result are encouraged to follow up this outcome 
with their PHCP. In accordance with the Clinical practice guidelines for the prevention, early 
detection and management of colorectal cancer (ACN 2005), PHCPs are encouraged to refer all 
participants with a positive FOBT for a colonoscopy, unless other information gained at the 
consultation suggests an alternative course of action.  
Colonoscopy is currently considered the most accurate method of investigation to assess the 
colon and rectum, as it enables biopsy and subsequent histopathological diagnosis. 
Colonoscopy also allows identification and endoscopic removal of polyps and adenomas.  
As most bowel cancers are known to initiate from polyps (Cappell 2005), their removal at 
colonoscopy provides a preventive measure to lower the risk of future bowel cancers. A 
study by Stryker and colleagues (1987) estimated that the cumulative risk of bowel cancer at 
the site of an untreated polyp was 2.5% at 5 years, 8% at 10 years and 24% at 20 years 
post-discovery.  
This is one of the advantages of the NBCSP: while bowel cancer screening aims to find 
cancers at an earlier and treatable stage, follow-up colonoscopy after a positive screen may 
also identify and remove precancerous lesions. This should result in lower bowel cancer 
incidence rates in future years. However, the effect may not be apparent until about 10 years 
from the start the program. 
Detailed primary health-care practitioner follow-up analyses  
Of the 37,744 participants invited who returned a positive FOBT result, 23,215 (61.5%) had a 
PHCP visit registered by 31 December 2014 (Table A3.1). Using Kaplan–Meier estimates to 
minimise any effect of time lag, an estimated 62.5% of participants had consulted a PHCP 
within 1 year of their positive FOBT result (Table A3.2). The reminder letter sent to 
participants and their PHCP 8 weeks after a positive FOBT clearly had a positive effect, with 
an increase in the follow-up rate seen between 10 and 14 weeks (figures A3.1a–c).  
Box 3.1: Interpretation of follow-up results 
Assessment form return has recently improved over that recorded in earlier monitoring 
reports. Some of this improvement is due to the time increase between the invitation and 
final data cut-offs used in recent reports, which has allowed sufficient time for the majority 
of participants with a positive FOBT result to attend their PHCP, thus allowing for greater 
completeness of data on participant progress through the NBCSP pathway.  
However, there is still room for more improvement in assessment form return as there were 
more recorded colonoscopies than recorded PHCP visits (tables A3.1 and A3.12), and PHCP 
referral is generally required to progress to colonoscopy.  
Of the participants who had a reported PHCP consultation: 
• 82.3% reported having no symptoms before the positive FOBT result (Table A3.8) 
• 92.2% were referred for colonoscopy (Table A3.9). 
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For those not referred for colonoscopy (1,142), the main reasons were: 
• having had a colonoscopy in the previous 18 months (43.8%) 
• participant declining a colonoscopy (31.5%)  
• other medical condition(s) (28.0%) (Table A3.11). 
Of the 573 participants who declined colonoscopy (Table A3.11), 346 were not referred for 
any other assessment (data not shown). 
As the invitation strategy at the time of this report sent invitations to all people who turned 
the target ages regardless of recent screening or surveillance—or current bowel cancer 
status—it is possible that some participants move through the screening pathway before 
these reasons potentially negate the need for further follow-up. However, without complete 
PHCP form return (as well as participant opt-off form return), it is not possible to accurately 
quantify the number of people that should be excluded from asymptomatic 
population-based bowel screening.  
Primary health-care practitioner follow-up by population subgroups 
Primary health-care practitioner follow-up by state and territory 
The provision of follow-up healthcare services for participants with a positive result is the 
shared responsibility of the Commonwealth and states and territories, and follow-up policies 
and procedures may vary between jurisdictions. There were large differences recorded in 
PHCP follow-up between the jurisdictions, with the Northern Territory, Victoria and the 
Australian Capital Territory recording the lowest levels of PHCP follow-up (Table A3.1). The 
Kaplan–Meier PHCP follow-up rates, up to 52 weeks from a positive FOBT result, showed a 
similar pattern to the crude data with respect to state and territory differences (Table A3.2 
and figures A3.1b and A3.1c). For clarity, Kaplan–Meier curves for the states and territories 
were divided between figures A3.1b and A3.1c. With the exception of those living in the 
Northern Territory, Victoria and the Australian Capital Territory, at least 40% of all people 
with a positive FOBT were estimated to have had follow-up with their PHCP within 4 weeks 
of their screening result. 
Primary health-care practitioner follow-up by age and sex 
PHCP follow-up rates increased with age (Figure 3.1 and Table A3.1). As it is unlikely that 
PCHPs would return assessment forms differently for different-aged participants, this 
suggests that older participants are more likely to follow up a positive result. 
More women (63.6%) than men (59.5%) had an assessment form recorded, suggesting that 
women are more likely to follow up a positive FOBT with their PHCP. This was a common 
finding when comparing sexes across all PHCP subgroup tables.  
From the PHCP visits recorded, women had a slightly higher rate of reported symptoms 
(Table A3.8), and a slightly lower rate of referral for colonoscopy, but a higher rate of 
non-colonoscopy follow-up procedures (Table A3.9). 
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Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure 3.1: Primary health-care practitioner follow-up, by age and sex, 2013–14 
Primary health-care practitioner follow-up by remoteness area and socioeconomic status 
area 
Participants in Outer regional (65.6%) and Inner regional areas (64.4%) had the highest rates of 
PHCP consultations (Table A3.3). Participants in Very remote areas had the lowest rates of 
PHCP follow-up recorded. Follow-up to a PHCP varied by remoteness area and jurisdiction 
(Figure 3.2). However, this could reflect differences in the return of assessment forms rather 
than a true difference in follow-up. Jurisdiction-specific figures (figures A3.2a–A3.2h) are 
provided in Appendix A. Referral for colonoscopy was similar across remoteness areas 
(Table A3.10).  
PHCP follow-up between participants from different socioeconomic status areas was similar 
(Table A3.4).  
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Notes 
1. Remoteness areas left unshaded contain data that are not publishable due to small numbers, confidentiality or other concerns.  
2. Rate per remoteness area is an average of PHCP follow-up reported across that remoteness area. 
3. PHCP follow-up rates rounded to integers. 
4. Differences in PHCP follow-up rates across remoteness areas may involve differences in assessment form return and not a real difference 
in follow-up. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure 3.2: Follow-up by primary health-care practitioners after a positive FOBT result, by 
remoteness area, 2013–14 
Primary health-care practitioner follow-up by Aboriginal and Torres Strait Islander status, 
language spoken at home and disability subgroups 
All 3 population subgroups had low numbers of participants with returned assessment 
forms. Care must be taken when interpreting results in these tables. 
There were no major differences in the rates of PHCP visits when comparing participants by 
Indigenous status (about 62% for both Indigenous and non-Indigenous participants). 
However, people who spoke a language other than English at home, and people with a 
severe or profound disability had a 3 percentage point drop in PHCP visits, when compared 
with people who spoke English at home, and with people who did not record a disability 
(tables A3.5–A3.7, respectively). 
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Detailed colonoscopy follow-up  
Background 
This section presents the rate at which participants with a positive FOBT had follow-up 
assessment by colonoscopy.  
Following a positive FOBT result, PHCPs should refer a participant for colonoscopy, and the 
results should be returned to the NBCSP Register on a colonoscopy report form (Figure B.1, 
Appendix B). Some of these colonoscopies would also have sent pathology samples for 
analysis, and these additional results should be returned to the register on histopathology 
report forms. Lastly, each participant may choose to have their colonoscopy through the 
private or public health-care system (depending on their individual circumstances and 
choice), and those who had a private colonoscopy may then make a Medicare claim for that 
procedure. The register records claims from NBCSP-related colonoscopies.  
Due to the recommendation that all referrals be for colonoscopy, it is not possible to analyse 
follow-up by other assessment methods (for example, sigmoidoscopy) as data are not 
available. 
As not all colonoscopy forms are returned to the register, a count of colonoscopy report 
forms only will not be a complete count of all colonoscopies performed as part of NBCSP 
follow-up. Therefore, in an effort to obtain the most comprehensive picture of true NBCSP 
colonoscopy follow-up, colonoscopy procedures up until 31 December 2014 were identified 
through 3 sources: 
1. colonoscopy report forms (colonoscopy outcomes can be analysed using data on these 
forms)  
2. additional histopathology report forms (from the subset of colonoscopies that, although 
not directly reported on a colonoscopy report form, must have sent samples to 
histopathology—which were reported on histopathology report forms)  
3. claims for Medicare benefits for NBCSP-related private colonoscopies that were not 
reported through a colonoscopy report form (from the subset of NBCSP colonoscopies 
that were undertaken through the private healthcare system, as identified by DHS).  
Figure 3.3 visually presents the number of colonoscopies counted, and from which source (or 
sources) they were identified. If all colonoscopy forms were returned and recorded, it would 
be expected that no extra colonoscopies would be counted from outside the colonoscopy 
report forms box. However, 6,849 NBCSP-related colonoscopies were identified by private 
colonoscopy Medicare claim only, and a further 381 were identified through a 
histopathology report form only. Details such as colonoscopic findings could not be obtained 
for these colonoscopies; however, they are still counted in the total number of colonoscopies 
performed as part of NBCSP follow-up activities. Even though using these 3 sources allows 
the count of NBCSP colonoscopies to be as complete as possible, further investigation has 
previously shown a number of additional colonoscopies are likely to be unaccounted for, so 
colonoscopy follow-up rates are underestimated. 
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NBCSP colonoscopies recorded for participants invited July 2013–June 2014 (n = 25,518)
Colonoscopy report forms (18,288)(a)+(b)
Medicare claims onlyHistopathology report forms (4,145)(b)+(c)
14,524(a)
6,849(d)
381(c)
3,764(b)
 
People invited in 2013–14 with: 
(a) colonoscopy report forms recorded in the NBCSP Register for which no histopathology report form has been received 
(b) colonoscopies performed as part of the NBCSP where a colonoscopy and histopathology report form were recorded on which confirmed 
outcomes can be calculated. The total number of colonoscopy report forms is given by (a)+(b) 
(c) colonoscopies performed as part of the NBCSP where only a histopathology report form was recorded 
(d) colonoscopies performed as part of the NBCSP where only a Medicare claim was recorded. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure 3.3: Sources of colonoscopy follow-up data, 2013–14 
2013–14 colonoscopy follow-up 
Of the 37,744 positive FOBT results from participants invited, 25,518 had a colonoscopy 
registered by 31 December 2014, giving a crude colonoscopy follow-up rate of 67.6% 
(Table A3.12). Of these, 6,849 colonoscopies were known to have taken place only due to a 
Medicare claim for the procedure; no colonoscopy or histopathology report forms were 
recorded for those colonoscopies.  
Reasons for this non-complete rate of follow-up are likely to be similar to reasons for the low 
rate of PHCP follow-up: not all participants may follow up a positive FOBT result (and the 
positive FOBT count was used as the denominator for colonoscopy follow-up instead of all 
PHCP colonoscopy referrals), there is a time lag between booking and having a colonoscopy, 
and there is some delay in returning (non-mandatory) colonoscopy report forms. (See 
‘Section 1 Data considerations’ and ‘Section 1 Colonoscopy follow-up’ for further details.) 
To adjust for the effect of time lag on the follow-up rate, an analysis using Kaplan–Meier 
estimates was performed. The Kaplan–Meier analysis of colonoscopy follow-up estimated 
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that 71.2% of participants with a positive FOBT had a colonoscopy within 52 weeks of 
notification of their positive result (Table A3.13 and Figure A3.3a).  
Colonoscopy follow-up by population subgroups 
Colonoscopy follow-up by state and territory 
There were differences in colonoscopy follow-up rates between states and territories 
(tables A3.12 and A3.13). Tasmania (77.7%), Queensland (74.9%) and South Australia (70.6%) 
had the highest rates of crude colonoscopy follow-up. Much like the PHCP follow-up 
differences by jurisdiction (Table A3.1), these colonoscopy follow-up differences 
(tables A3.12 and A3.13 and figures A3.3b and A3.3c) may also be affected by NBCSP 
implementation procedures specific to each jurisdiction. Overall, an estimated 50.8% of those 
with a positive FOBT had undergone a colonoscopy within 12 weeks of their positive screen. 
Colonoscopy follow-up by age and sex 
The crude rate of colonoscopy follow-up for people aged 65 (70.0%) was higher than for 
those aged 60, 55 and 50 (68.4%, 64.7% and 65.2%, respectively) (Figure 3.4 and Table A3.12).  
The difference in crude colonoscopy follow-up between men and women was smaller (66.6% 
and 68.6%, respectively) (Table A3.12). 
 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure 3.4: Colonoscopy follow-up, by age and sex, 2013–14  
Colonoscopy follow-up by remoteness area and socioeconomic status area 
Colonoscopy follow-up for participants living in Major cities was higher than in all other 
regions (Table A3.14), yet PHCP follow-up in Major cities was lower than all regions except 
Very remote (Table A3.3). As time lag is not considered a contributing factor towards PHCP 
or colonoscopy rates in this report, there may be differences in form return between PHCPs 
and colonoscopists between regions.  
Colonoscopy follow-up rates varied by remoteness area and jurisdiction (Figure 3.5). 
Queensland had a high percentage of colonoscopy follow-up for most remoteness areas. 
However, these differences may be affected by colonoscopy and histopathology form return 
practices within medical facilities across remoteness areas and jurisdictions. 
Jurisdiction-specific figures (figures A3.4a–A3.4h) are provided in Appendix A. 
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There were also differences in colonoscopy follow-up between participants living in areas of 
differing socioeconomic status (Table A3.15); those living in areas with greater 
socioeconomic disadvantage had lower rates of colonoscopy follow-up than those living in 
areas with less socioeconomic disadvantage.  
 
Notes 
1. Remoteness areas left unshaded contain data that are not publishable due to small numbers, confidentiality or other concerns.  
2. Rate per remoteness area is an average of colonoscopy follow-up reported across that remoteness area. 
3. Colonoscopy follow-up rates rounded to integers. 
4. Differences in colonoscopy follow-up rates across remoteness areas may involve differences in form return and not a real difference in 
follow-up. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure 3.5: Colonoscopy follow-up after a positive FOBT result, by remoteness area, 2013–14 
Colonoscopy follow-up by Aboriginal and Torres Strait Islander status, language spoken 
at home and disability subgroups 
All 3 population subgroups had low numbers of participants with returned colonoscopy 
report forms. Care must be taken when interpreting results in these tables. 
Although Aboriginal and Torres Strait Islander participants had a lower rate of colonoscopy 
follow-up (56.5%) than non-Indigenous participants (68.2%), this difference should be 
interpreted with caution because the low number of Aboriginal and Torres Strait Islander 
participants recorded as having a colonoscopy may affect reliability (313) (Table A3.16). 
Participants who spoke English at home had a higher rate of colonoscopy follow-up (68.3%) 
than participants who spoke a language other than English (63.6%) (Table A3.17).  
Participants with a severe or profound activity limitation had a lower rate of colonoscopy 
follow-up (56.2%) than participants without such limitations (69.5%) (Table A3.18). Further 
analysis of referrals and reasons for non-referral data showed 8.9% of participants with a 
severe or profound activity limitation were not referred to colonoscopy in the first place, 
compared with 5.1% of participants without such limitations (data not shown). Participants 
Colonoscopy follow-up (per cent)
<45
45–54
55–64
65–74
75–84
85+
 National Bowel Cancer Screening Program: monitoring report 2013–14 31 
with a severe or profound activity limitation were more likely to cite limited life expectancy, 
a significant comorbidity or other medical condition as the reason for non-referral. They 
were less likely to report having had a recent colonoscopy as the reason for non-referral. 
Detailed histopathology follow-up  
Background 
If a NBCSP colonoscopy procedure removed specimens (such as polyps or adenomas) for 
analysis by histopathology, this is noted on the colonoscopy report form and the result of the 
histopathology analysis should then be returned to the NBCSP Register. However, there was 
a high rate of non-return of histopathology data, which may be due to the time lag in 
processing of samples, or poor form return from pathology laboratories. 
In recent years, several jurisdictions have started projects to improve histopathology data 
return, and this may have resulted in some jurisdictions having a higher proportion of 
confirmed colonoscopy outcomes than other jurisdictions.  
As the final diagnosis of cancers suspected at colonoscopy requires confirmation by 
histopathology, the suspected number of missing histopathology report forms means the 
confirmed cancer numbers in ‘Chapter 4 Bowel abnormality detection’ in Section 2 are likely 
to be under-reported, and under-reported by different degrees for different jurisdictions.  
For example, the recent Analysis of bowel cancer outcomes for the National Bowel Cancer Screening 
Program report (AIHW 2014a) found that for 2006–2008 invitees, the National Bowel Cancer 
Screening Program register had 337 recorded bowel cancer diagnoses. However, after 
linkage to national bowel cancer registry data, 1,575 of those invitees were found to have 
been diagnosed with bowel cancer. 
2013–14 histopathology follow-up 
Data recorded on the 18,288 colonoscopy report forms returned indicated samples were sent 
to histopathology for 9,942 participants (54.4%, data not shown). However, as at 
31 December 2014, only 4,145 histopathology report forms (41.7%) had been returned. 
Outcomes of these are discussed in ‘Section 2, Chapter 4 Bowel abnormality detection’. 
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4 Bowel abnormality detection 
What do we mean by bowel abnormality detection? 
Definition: The proportion of the eligible population invited to participate who returned a 
positive result from a correctly completed FOBT kit who then had an abnormality detected 
at follow-up. 
Rationale: Monitoring of abnormalities detected through the NBCSP by various 
stratifications is important to determine the effectiveness of the program, and to help 
determine the rate of false positive screening results. 
Data source: National Bowel Cancer Screening Program Register 
Data quality: Reporting of follow-up care by colonoscopists, surgeons and pathologists is 
not mandatory, so outcomes may be underestimated. (See ‘Data considerations’ in Section 1, 
for further details.) 
Guide to interpretation: Follow-up data are based on data recorded in the register to 
31 December 2014 for persons invited between 1 July 2013 and 30 June 2014. Due to the time 
delay between notification of a positive FOBT result, progression to colonoscopy and 
histopathological confirmation of results, outcome data are incomplete. 
Only outcomes from colonoscopies with returned report forms are included in Table A4.1; 
additional data from histopathology report forms are then included in Figure 4.1 and tables 
A4.2–A4.4. Due to the return of Medicare claim forms (see ‘Chapter 3 Follow-up of positive 
FOBT results’ in Section 2), additional colonoscopies are known to have taken place. 
However, they do not have outcome data available for reporting purposes.  
Persons are counted only once in the reporting period, even if they have more than 1 
abnormality detected during this period. Results confirmed by histopathology are reported 
in preference to results suspected by the colonoscopist. 
The abnormalities analysed in this chapter include polyps, adenomas and cancers 
diagnosed, and these are reported firstly using colonoscopy findings only, then with the 
addition of available histopathology confirmation data. The stage of confirmed cancer 
spread is not reported because sufficient staging data were not available.  
Some jurisdictions have started specific projects to improve the quantity and quality of the 
outcome data reported to the register in recent years. 
Key results 
• Of the 37,744 participants with a positive FOBT, 18,669 (50%) had a valid colonoscopy or 
histopathology report form recorded (Figure 3.3). A further 8,669 (23%) had other 
recorded outcomes (Figure 3.3 and Table A3.9). Recorded outcomes for the remaining 
10,406 (27%) people with a positive FOBT were unknown as at 31 December 2014. 
• Of those with outcome data, there were 149 participants diagnosed with a confirmed 
cancer, and 599 found with a suspected cancer, equating to 1 suspected or confirmed 
cancer for every 25 participants undergoing colonoscopy after a positive FOBT. 
• A further 1,691 participants had an advanced adenoma detected during colonoscopy. 
• The proportion of people for whom abnormalities were detected at colonoscopy 
increased with age and was higher for men than women. 
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Background information 
This chapter presents outcomes from the NBCSP as at 31 December 2014, based on those 
people invited who returned a positive FOBT and proceeded to colonoscopy. Program 
outcomes at key pathway points are summarised in Figure 4.1. 
Data for colonoscopy outcomes were derived from information recorded on the colonoscopy 
and histopathology report forms. From 2011, a new combined colonoscopy/histopathology 
form has been implemented, with the aim to improve the level of outcome data returned to 
the NBCSP Register. A new surgical resection form that will collect staging data is also to be 
implemented. 
Outcome information comes from the last points in the NBCSP pathway, and by 
31 December 2014 there were still colonoscopy and histopathology report forms yet to be 
returned. Ultimately, for cancers and adenomas detected at colonoscopy, the final diagnosis 
must be returned by histopathology. However, as reporting by clinicians to the NBCSP is not 
mandatory, a participant may have colonoscopy details, histopathology details or both 
recorded in the register. As a result, outcomes were classified in the following order: 
• ‘Confirmed cancers’ included suspected cancers at colonoscopy where a biopsy sample 
was taken that was confirmed as cancer by histopathology. Confirmed cancers also 
included any tissue samples from surgical resection or colonoscopic excisions that were 
confirmed to be cancerous, and subsequently reported by histopathology report form. 
Confirmed cancers were given a higher priority than suspected cancers.  
• ‘Suspected cancers’ were abnormalities detected at colonoscopy that the colonoscopist 
suspected to be cancer, but did not have histopathology outcomes available. Final 
diagnoses cannot be confirmed until histopathology results are returned, though bowel 
cancer is highly likely if the colonoscopist has suspected a cancerous lesion.  
• Adenomas confirmed by histopathology were categorised into 3 risk levels—advanced, 
small and diminutive. These risk levels are described in Appendix B.  
• Polyps awaiting histopathology were polyps detected at colonoscopy that had not had 
an associated histopathology report form returned. There is the potential that a number 
of these may be reclassified as adenomas by histopathology, so the number of adenomas 
counted may be under-reported. 
• Participants recorded as having no cancer or adenoma were those who had no polyps or 
suspected cancers detected at colonoscopy, or had polyps detected at colonoscopy that 
were confirmed as non-adenomatous by histopathology. 
Detailed analyses 
Three separate analyses regarding abnormality detection are presented here. As it is 
important to understand what results the colonoscopists are reporting initially, the first 
analysis (Table A4.1) reports findings when only analysing colonoscopy report forms. The 
second analysis (Figure 4.1 and tables A4.2 and A4.3) reports updated colonoscopy 
outcomes, when including histopathology results recorded as part of the colonoscopy 
procedures.  
Bowel abnormality detection at colonoscopy 
Of the 509,736 people invited into the NBCSP from 1 July 2013 to 30 June 2014 who returned 
FOBT kits, 37,744 were found to have blood in their samples (Figure 4.1), giving a positive 
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result that should be followed up by colonoscopy. However, only 18,288 (48.5%) of these had 
colonoscopy report form details recorded from which colonoscopy outcome data could be 
reported (Figure 3.3).  
Results from the 18,288 colonoscopies with a completed colonoscopy report form showed 
957 (5.2%) participants with a suspected cancer and 3,041 (16.6%) with 1 or more polyps 10 
millimetres or greater in size (Table A4.1). The cumulative risk of polyps (mainly adenomas) 
greater than 10 millimetres developing into bowel cancer within 10 years is considered to be 
8% (Stryker et al. 1987). The removal of these polyps alone could be estimated to have 
stopped a future bowel cancer from developing in about 243 of the participants screened in 
2013–14.  
There were a further 6,402 (35.0%) participants with polyps less than 10 millimetres, and 
4,120 (22.5%) other diagnoses such as diverticular disease or haemorrhoids (Table A4.1). 
About 1 in 5 participants with a positive FOBT who had a colonoscopy report form returned 
were found to have no abnormality.  
Specimen samples were sent to histopathology for most polyps and suspected cancers found 
(data not shown).  
Bowel abnormality detection, including histopathology 
After including the 4,145 histopathology report forms—many of which updated the original 
‘suspected’ colonoscopy diagnosis—the outcomes available for the 18,669 who had a 
colonoscopy or histopathology report form were as follows: 
• 149 participants had bowel cancer detected and confirmed by histopathology 
• 599 participants had suspected bowel cancers that were still awaiting histopathological 
diagnosis 
• 3,255 participants had an adenoma diagnosed by histopathology 
• 8,839 participants were found to have no abnormality (Figure 4.1 and Table A4.2). 
Results for another 5,827 participants awaiting histopathology outcomes for excised polyps 
were not available by 31 December 2014.  
In summary, of the 37,744 people with a positive FOBT: 
• 18,669 had diagnostic outcome information available (above) 
• 6,849 had a colonoscopy that was identified only through a NBCSP-related Medicare 
claim and therefore had no diagnostic outcome data (Figure 3.3) 
• 1,820 were not referred to colonoscopy (Table A3.9).  
Therefore, there were 10,406 (27.6%) people remaining who had received a positive FOBT 
but had no follow-up information recorded.  
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Recruitment
1,415,555 eligible invitations sent
Screening
509,736 participants returned an 
FOBT for screening
(36.0%)
Assessment
37,744 positive FOBTs
(7.5%)(a)
Diagnosis(b)
18,669 recorded 
colonoscopies
(49.5%)
Recorded colonoscopy outcomes
No cancer or adenoma 8,839 (47.3%)
Polyp awaiting histopathology 5,827  (31.2%)
Diminutive adenoma 1,325 (7.1%)
Small adenoma 239 (1.3%)
Advanced adenoma 1,691 (9.1%)
Suspected cancer 599 (3.2%)
Confirmed cancer 149 (0.8%)
 
(a) Based on the 501,289 participants who returned a valid FOBT. 
(b) Additionally, 6,849 participants underwent colonoscopic diagnostic assessment as identified through a Medicare claim. However, these 
were not included as there were no associated outcome data available for analysis. 
Notes 
1. Adenoma classifications are described in Appendix B. 
2. Figure is not to scale. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure 4.1: NBCSP participant outcomes, 2013–14 
Bowel abnormality detection, including histopathology, by population subgroups 
Bowel abnormality detection by state and territory 
As mentioned in the previous chapter, a number of jurisdictions have undertaken projects to 
improve their level of returned histopathology data. For example, some jurisdictions have 
much higher proportions of histopathology-confirmed abnormalities (adenomas and 
cancers) compared with others (Table A4.2). However, this is mainly due to having more 
complete data for participant outcomes, rather than a geographical link to higher bowel 
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cancer incidence. Therefore, outcome data completeness between jurisdictions needs to be 
taken into account when analysing Table A4.2. 
This report is the first to show an improvement in the percentage of histology-confirmed 
outcomes (and the percentage of polyps awaiting histopathology) compared with previous 
reports (AIHW 2009; AIHW 2010; AIHW 2012; AIHW 2013; AIHW 2014e). This may indicate 
that the jurisdictional projects to collect histopathology data are retrieving significant data. 
Bowel abnormality detection by age and sex 
Table A4.1 presents the recorded colonoscopy diagnoses for people invited into the NBCSP 
in 2013–14; these numbers do not take into account histopathology results that may have 
updated these diagnoses. Conversely, colonoscopist-suspected cancers shown in tables A4.2 
and A4.3 include only those that have not been updated by histopathology to their final 
diagnosis; therefore, Table A4.1 and the later tables show different numbers of suspected 
cancers.  
As would be expected from the known increase in bowel cancer incidence with age 
(see ’Chapter 6 Incidence of bowel cancer’ in Section 2), the incidence of abnormalities 
detected at colonoscopy increased with age; 2.8% of people aged 50 who had a colonoscopy 
returned a suspected or confirmed cancer outcome compared with 5.5% for those aged 65 
(Table A4.3).  
Similarly, men (4.8%) showed an incidence of suspected or confirmed cancers that was 
1.5 times that of women (3.2%) (Table A4.3). This was also consistent with known bowel 
cancer incidence in the Australian population. 
Cancer spread status 
While the scope of the NBCSP is to monitor participants up to the point of ‘definite 
diagnosis’ (Health 2015b), staging data for confirmed cancers are useful to determine the 
effectiveness of the NBCSP at detecting bowel cancers at a more treatable stage than for those 
diagnosed with symptomatic bowel cancers. Cancers diagnosed at earlier stages are 
generally associated with improved patient prognosis (Morris et al. 2007). 
A biopsy of a suspected cancer taken at colonoscopy is adequate to confirm a cancerous 
growth, but is not usually sufficient to obtain information on the stage and potential 
metastatic spread of the cancer. To gain these data, a sample from a surgical resection (or 
colonoscopic local excision) plus additional biopsies (for example, lymph node) are required. 
If available, these additional data can be recorded on the histopathology report form, but not 
the combined colonoscopy/histopathology form. 
Therefore, these data cannot be presented in this report due to limited cancer spread 
information currently available for the 149 participants with confirmed cancers. A new 
resection form will be implemented in 2015 which will allow information on the stage of 
cancers resected to be reported. 
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5 Adverse events 
What is the adverse event rate within the NBCSP? 
Definition: The proportion of eligible people invited between 1 July 2013 and 30 June 2014 
who had an adverse event (such as bleeding or perforation) reported after having a 
colonoscopy as part of NBCSP follow-up. 
Rationale: As with any invasive procedure, there is the risk of an adverse event occurring 
with a colonoscopy. Monitoring of adverse events through the NBCSP is important to 
ensure participant safety in the program.  
Data source: National Bowel Cancer Screening Program Register 
Data quality: Reporting of adverse events after a NBCSP colonoscopy is not mandatory. 
There is a risk an adverse event that occurs days or weeks after the colonoscopy (for 
example, unplanned hospital admission within 30 days of procedure) will not be associated 
with the NBCSP procedure, thus not be recorded in the register using the relevant NBCSP 
adverse event form. These issues would be expected to cause an underestimation of adverse 
events. (See ‘Section 1 Data considerations’ for further details.) 
Guide to interpretation: This chapter discusses the recorded adverse events for participants 
invited into the NBCSP who had a colonoscopy as a result of a positive FOBT. Adverse 
event data are based on data recorded in the register to 31 December 2014 for persons 
invited from 1 July 2013 to 30 June 2014. Due to the time delay between notification of a 
positive FOBT result and progression to colonoscopy or surgery, data may be incomplete. 
While the NBCSP records the number of people referred by PHCPs for various procedures 
(for example, sigmoidoscopy, barium enema, colonoscopy), only outcomes (including 
adverse outcomes) of colonoscopy are analysed in this report. 
Persons are counted only once in the reporting period, even if they have more than 1 
adverse event reported during this period. 
As per the adverse event form, unplanned hospital admissions after a colonoscopy are 
recorded only if they occurred within 30 days of the procedure. 
Key results 
• For participants invited in 2013–14, 69 out of 25,518 who underwent colonoscopy (about 
1 in every 370 participants undergoing colonoscopy) recorded an adverse event. 
• Bleeding was the most commonly recorded adverse event, with more recorded for men 
than women. 
• About 1 in every 1,109 participants undergoing colonoscopy required an unplanned 
hospital admission within 30 days of the colonoscopy. 
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Background information 
Colonoscopy is an invasive procedure performed after preparation of the bowel. The 
procedure is performed under sedation and is considered safe and relatively pain free. 
However, several complications and adverse events are associated with colonoscopy, 
including:  
• intolerance of the bowel preparation—some people develop dizziness, headaches or 
vomiting  
• reaction to the sedatives or anaesthetic—this is very uncommon but is of concern in 
people who have severe heart disease or lung disease  
• perforation (making a hole in the bowel wall) 
• major bleeding from the bowel—this can occur as a result of polyps being removed. 
The draft report of the Quality Working Group to the NBCSP noted that the 2 main 
complications arising were perforation and post-colonoscopic bleeding. A literature review 
by the Quality Working Group showed the risk of death associated with colonoscopy to be 
low, with incidence rates 0.03% or lower. The incidence rate of perforation was 0.07–0.30%, 
and bleeding was found to have an incidence rate of 0.03–2.00% (NBCSP-QWG 2009).  
Overall adverse events  
Table A5.1 shows adverse events recorded up to 31 December 2014 for people invited to 
participate in the NBCSP from 1 July 2013 to 30 June 2014. Of participants with a positive 
FOBT, 25,518 were known to have had a colonoscopy, with 69 (0.3%) having an adverse 
outcome recorded (data not shown). Men recorded more adverse events, with bleeding being 
the most common. The most frequent additional service required because of an adverse 
event was unplanned hospital admission within 30 days of colonoscopy.  
Overall, the recorded incidence rate of a bleeding event related to colonoscopy was 0.09%. 
Smaller numbers were recorded for all other types of adverse event. 
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6 Incidence of bowel cancer 
What do we mean by bowel cancer incidence? 
Definition: The number of people diagnosed with bowel cancer, reported for various 
population subgroups.  
Rationale: Monitoring of bowel cancer incidence statistics alongside the implementation of 
the NBCSP allows an understanding of the potential effect of screening on incidence. 
Data source: Australian Cancer Database (ACD) 
Data quality: Each Australian state and territory has legislation that makes the reporting of 
cancers (excluding basal cell and squamous cell carcinomas of the skin) mandatory. The 
AIHW compiles and maintains the ACD, in partnership with the Australasian Association 
of Cancer Registries, whose member registries provide data to the AIHW annually. This 
began with cases first diagnosed in 1982, and the ACD currently has data on cancers 
diagnosed up to and including 2011 – though the 2010 and 2011 incidence counts (and 2009 
death-certificate-only cases) for New South Wales and the Australian Capital Territory are 
estimates. 
Guide to interpretation: Bowel cancer comprises cancer of the colon and cancer of the 
rectum. It is also known as colorectal cancer. An objective of the NBCSP is to reduce the 
incidence of bowel cancer in Australia. Positive FOBTs and subsequent colonoscopies 
identify and remove polyps and adenomas that might develop into cancer, thereby 
reducing future incidence. However, it is expected that during the first few years of the 
NBCSP, incidence rates may increase, as pre-existing, developed cancers (in addition to 
polyps and adenomas) that had not resulted in symptoms are found earlier through 
screening. This should stabilise over time as retesting of participants occurs (for example,  
50 year olds who are reinvited when they turn 55).  
This chapter provides bowel cancer incidence data, grouped by age, sex and population 
subgroups. See the AIHW National Bowel Cancer Screening Program monitoring report:  
2013–14 supplementary tables webpage for additional tables. 
Detailed numbers and rates for bowel cancer in Australia over time are in the AIHW 
Australian Cancer Incidence and Mortality workbook for colorectal (bowel) cancer—an 
interactive workbook that currently includes incidence data from 1982 to 2011 and mortality 
data from 1968 to 2012. It is available at <www.aihw.gov.au/acim-books>.  
Key results 
In 2011: 
• 15,151 people were diagnosed with bowel cancer (8,351 males; 6,800 females). 
• Bowel cancer accounted for 13% of all invasive cancers diagnosed, making it the second 
most commonly diagnosed cancer in Australia, after prostate cancer. 
• The age-standardised incidence rate for bowel cancer was 73 per 100,000 males, 52 per 
100,000 females and 62 per 100,000 persons. 
• The risk of being diagnosed by the age of 85 was 1 in 10 for males and 1 in 15 for females.  
• The average age of diagnosis was 69 for males and 71 for females. 
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Detailed bowel cancer incidence analyses 
Bowel cancer incidence by state and territory 
The incidence of bowel cancer varied between jurisdictions in the period 2007 to 2011 
(supplementary tables S1.3a–S1.4c). Tasmania (78 cases per 100,000 persons) and Queensland 
(65) had the highest age-standardised incidence rates, and the Northern Territory (54) had 
the lowest.  
Bowel cancer incidence by age and sex 
In 2011, and similar to previous years, newly diagnosed cases of bowel cancer were relatively 
rare in people under 45; however, the incidence rate increased sharply for older age groups 
(Figure 6.1). The highest incidence rates were in people aged 80 and over (more than 500 
cases per 100,000 population). 
 
Source: AIHW Australian Cancer Database. 
Figure 6.1: Age-specific incidence rates of bowel cancer, Australia, 2011 
Trends 
The number of new cases of bowel cancer for males increased between 1997 and 2011 by 
37%, with incidence in females showing a similar increase (35%). While the age-standardised 
rates have decreased gradually between 1997 and 2011 for males (0.4% per year) and for 
females (0.2% per year), the increase in the number of cases due to the ageing population in 
Australia means the burden bowel cancer places on the health-care system is still increasing 
(Figure 6.2 and supplementary tables S1.1a–S1.2c).  
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Note: Rates age-standardised to the Australian 2001 population. 
Source: AIHW Australian Cancer Database. 
Figure 6.2: Incidence and age-standardised incidence rates of bowel cancer, Australia, 1997–2011  
Analysis of NBCSP data shows 454 suspected cancers were detected within the NBCSP in 
2011. Due to limitations in histopathology report form return, it is not possible to accurately 
determine how many of these were actually confirmed and thus registered in the ACD as 
bowel cancers. (The NBCSP data for 2011 show 138 of these were confirmed by NBCSP 
histopathology report form).  
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7 Mortality from bowel cancer 
What do we mean by bowel cancer mortality? 
Definition: The number of people who have died from bowel cancer (as the underlying 
cause of death), by various stratifications.  
Rationale: Changes in the number and rate of bowel cancer deaths are monitored to help 
understand the effect of interventions (such as screening and improved treatments). 
Data source: National Mortality Database (NMD) 
Data quality: See Appendix C for further information on mortality data.  
Guide to interpretation: Bowel cancer mortality data from the NMD includes deaths up to 
2012. The denominator is based on ABS estimated resident populations up to 2012. As these 
data are for years prior to the screening data in this report, these outcomes are not currently 
related in any way to the screening activities presented in this report. However, they 
provide a baseline against which to monitor future outcomes. 
A major objective of the NBCSP is to reduce mortality from bowel cancer in Australia 
through early detection and treatment of bowel cancers, and through identifying and 
treating polyps and adenomas that might develop into cancer. It is hoped these outcomes 
will eventually result in a reduction in the number of people who die from bowel cancer; 
however, it may take many years for this effect to become apparent, as polyps and 
adenomas detected at screening now may not have become cancers resulting in death for 
many years. However, even then it is not possible to provide a causal link between the 
NBCSP and any changes in mortality rates. 
See the AIHW National Bowel Cancer Screening Program monitoring report: 2013–14 
supplementary tables webpage for additional tables. As mortality data are enumerated by age 
at death, not age at diagnosis, it is not accurate to analyse NBCSP performance by looking at 
mortality rates of people aged 50, 55, 60 and 65; the NBCSP target ages were included for 
illustrative purposes only. 
Key results 
In 2012: 
• There were 3,980 deaths from bowel cancer in Australia (2,208 males; 1,772 females). 
Bowel cancer accounted for 9% of all deaths from invasive cancers, second only to lung 
cancer. 
• The age-standardised death rate was 19 per 100,000 males and 12 per 100,000 females.  
• The risk of dying from bowel cancer by the age of 85 was 1 in 38 for males, 1 in 61 for 
females and 1 in 48 overall. 
 National Bowel Cancer Screening Program: monitoring report 2013–14 43 
Detailed bowel cancer mortality analyses 
Bowel cancer mortality by state and territory 
In 2008–2012, Tasmania and the Northern Territory experienced the highest 
age-standardised rate of deaths from bowel cancer (19 deaths per 100,000 population). 
Western Australia experienced the lowest age-standardised rate of deaths from bowel cancer 
(13) (supplementary tables S2.3a–S2.4c). 
Bowel cancer mortality by age and sex 
Death from bowel cancer is relatively rare before 50 years of age, with 95% of deaths for 
those aged 50 or over (Figure 7.1). In 2012, the highest age-specific death rates were in the 
oldest age groups—people aged 80–84 (139 per 100,000 population) and 85 and over (208 per 
100,000). There were 1,193 deaths in the 50–69 year age group, 30% of all bowel cancer 
deaths. This age group is currently targeted by the NBCSP; however, the outcomes of 
screening participation may also affect mortality rates in older ages. 
 
Notes 
1. Deaths registered in 2012 are based on preliminary versions of cause-of-death data and are subject to further revision by the ABS. 
Source: AIHW National Mortality Database. 
Figure 7.1: Age-specific mortality rates for bowel cancer (ICD-10 C18–C20), Australia, 2012 
Trends 
Between 1998 and 2012, the age-standardised death rate from bowel cancer fell by an average 
of 2.7% per year for males, 2.8% per year for females, and 2.7% per year overall (Figure 7.2 
and supplementary tables S3.1a–S3.2c). It is expected the NBCSP will, in time, continue to 
contribute to this decline in the death rate.  
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Notes 
1. Rates age-standardised to the Australian 2001 population and are expressed per 100,000 population. 
2. Deaths registered in 1998–2010 are based on the final version of cause-of-death data; deaths registered in 2011 and 2012 are based on 
revised and preliminary versions, respectively and are subject to further revision by the ABS. 
Source: AIHW National Mortality Database. 
Figure 7.2: Age-standardised mortality rates for bowel cancer, Australia, 1998–2012  
Bowel cancer mortality by region 
In 2008–2012, age-standardised deaths from bowel cancer were higher in Inner regional and 
Outer regional areas of Australia, each with 17 deaths per 100,000 (supplementary tables 
S3.5a–S3.6c). Age-standardised death rates were lowest in Very remote areas (11 deaths 
per 100,000). 
Bowel cancer mortality of Aboriginal and Torres Strait Islander peoples 
Information in the NMD on Indigenous status is currently considered of sufficient quality for 
reporting for New South Wales, Queensland, Western Australia, South Australia and the 
Northern Territory only. 
In 2008–2012 in these jurisdictions, the age-standardised rate of deaths from bowel cancer 
was lower for Aboriginal and Torres Strait Islander people (11 deaths per 100,000) than for 
non-Indigenous people (16 deaths per 100,000) (supplementary tables S3.7a and S3.7b).  
Bowel cancer mortality-to-incidence ratio 
The trends in bowel cancer mortality-to-incidence ratios have been steadily falling for many 
years (Figure 7.3). Any change in these rates due to the NBCSP would depend on the 
number of people screened, the number of precancerous polyps removed and the stage of 
growth at which cancers were detected. However, it would be expected that, at least until 
biennial screening is fully implemented, the NBCSP would assist in ongoing reductions in 
these ratios. 
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Notes 
1. Ratios calculated from rates, age-standardised to the Australian 2001 population. 
2. Deaths registered in 1998–2010 are based on the final version of cause-of-death data; deaths registered in 2011 are based on revised 
version and are subject to further revision by the ABS. 
Source: AIHW Australian Cancer Database and AIHW National Mortality Database. 
Figure 7.3: Trends in mortality-to-incidence ratios for bowel cancer, Australia, 1998–2011  
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8 Expenditure on the NBCSP 
Expenditure on Australia’s cancer screening programs  
In Australia, there are 3 cancers for which screening is recommended—breast, cervical and 
bowel. Each cancer has a national screening program, with both Australian government and 
state and territory government components.  
The National Bowel Cancer Screening Program (NBCSP) uses a different program model to 
the 2 other screening programs. It is funded through direct appropriation from the 
Australian government, plus a National Partnership payment for the participant follow-up 
functions. NBCSP invitations are managed and sent out centrally, with states and territories 
providing local program promotion and a follow up function for those who receive a 
positive screening result.  
For the BreastScreen Australia Program and the National Cervical Screening Program 
(NCSP), the Australian government provides funding to the states and territories for a range 
of public health services through National Health Reform payments (known as National 
Specific Purpose payments prior to 1 July 2012) and National Partnership payments.  State 
and territory governments have full discretion over the application of National Health 
Reform payments for public health funding, including the amount expended on the 
BreastScreen Australia Program and the NCSP. 
In addition to the funding provided by the Australian government, state and territory 
governments also contribute funding towards these programs. 
Table 8.1 shows expenditure for the 3 national cancer screening programs (expenditure by 
Australian and state and territory governments combined), as well as total expenditure on 
cancer screening for the 2012–13 financial year. 
Table 8.1: Government funding for cancer screening programs, 2012–13, $ million 
Screening programs Expenditure 2012–13 
BreastScreen Australia(a) 204.9 
National Cervical Screening Program(b) 89.3 
National Bowel Cancer Screening Program(c) 32.9 
Total 327.1 
(a) Excludes mammography for breast cancer screening that occurs outside BreastScreen Australia. 
(b) Excludes the proportion of the costs associated with GP, specialist and nurse attendances that would have been for Pap smears. 
(c) Excludes MBS flow-on costs as well as bowel screening that occurs outside the National Bowel Cancer Screening Program. 
Note: These expenditure data only include recurrent expenditure; health infrastructure payments for cancer have been excluded as well as any 
health workforce expenditure. 
Sources: AIHW Health expenditure database; Medicare Australia Statistics. 
NBCSP expenditure 
In 2012–13 an estimated $32.9 million was spent on the NBCSP (Table 8.1). As the rollout of 
biennial screening for those aged 50–74 expands (due to be completed by 2020), this amount 
will increase. Care should be taken to consider the inclusions and exclusions detailed in the 
notes for Table 8.1, as well as in the introductory text, to ensure the limitations of these data 
are clear. 
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Appendix A: Supporting data 
A1: Participation tables and figures 
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Table A1.1: Screening invitation, by state and territory, 2013–14 
 NSW Vic Qld WA SA Tas ACT NT Australia 
Invitations issued to the eligible population(a)(b) 
50 years 148,451 107,495 88,781 44,060 32,407 9,718 7,293 3,432 441,637 
55 years 99,513 70,853 58,623 29,403 22,175 6,931 5,000 2,702 295,200 
60 years 117,353 83,581 69,170 34,912 26,781 8,514 5,679 2,925 348,915 
65 years 112,039 79,765 66,216 30,547 25,892 8,368 5,185 1,791 329,803 
Total 477,356 341,694 282,790 138,922 107,255 33,531 23,157 10,850 1,415,555 
 Persons suspended(c) 
50 years 1,200 1,020 842 409 347 95 75 32 4,020 
55 years 1,532 1,216 1,050 518 422 143 119 37 5,037 
60 years 1,588 1,081 1,081 500 450 140 98 27 4,965 
65 years 2,132 1,515 1,315 611 623 191 128 31 6,546 
Total 6,452 4,832 4,288 2,038 1,842 569 420 127 20,568 
Persons opting off(d) 
50 years 2,851 2,147 1,766 804 678 217 176 42 8,681 
55 years 1,593 1,104 1,124 485 340 112 84 28 4,870 
60 years 2,797 1,835 1,848 781 599 210 138 45 8,253 
65 years 7,140 4,990 4,419 1,870 1,606 565 341 77 21,008 
Total 14,381 10,076 9,157 3,940 3,223 1,104 739 192 42,812 
Persons participating(e) 
50 years 37,159 31,149 23,447 12,942 10,592 2,853 2,097 660 120,899 
55 years 33,127 26,540 20,449 11,207 9,273 2,807 1,928 728 106,059 
60 years 46,341 36,638 29,389 15,764 13,153 4,144 2,590 967 148,986 
65 years 41,900 32,176 27,123 13,350 12,533 3,946 2,222 542 133,792 
Total 158,527 126,503 100,408 53,263 45,551 13,750 8,837 2,897 509,736 
Total respondents(f) 
50 years 41,210 34,316 26,055 14,155 11,617 3,165 2,348 734 133,600 
55 years 36,252 28,860 22,623 12,210 10,035 3,062 2,131 793 115,966 
60 years 50,726 39,554 32,318 17,045 14,202 4,494 2,826 1,039 162,204 
65 years 51,172 38,681 32,857 15,831 14,762 4,702 2,691 650 161,346 
Total 179,360 141,411 113,853 59,241 50,616 15,423 9,996 3,216 573,116 
(a) Invitations to participate in screening were issued from 1 July 2013 to 30 June 2014 to members of the Australian population (registered as 
Australian citizens or migrants in the Medicare enrolment file, or who are registered with a Department of Veterans’ Affairs gold card) who 
turned 50, 55, 60 or 65 from 1 January 2013 to 30 June 2014. 
(b) There were 910 invitations sent to those not of the 4 target ages, or to addresses overseas (making 1,416,465 invitations in total). These 
were excluded from the eligible population and further analysis. 
(c) ‘Persons suspended’ refers to the eligible population invited who did not return a faecal occult blood test (FOBT) kit, but elected to suspend 
participation until a later date.  
(d) ‘Persons opting off’ refers to the eligible population invited who did not return an FOBT kit, but elected to opt off. 
(e) ‘Persons participating’ refers to the eligible population invited who returned an FOBT kit for analysis, regardless of whether it was correctly 
completed or if they later suspended or opted off. 
(f) ‘Total respondents’ refers to the eligible population invited who returned any response (returned an FOBT kit, or suspension/opt-off request). 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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Table A1.2: Crude participation, by state and territory, 2013–14 
 NSW Vic Qld WA SA Tas ACT NT Australia 
Males 
50 years Number 17,487 14,165 11,113 6,146 4,838 1,278 963 305 56,295 
 Per cent 23.5 26.4 25.0 27.4 29.7 26.4 26.9 17.3 25.4 
55 years Number 15,387 12,191 9,500 5,278 4,282 1,247 850 358 49,093 
 Per cent 30.9 34.5 32.5 35.8 38.9 36.9 35.4 25.6 33.3 
60 years Number 21,386 16,609 13,653 7,377 5,976 1,876 1,185 486 68,548 
 Per cent 36.7 40.3 39.6 41.8 45.2 45.0 42.7 31.2 39.5 
65 years Number 19,926 14,751 12,964 6,425 5,888 1,780 1,030 292 63,056 
 Per cent 35.7 37.8 38.9 41.6 46.1 44.0 40.6 30.2 38.5 
Total Number 74,186 57,716 47,230 25,226 20,984 6,181 4,028 1,441 236,992 
 Per cent 31.1 34.1 33.4 35.9 39.4 37.6 35.7 25.4 33.6 
Females 
50 years Number 19,672 16,984 12,334 6,796 5,754 1,575 1,134 355 64,604 
 Per cent 26.6 31.6 27.8 31.4 35.7 32.3 30.5 21.3 29.3 
55 years Number 17,740 14,349 10,949 5,929 4,991 1,560 1,078 370 56,966 
 Per cent 35.7 40.4 37.3 40.5 44.7 44.0 41.5 28.3 38.5 
60 years Number 24,955 20,029 15,736 8,387 7,177 2,268 1,405 481 80,438 
 Per cent 42.3 47.2 45.4 48.6 53.0 52.2 48.4 35.2 45.8 
65 years Number 21,974 17,425 14,159 6,925 6,645 2,166 1,192 250 70,736 
 Per cent 39.1 42.8 43.1 45.8 50.7 50.1 45.0 30.3 42.7 
Total Number 84,341 68,787 53,178 28,037 24,567 7,569 4,809 1,456 272,744 
 Per cent 35.3 39.9 37.7 40.8 45.5 44.3 40.5 28.2 38.5 
Persons 
50 years Number 37,159 31,149 23,447 12,942 10,592 2,853 2,097 660 120,899 
 Per cent 25.0 29.0 26.4 29.4 32.7 29.4 28.8 19.2 27.4 
55 years Number 33,127 26,540 20,449 11,207 9,273 2,807 1,928 728 106,059 
 Per cent 33.3 37.5 34.9 38.1 41.8 40.5 38.6 26.9 35.9 
60 years Number 46,341 36,638 29,389 15,764 13,153 4,144 2,590 967 148,986 
 Per cent 39.5 43.8 42.5 45.2 49.1 48.7 45.6 33.1 42.7 
65 years Number 41,900 32,176 27,123 13,350 12,533 3,946 2,222 542 133,792 
 Per cent 37.4 40.3 41.0 43.7 48.4 47.2 42.9 30.3 40.6 
Total Number 158,527 126,503 100,408 53,263 45,551 13,750 8,837 2,897 509,736 
 Per cent 33.2 37.0 35.5 38.3 42.5 41.0 38.2 26.7 36.0 
Notes 
1. Participants in the program were defined as members of the eligible population who returned a completed FOBT kit, regardless of whether it 
was correctly completed.  
2. Percentages equal people participating as a proportion of the total number of the eligible population who were invited to screen. This includes 
people who suspended or opted off. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A1.1: Participation, by weeks since invitation, using Kaplan–Meier estimates,  
by state and territory, 2013–14  
 
 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A1.2: Participation, by weeks since invitation, using Kaplan–Meier estimates,  
by age, 2013–14 
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Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A1.3: Participation, by weeks since invitation, using Kaplan–Meier estimates,  
by sex, 2013–14 
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Table A1.3: Crude participation, by remoteness area, 2013–14  
 Remoteness area  
 Major cities Inner regional Outer regional Remote Very remote Unknown Total 
Males 
50 years Number 39,686 10,483 4,728 629 204 565 56,295 
 Per cent 25.6 25.9 24.4 22.5 16.1 25.1 25.4 
55 years Number 33,202 9,912 4,608 619 203 549 49,093 
 Per cent 33.2 34.1 33.3 30.1 22.7 33.3 33.3 
60 years Number 44,393 15,032 7,155 863 309 796 68,548 
 Per cent 38.7 42.0 40.6 37.3 30.0 38.6 39.5 
65 years Number 40,003 14,786 6,692 723 227 625 63,056 
 Per cent 37.3 41.4 41.1 36.4 29.0 32.2 38.5 
Total Number 157,284 50,213 23,183 2,835 943 2,535 236,992 
 Per cent 33.0 35.6 34.5 31.0 23.7 32.1 33.6 
Females 
50 years Number 45,148 12,521 5,542 674 209 510 64,604 
 Per cent 29.1 30.6 30.0 25.9 18.3 26.3 29.3 
55 years Number 38,118 12,039 5,378 685 220 526 56,966 
 Per cent 37.8 41.0 40.0 36.4 26.2 37.5 38.5 
60 years Number 52,744 17,959 7,864 804 294 773 80,438 
 Per cent 44.5 49.7 48.0 42.8 33.6 42.8 45.8 
65 years Number 45,344 16,947 6,986 659 184 617 70,736 
 Per cent 40.7 47.6 46.3 40.3 28.7 40.5 42.7 
Total Number 181,354 59,466 25,770 2,822 906 2,426 272,744 
 Per cent 37.3 41.9 40.6 35.3 25.9 36.4 38.5 
Persons 
50 years Number 84,834 23,004 10,270 1,303 412 1,075 120,899 
 Per cent 27.3 28.3 27.1 24.1 17.1 25.7 27.4 
55 years Number 71,320 21,950 9,987 1,304 422 1,075 106,059 
 Per cent 35.5 37.6 36.6 33.1 24.3 35.3 35.9 
60 years Number 97,137 32,991 15,019 1,667 603 1,569 148,986 
 Per cent 41.7 45.9 44.1 39.8 31.7 40.6 42.7 
65 years Number 85,347 31,733 13,678 1,382 411 1,242 133,792 
 Per cent 39.0 44.5 43.6 38.2 28.9 35.9 40.6 
Total Number 338,639 109,678 48,953 5,656 1,848 4,961 509,736 
 Per cent 35.2 38.8 37.5 33.0 24.7 34.1 36.0 
Notes  
1. Percentages equal the number of people returning a completed FOBT kit (regardless of whether it was correctly completed) as a proportion 
of the eligible population invited to screen. 
2. The residential postcodes of invitees and respondents were mapped to remoteness areas in the 2011 Australian Statistical Geography 
Standard remoteness structure through a postal area correspondence. Those that could not be mapped were included in the ‘Unknown’ 
column. 
3. Discrepancies may occur between totals and sums of the component items due to rounding—see ‘Geographical classification’, Appendix C. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014.  
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Notes 
1. Rate per remoteness area is an average of participation across that remoteness area. 
2. Participation rates rounded to integers. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A1.4a: Crude participation, by remoteness area, New South Wales, 2013–14 
 
 
Notes 
1. Rate per remoteness area is an average of participation across that remoteness area. 
2. Participation rates rounded to integers. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A1.4b: Crude participation, by remoteness area, Victoria, 2013–14 
Crude participation (per cent)
<27
27–30
31–34
35–38
39–42
43+
Crude participation (per cent)
<27
27–30
31–34
35–38
39–42
43+
 54 National Bowel Cancer Screening Program: monitoring report 2013–14 
 
Notes 
1. Rate per remoteness area is an average of participation across that remoteness area. 
2. Participation rates rounded to integers. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A1.4c: Crude participation, by remoteness area, Queensland, 2013–14 
 
 
Notes 
1. Rate per remoteness area is an average of participation across that remoteness area. 
2. Participation rates rounded to integers. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A1.4d: Crude participation, by remoteness area, Western Australia, 2013–14 
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Notes 
1. Rate per remoteness area is an average of participation across that remoteness area. 
2. Participation rates rounded to integers. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A1.4e: Crude participation, by remoteness area, South Australia, 2013–14 
 
 
Notes 
1. Rate per remoteness area is an average of participation across that remoteness area. 
2. Participation rates rounded to integers. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A1.4f: Crude participation, by remoteness area, Tasmania, 2013–14 
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Notes 
1. Rate per remoteness area is an average of participation across that remoteness area. 
2. Participation rates rounded to integers. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A1.4g: Crude participation, by remoteness area, Australian Capital Territory, 2013–14 
 
 
Notes 
1. Rate per remoteness area is an average of participation across that remoteness area. 
2. Participation rates rounded to integers. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A1.4h: Crude participation, by remoteness area, Northern Territory, 2013–14 
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Table A1.4: Crude participation, by socioeconomic status area, 2013–14 
 Socioeconomic status area  
 1 (lowest) 2 3 4 5 (highest) Unknown Total 
Males 
50 years Number 9,648 10,042 11,035 11,915 12,927 728 56,295 
 Per cent 23.0 23.9 25.2 26.5 28.2 25.8 25.4 
55 years Number 9,104 9,532 9,600 9,806 10,361 690 49,093 
 Per cent 31.6 32.8 32.8 34.0 35.3 34.4 33.3 
60 years Number 12,863 13,957 13,406 13,465 13,860 997 68,548 
 Per cent 37.6 39.6 39.4 40.4 40.7 39.3 39.5 
65 years Number 12,372 13,255 12,286 11,995 12,342 806 63,056 
 Per cent 37.1 39.3 38.5 39.3 38.5 34.2 38.5 
Total Number 43,987 46,786 46,327 47,181 49,490 3,221 236,992 
 Per cent 31.8 33.4 33.3 34.3 35.0 33.1 33.6 
Females 
50 years Number 10,860 11,844 12,629 13,642 14,929 700 64,604 
 Per cent 27.1 28.3 28.8 30.5 31.6 28.4 29.3 
55 years Number 10,303 10,989 11,095 11,595 12,307 677 56,966 
 Per cent 36.2 37.8 38.0 39.6 40.7 38.7 38.5 
60 years Number 14,856 16,392 15,848 15,778 16,568 996 80,438 
 Per cent 43.6 46.2 45.7 46.7 47.0 44.8 45.8 
65 years Number 13,626 14,940 13,774 13,448 14,159 789 70,736 
 Per cent 41.0 43.9 42.5 43.0 42.8 42.0 42.7 
Total Number 49,645 54,165 53,346 54,463 57,963 3,162 272,744 
 Per cent 36.6 38.6 38.1 39.2 39.8 38.0 38.5 
Persons 
50 years Number 20,508 21,886 23,664 25,557 27,856 1,428 120,899 
 Per cent 25.0 26.1 27.0 28.5 29.9 27.0 27.4 
55 years Number 19,407 20,521 20,695 21,401 22,668 1,367 106,059 
 Per cent 33.9 35.3 35.4 36.8 38.1 36.4 35.9 
60 years Number 27,719 30,349 29,254 29,243 30,428 1,993 148,986 
 Per cent 40.6 42.9 42.6 43.6 43.9 41.8 42.7 
65 years Number 25,998 28,195 26,060 25,443 26,501 1,595 133,792 
 Per cent 39.0 41.6 40.5 41.2 40.7 37.7 40.6 
Total Number 93,632 100,951 99,673 101,644 107,453 6,383 509,736 
 Per cent 34.1 36.0 35.7 36.7 37.4 35.4 36.0 
Notes  
1. Percentages equal the number of people returning a completed FOBT kit as a proportion of the total number of the eligible population who 
were invited to screen. 
2. An invitee’s socioeconomic status area was classified by mapping their residential postcode (through a postal area) to the Australian Bureau 
of Statistics (ABS) Index of Relative Socio-economic Disadvantage (IRSD) for 2011. Those that could not be mapped were included in the 
‘Unknown’ column.  
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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Table A1.5: Proportion of participants who indicated Aboriginal and Torres Strait Islander status, 2013–14 
 NBCSP participants  2011 Census 
 Indigenous Non-Indigenous Not stated Total 
Number  
 Indigenous Non-Indigenous Not stated 
 Number Per cent Number Per cent Number Per cent  Per cent 
Males            
50 years 553 1.0 53,719 95.4 2,023 3.6 56,295  1.7 93.1 5.2 
55 years 498 1.0 47,725 97.2 870 1.8 49,093  1.5 93.4 5.1 
60 years 619 0.9 66,618 97.2 1,311 1.9 68,548  1.3 93.8 4.9 
65 years 552 0.9 60,408 95.8 2,096 3.3 63,056  1.0 94.2 4.9 
Total 2,222 0.9 228,470 96.4 6,300 2.7 236,992  1.4 93.5 5.0 
Females              
50 years 696 1.1 62,436 96.6 1,472 2.3 64,604  1.9 94.2 3.9 
55 years 534 0.9 55,708 97.8 724 1.3 56,966  1.6 94.5 4.0 
60 years 688 0.9 78,719 97.9 1,031 1.3 80,438  1.4 94.6 3.9 
65 years 602 0.9 68,422 96.7 1,712 2.4 70,736  1.1 94.7 4.2 
Total 2,520 0.9 265,285 97.3 4,939 1.8 272,744  1.5 94.5 4.0 
Persons            
50 years 1,249 1.0 116,155 96.1 3,495 2.9 120,899  1.8 93.7 4.5 
55 years 1,032 1.0 103,433 97.5 1,594 1.5 106,059  1.5 93.9 4.5 
60 years 1,307 0.9 145,337 97.6 2,342 1.6 148,986  1.3 94.2 4.4 
65 years 1,154 0.9 128,830 96.3 3,808 2.8 133,792  1.0 94.4 4.5 
Total 4,742 0.9 493,755 96.9 11,239 2.2 509,736  1.5 94.0 4.5 
Notes  
1. National Bowel Cancer Screening Program (NBCSP) percentages equal the number of people returning a completed FOBT who indicated their Aboriginal and Torres Strait Islander status as a proportion 
of all people returning an FOBT (regardless of whether they were correctly completed).  
2. NBCSP Aboriginal and Torres Strait Islander status was reported by the participant on the returned participant details form. Participants who did not indicate Aboriginal and Torres Strait Islander status 
were included in the ‘Not stated’ column. 
3. Indigenous status proportions. as recorded at the 2011 Australian Census of Population and Housing. are included for comparative purposes. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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Table A1.6: Proportion of participants who indicated preferred language spoken at home, 2013–14 
 NBCSP participants  2011 Census 
 
Language other than 
English English Total 
Number  
 Language other 
than English English Not stated 
 Number Per cent Number Per cent  Per cent 
Males          
50 years 8,342 14.8 47,953 85.2 56,295  16.4 78.3 5.3 
55 years 7,703 15.7 41,390 84.3 49,093  15.8 79.1 5.1 
60 years 9,684 14.1 58,864 85.9 68,548  14.4 80.8 4.8 
65 years 7,631 12.1 55,425 87.9 63,056  14.5 80.8 4.7 
Total 33,360 14.1 203,632 85.9 236,992  15.4 79.6 5.0 
Females            
50 years 10,651 16.5 53,953 83.5 64,604  17.4 78.9 3.7 
55 years 9,313 16.3 47,653 83.7 56,966  17.6 78.6 3.8 
60 years 11,883 14.8 68,555 85.2 80,438  16.2 80.1 3.7 
65 years 8,565 12.1 62,171 87.9 70,736  15.5 80.6 3.9 
Total 40,412 14.8 232,332 85.2 272,744  16.8 79.4 3.8 
Persons          
50 years 18,993 15.7 101,906 84.3 120,899  16.9 78.6 4.5 
55 years 17,016 16.0 89,043 84.0 106,059  16.7 78.8 4.4 
60 years 21,567 14.5 127,419 85.5 148,986  15.3 80.4 4.2 
65 years 16,196 12.1 117,596 87.9 133,792  15.0 80.7 4.3 
Total 73,772 14.5 435,964 85.5 509,736  16.1 79.5 4.4 
Notes  
1. NBCSP percentages equal the number of people returning a completed FOBT who indicated their preferred language spoken at home as a proportion of all people returning 
an FOBT (regardless of whether they were correctly completed).  
2. NBCSP preferred language spoken at home was reported by the participant on the returned participant details form. Participants who did not indicate preferred language 
spoken at home were assumed to speak English. 
3. Language spoken at home proportions as recorded at the 2011 Australian Census of Population and Housing are included for comparative purposes. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
 60 National Bowel Cancer Screening Program: monitoring report 2013–14 
Table A1.7: Proportion of participants who indicated disability status, 2013–14 
 NBCSP participants  2011 Census 
 
Severe or profound 
activity limitation 
No severe or profound 
activity limitation Not stated Total 
Number  
 Severe or profound 
activity limitation 
No severe or profound 
activity limitation Not stated 
 Number Per cent Number Per cent Number Per cent  Per cent 
Males            
50 years 2,050 3.6 49,941 88.7 4,304 7.6 56,295  3.1 91.0 5.9 
55 years 1,990 4.1 43,493 88.6 3,610 7.4 49,093  3.9 90.5 5.6 
60 years 3,389 4.9 60,383 88.1 4,776 7.0 68,548  5.7 89.0 5.3 
65 years 4,067 6.4 54,694 86.7 4,295 6.8 63,056  8.1 86.7 5.2 
Total 11,496 4.9 208,511 88.0 16,985 7.2 236,992  4.9 89.5 5.5 
Females              
50 years 2,829 4.4 58,049 89.9 3,726 5.8 64,604  3.3 92.4 4.3 
55 years 2,803 4.9 50,960 89.5 3,203 5.6 56,966  4.3 91.4 4.3 
60 years 4,299 5.3 71,969 89.5 4,170 5.2 80,438  5.5 90.4 4.2 
65 years 4,109 5.8 63,074 89.2 3,553 5.0 70,736  6.2 89.5 4.4 
Total 14,040 5.1 244,052 89.5 14,652 5.4 272,744  4.7 91.1 4.3 
Persons            
50 years 4,879 4.0 107,990 89.3 8,030 6.6 120,899  3.2 91.7 5.1 
55 years 4,793 4.5 94,453 89.1 6,813 6.4 106,059  4.1 91.0 4.9 
60 years 7,688 5.2 132,352 88.8 8,946 6.0 148,986  5.6 89.7 4.7 
65 years 8,176 6.1 117,768 88.0 7,848 5.9 133,792  7.1 88.1 4.8 
Total 25,536 5.0 452,563 88.8 31,637 6.2 509,736  4.8 90.3 4.9 
Notes  
1. NBCSP percentages equal the number of people returning a completed FOBT who indicated their disability status as a proportion of all people returning an FOBT (regardless of whether they were correctly completed).  
2. NBCSP disability status was reported by the participant on the participant details form. Participants who did not indicate disability status are included in the ‘Not stated’ column. 
3. A ‘profound’ activity limitation indicates that a person always needs assistance with self-care, movement and/or communications activities. A ‘severe’ activity limitation indicates that a person sometimes needs assistance 
with these activities.  
4. Activity limitation status proportions, as recorded at the 2011 Australian Census of Population and Housing, are included for comparative purposes. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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Table A1.8: Participation rates for 2013-14 invitees, based on previous invitation and 
participation status 
   
Invitation round 
   
Round 1 
 
Round 2(a) 
 
All 
     
Screened in round 1 
  
   
Total
 
No Yes Total 
 
Total
Males 50 years Number 56,209 
 
n.p. n.p. n.p. 
 
56,295 
  
Per cent 25.4 
 
n.p. n.p. n.p. 
 
25.4 
 
55 years(b) Number 2,144 
 
13,551 33,398 46,949 
 
49,093 
  
Per cent 25.9 
 
14.9 69.4 33.8 
 
33.3 
 
60 years(b) Number 1,031 
 
19,348 48,169 67,517 
 
68,548 
  
Per cent 25.4 
 
18.4 75.3 39.9 
 
39.5 
 
65 years Number 62,938 
 
n.p. n.p. n.p. 
 
63,056 
  
Per cent 38.4 
 
n.p. n.p. n.p. 
 
38.5 
 
Total Number 122,322 
 
33,050 81,620 114,670 
 
236,992 
  
Per cent 30.8 
 
16.8 72.8 37.1 
 
33.6 
Females 50 years Number 64,517 
 
n.p. n.p. n.p. 
 
64,604 
  
Per cent 29.3 
 
n.p. n.p. n.p. 
 
29.3 
 
55 years(b) Number 2,588 
 
14,034 40,344 54,378 
 
56,966 
  
Per cent 31.2 
 
16.9 71.1 39.0 
 
38.5 
 
60 years(b) Number 1,319 
 
18,507 60,612 79,119 
 
80,438 
  
Per cent 30.3 
 
20.2 76.3 46.2 
 
45.8 
 
65 years Number 70,608 
 
n.p. n.p. n.p. 
 
70,736 
  
Per cent 42.7 
 
n.p. n.p. n.p. 
 
42.7 
 
Total Number 139,032 
 
32,689 101,023 133,712 
 
272,744 
  
Per cent 34.9 
 
18.7 74.1 43.0 
 
38.5 
Persons 50 years Number 120,726 
 
n.p. n.p. n.p. 
 
120,899 
  
Per cent 27.4 
 
n.p. n.p. n.p. 
 
27.4 
 
55 years(b) Number 4,732 
 
27,585 73,742 101,327 
 
106,059 
  
Per cent 28.6 
 
15.9 70.3 36.4 
 
35.9 
 
60 years(b) Number 2,350 
 
37,855 108,781 146,636 
 
148,986 
  
Per cent 28.0 
 
19.2 75.9 43.1 
 
42.7 
 
65 years Number 133,546 
 
n.p. n.p. n.p. 
 
133,792 
  
Per cent 40.6 
 
n.p. n.p. n.p. 
 
40.6 
 
Total Number 261,354 
 
65,739 182,643 248,382 
 
509,736 
  
Per cent 32.9 
 
17.7 73.5 40.0 
 
36.0 
(a) Due to previous manual invitations, pilot program participation, or other reasons, a small number of 50 and 65 year olds were 
receiving a second invitation in 2013–14. These were excluded from this table. 
(b) A small number of 55 and 60 year olds (less than 6% and 3% respectively) were receiving their first invitation in 2013-14. These 
are likely to be those newly registered at Medicare or DVA after 2008. 
Note: Percentages equal people participating as a proportion of the total number of the eligible population who were invited to screen. 
This includes people who suspended or opted off. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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A2: Faecal occult blood test outcome tables 
Table A2.1: FOBT results for correctly completed kits, by age and sex, 2013–14 
 
FOBT positive FOBT negative FOBT inconclusive Total 
Number Per cent Number Per cent Number Per cent Number 
Males        
50 years 3,923 7.1 51,252 92.9 17 — 55,192 
55 years 3,384 7.0 44,853 93.0 10 — 48,247 
60 years 5,350 7.9 62,175 92.1 13 — 67,538 
65 years 6,703 10.8 55,423 89.2 11 — 62,137 
Total 19,360 8.3 213,703 91.7 51 — 233,114 
Females        
50 years 3,964 6.3 59,352 93.7 17 — 63,333 
55 years 3,428 6.1 52,629 93.9 6 — 56,063 
60 years 5,211 6.6 74,085 93.4 12 — 79,308 
65 years 5,781 8.3 63,776 91.7 7 — 69,564 
Total 18,384 6.9 249,842 93.1 42 — 268,268 
Persons        
50 years 7,887 6.7 110,604 93.3 34 — 118,525 
55 years 6,812 6.5 97,482 93.5 16 — 104,310 
60 years 10,561 7.2 136,260 92.8 25 — 146,846 
65 years 12,484 9.5 119,199 90.5 18 — 131,701 
Total 37,744 7.5 463,545 92.5 93 — 501,382 
Notes 
1. Percentages equal the number of participants with FOBT results in each category in terms of ‘positive’, ‘negative’ and ‘inconclusive’ as a 
proportion of the total number of participants with correctly completed FOBTs. 
2. For participants who returned more than 1 FOBT kit, a positive result was reported over any other result, and a negative result was reported 
over an inconclusive result. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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Table A2.2: FOBT positivity rates, by screening round, age and sex, 2013–14 
Screening round 
Positive tests 
(number) 
Valid results 
(number) 
Positivity rate  
(per cent) 
First screen Males    
 50 years 3,921 55,167 7.1 
55 years 1,357 15,191 8.9 
60 years 1,963 19,737 9.9 
65 years 6,698 62,081 10.8 
Total 13,939 152,176 9.2 
Females    
50 years 3,963 63,308 6.3 
55 years 1,135 16,122 7.0 
60 years 1,487 19,171 7.8 
65 years 5,777 69,499 8.3 
Total 12,362 168,100 7.4 
Persons    
50 years 7,884 118,475 6.7 
55 years 2,492 31,313 8.0 
60 years 3,450 38,908 8.9 
65 years 12,475 131,580 9.5 
Total 26,301 320,276 8.2 
Second screen Males    
 50 years n.p. n.p. n.p. 
55 years 2,027 33,046 6.1 
60 years 3,387 47,788 7.1 
65 years n.p. n.p. n.p. 
Total 5,421 80,887 6.7 
Females    
50 years n.p. n.p. n.p. 
55 years 2,293 39,935 5.7 
60 years 3,724 60,125 6.2 
65 years n.p. n.p. n.p. 
Total 6,022 100,126 6.0 
Persons    
50 years n.p. n.p. n.p. 
55 years 4,320 72,981 5.9 
60 years 7,111 107,913 6.6 
65 years n.p. n.p. n.p. 
Total 11,443 181,013 6.3 
(continued) 
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Table A2.2 (continued): FOBT positivity rates, by screening round, age and sex, 2013–14 
Screening round 
Positive tests 
(number) 
Valid results 
(number) 
Positivity rate  
(per cent) 
All screens Males    
 50 years 3,923 55,175 7.1 
55 years 3,384 48,237 7.0 
60 years 5,350 67,525 7.9 
65 years 6,703 62,126 10.8 
Total 19,360 233,063 8.3 
Females    
50 years 3,964 63,316 6.3 
55 years 3,428 56,057 6.1 
60 years 5,211 79,296 6.6 
65 years 5,781 69,557 8.3 
Total 18,384 268,226 6.9 
Persons    
50 years 7,887 118,491 6.7 
55 years 6,812 104,294 6.5 
60 years 10,561 146,821 7.2 
65 years 12,484 131,683 9.5 
Total 37,744 501,289 7.5 
Note: Positivity rate equals the number of participants with positive FOBT results as a percentage of the total number of participants with valid 
results. A valid result was either positive or negative; inconclusive results were excluded. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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Table A2.3: FOBT positivity rates, by state and territory, 2013–14  
 NSW Vic Qld WA SA Tas ACT NT Australia 
Males 
50 years Positive tests 1,203 989 768 426 376 88 51 22 3,923 
 Positivity rate 7.0 7.1 7.1 7.1 7.9 7.0 5.4 7.4 7.1 
55 years Positive tests 1,060 823 651 339 324 107 50 30 3,384 
 Positivity rate 7.0 6.8 7.0 6.6 7.7 8.7 5.9 8.6 7.0 
60 years Positive tests 1,610 1,291 1,074 599 490 150 95 41 5,350 
 Positivity rate 7.7 7.9 8.0 8.3 8.3 8.1 8.1 8.7 7.9 
65 years Positive tests 2,115 1,599 1,401 651 618 199 86 34 6,703 
 Positivity rate 10.8 11.0 11.0 10.3 10.7 11.3 8.5 12.2 10.8 
Total Positive tests 5,988 4,702 3,894 2,015 1,808 544 282 127 19,360 
 Positivity rate 8.2 8.3 8.4 8.2 8.8 8.9 7.1 9.1 8.3 
Females 
50 years Positive tests 1,187 1,082 765 406 355 94 57 18 3,964 
 Positivity rate 6.2 6.5 6.3 6.1 6.3 6.1 5.1 5.3 6.3 
55 years Positive tests 1,066 891 616 346 317 106 66 20 3,428 
 Positivity rate 6.1 6.3 5.7 6.0 6.4 6.9 6.2 5.6 6.1 
60 years Positive tests 1,610 1,254 1,007 532 524 159 90 35 5,211 
 Positivity rate 6.6 6.3 6.5 6.4 7.4 7.1 6.5 7.5 6.6 
65 years Positive tests 1,828 1,426 1,115 543 575 187 89 18 5,781 
 Positivity rate 8.5 8.3 8.0 8.0 8.8 8.7 7.6 7.6 8.3 
Total Positive tests 5,691 4,653 3,503 1,827 1,771 546 302 91 18,384 
 Positivity rate 6.9 6.9 6.7 6.7 7.3 7.3 6.4 6.5 6.9 
Persons 
50 years Positive tests 2,390 2,071 1,533 832 731 182 108 40 7,887 
 Positivity rate 6.6 6.8 6.7 6.6 7.0 6.5 5.2 6.3 6.7 
55 years Positive tests 2,126 1,714 1,267 685 641 213 116 50 6,812 
 Positivity rate 6.5 6.5 6.3 6.3 7.0 7.7 6.1 7.1 6.5 
60 years Positive tests 3,220 2,545 2,081 1,131 1,014 309 185 76 10,561 
 Positivity rate 7.1 7.0 7.2 7.3 7.8 7.5 7.3 8.1 7.2 
65 years Positive tests 3,943 3,025 2,516 1,194 1,193 386 175 52 12,484 
 Positivity rate 9.6 9.5 9.4 9.1 9.7 9.9 8.0 10.1 9.5 
Total Positive tests 11,679 9,355 7,397 3,842 3,579 1,090 584 218 37,744 
 Positivity rate 7.5 7.5 7.5 7.4 8.0 8.0 6.7 7.8 7.5 
Notes 
1. Positive tests equal the number of FOBTs that returned a positive result. 
2. Positivity rate equals the number of participants with positive FOBT results as a percentage of the total number of participants with valid 
results. A valid result was either positive or negative; inconclusive results were excluded. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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Table A2.4: FOBT positivity rates, by geographical region, 2013–14 
 Remoteness area  
 Major cities Inner regional Outer regional Remote Very remote Unknown Total 
Males 
50 years Positive tests 2,698 739 368 57 21 40 3,923 
 Positivity rate 6.9 7.2 8.0 9.2 11.3 7.3 7.1 
55 years Positive tests 2,206 712 363 46 19 39 3,384 
 Positivity rate 6.8 7.3 8.0 7.6 9.8 7.3 7.0 
60 years Positive tests 3,411 1,185 603 70 28 53 5,350 
 Positivity rate 7.8 8.0 8.6 8.3 9.4 6.8 7.9 
65 years Positive tests 4,128 1,594 802 87 32 59 6,703 
 Positivity rate 10.5 10.9 12.2 12.3 14.9 9.6 10.8 
Total Positive tests 12,442 4,230 2,136 260 100 191 19,360 
 Positivity rate 8.0 8.5 9.4 9.4 11.2 7.7 8.3 
Females 
50 years Positive tests 2,770 769 338 46 11 30 3,964 
 Positivity rate 6.3 6.3 6.2 7.0 5.4 6.0 6.3 
55 years Positive tests 2,258 736 356 40 13 26 3,428 
 Positivity rate 6.0 6.2 6.7 6.0 5.9 5.0 6.1 
60 years Positive tests 3,352 1,183 557 50 25 44 5,211 
 Positivity rate 6.5 6.7 7.2 6.3 8.7 5.8 6.6 
65 years Positive tests 3,661 1,381 622 55 21 40 5,781 
 Positivity rate 8.2 8.3 9.0 8.5 12.2 6.6 8.3 
Total Positive tests 12,042 4,069 1,872 191 69 140 18,384 
 Positivity rate 6.8 6.9 7.4 6.9 8.0 5.9 6.9 
Persons 
50 years Positive tests 5,468 1,508 706 103 32 70 7,887 
 Positivity rate 6.6 6.7 7.0 8.1 8.2 6.7 6.7 
55 years Positive tests 4,463 1,448 719 86 31 65 6,812 
 Positivity rate 6.4 6.7 7.3 6.8 7.8 6.2 6.5 
60 years Positive tests 6,763 2,368 1,160 120 53 97 10,561 
 Positivity rate 7.1 7.3 7.8 7.3 9.1 6.3 7.2 
65 years Positive tests 7,789 2,976 1,424 143 53 99 12,484 
 Positivity rate 9.3 9.5 10.6 10.5 13.7 8.1 9.5 
Total Positive tests 24,484 8,299 4,009 452 169 331 37,744 
 Positivity rate 7.4 7.7 8.3 8.2 9.6 6.8 7.5 
Notes  
1. Positive tests equal the number of FOBTs that returned a positive result. 
2. Positivity rate equals the number of participants with positive FOBT results as a percentage of the total number of participants with valid 
results. A valid result was either positive or negative; inconclusive results were excluded. 
3. The residential postcodes of participants were mapped to remoteness areas in the 2011 Australian Statistical Geography Standard 
remoteness structure through a postal area correspondence. Those that could not be mapped were included in the ‘Unknown’ column.  
4. Discrepancies may occur between totals and sums of the component items due to rounding—see ‘Geographical classification’, Appendix C. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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Notes 
1. Rate per remoteness area is an average of positivity across that remoteness area. 
2. Positivity rates rounded to 1 decimal place. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A2.1a: FOBT positivity, by remoteness area, New South Wales, 2013–14 
 
 
Notes 
1. Rate per remoteness area is an average of positivity across that remoteness area. 
2. Positivity rates rounded to 1 decimal place. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A2.1b: FOBT positivity, by remoteness area, Victoria, 2013–14 
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Notes 
1. Rate per remoteness area is an average of positivity across that remoteness area. 
2. Positivity rates rounded to 1 decimal place. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A2.1c: FOBT positivity, by remoteness area, Queensland, 2013–14 
 
 
Notes 
1. Rate per remoteness area is an average of positivity across that remoteness area. 
2. Positivity rates rounded to 1 decimal place. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A2.1d: FOBT positivity, by remoteness area, Western Australia, 2013–14 
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Notes 
1. Rate per remoteness area is an average of positivity across that remoteness area. 
2. Positivity rates rounded to 1 decimal place. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A2.1e: FOBT positivity, by remoteness area, South Australia, 2013–14 
 
 
Notes 
1. Rate per remoteness area is an average of positivity across that remoteness area. 
2. Positivity rates rounded to 1 decimal place. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A2.1f: FOBT positivity, by remoteness area, Tasmania, 2013–14 
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Notes 
1. Remoteness areas left unshaded contain data that are not publishable due to small numbers, confidentiality or other concerns.  
2. Rate per remoteness area is an average of positivity across that remoteness area. 
3. Positivity rates rounded to 1 decimal place. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A2.1g: FOBT positivity, by remoteness area, Australian Capital Territory, 2013–14 
 
 
Notes 
1. Rate per remoteness area is an average of positivity across that remoteness area. 
2. Positivity rates rounded to 1 decimal place. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A2.1h: FOBT positivity, by remoteness area, Northern Territory, 2013–14 
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Table A2.5: FOBT positivity rates, by socioeconomic status area, 2013–14  
 Socioeconomic status area  
 1 (lowest) 2 3 4 5 (highest) Unknown Total 
Males 
50 years Positive tests 791 743 757 798 787 47 3,923 
 Positivity rate 8.4 7.6 7.0 6.8 6.2 6.6 7.1 
55 years Positive tests 715 721 709 604 591 44 3,384 
 Positivity rate 8.0 7.7 7.5 6.3 5.8 6.5 7.0 
60 years Positive tests 1,127 1,145 1,031 1,054 927 66 5,350 
 Positivity rate 8.9 8.3 7.8 7.9 6.8 6.7 7.9 
65 years Positive tests 1,512 1,458 1,356 1,223 1,076 78 6,703 
 Positivity rate 12.5 11.2 11.2 10.3 8.8 9.9 10.8 
Total Positive tests 4,145 4,067 3,853 3,679 3,381 235 19,360 
 Positivity rate 9.6 8.8 8.5 7.9 6.9 7.4 8.3 
Females 
50 years Positive tests 738 764 750 854 822 36 3,964 
 Positivity rate 7.0 6.6 6.1 6.4 5.6 5.2 6.3 
55 years Positive tests 726 697 651 663 658 33 3,428 
 Positivity rate 7.2 6.5 6.0 5.8 5.4 5.0 6.1 
60 years Positive tests 1,078 1,118 1,001 971 981 62 5,211 
 Positivity rate 7.4 6.9 6.4 6.2 6.0 6.3 6.6 
65 years Positive tests 1,269 1,267 1,157 1,035 997 56 5,781 
 Positivity rate 9.5 8.6 8.6 7.8 7.1 7.3 8.3 
Total Positive tests 3,811 3,846 3,559 3,523 3,458 187 18,384 
 Positivity rate 7.8 7.2 6.8 6.6 6.0 6.0 6.9 
Persons 
50 years Positive tests 1,529 1,507 1,507 1,652 1,609 83 7,887 
 Positivity rate 7.6 7.0 6.5 6.6 5.9 5.9 6.7 
55 years Positive tests 1,441 1,418 1,360 1,267 1,249 77 6,812 
 Positivity rate 7.6 7.0 6.7 6.0 5.6 5.8 6.5 
60 years Positive tests 2,205 2,263 2,032 2,025 1,908 128 10,561 
 Positivity rate 8.1 7.6 7.0 7.0 6.4 6.5 7.2 
65 years Positive tests 2,781 2,725 2,513 2,258 2,073 134 12,484 
 Positivity rate 10.9 9.8 9.8 9.0 7.9 8.6 9.5 
Total Positive tests 7,956 7,913 7,412 7,202 6,839 422 37,744 
 Positivity rate 8.7 8.0 7.6 7.2 6.5 6.7 7.5 
Notes  
1. Positive tests equal the number of FOBTs that returned a positive result. 
2. Positivity rate equals the number of participants with positive FOBT results as a percentage of the total number of participants with valid 
results. A valid result was either positive or negative; inconclusive results were excluded. 
3. A participant’s socioeconomic status area was classified by mapping their residential postcode (through a postal area) to the ABS IRSD for 
2011. Those that could not be mapped were included in the ‘Unknown’ column. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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Table A2.6: FOBT positivity rates, by Aboriginal and Torres Strait Islander status, 2013–14  
 Indigenous Non-Indigenous Not stated Total 
Males      
50 years Positive tests 73 3,691 159 3,923 
 Positivity rate 13.6 7.0 8.3 7.1 
55 years Positive tests 58 3,253 73 3,384 
 Positivity rate 12.1 6.9 8.8 7.0 
60 years Positive tests 86 5,127 137 5,350 
 Positivity rate 14.4 7.8 11.0 7.9 
65 years Positive tests 86 6,348 269 6,703 
 Positivity rate 16.1 10.6 13.6 10.8 
Total Positive tests 303 18,419 638 19,360 
 Positivity rate 14.1 8.2 10.7 8.3 
Females 
50 years Positive tests 54 3,806 104 3,964 
 Positivity rate 8.2 6.2 7.5 6.3 
55 years Positive tests 40 3,324 64 3,428 
 Positivity rate 7.7 6.1 9.5 6.1 
60 years Positive tests 67 5,071 73 5,211 
 Positivity rate 10.0 6.5 7.7 6.6 
65 years Positive tests 90 5,539 152 5,781 
 Positivity rate 15.3 8.2 9.4 8.3 
Total Positive tests 251 17,740 393 18,384 
 Positivity rate 10.3 6.8 8.5 6.9 
Persons 
50 years Positive tests 127 7,497 263 7,887 
 Positivity rate 10.6 6.6 8.0 6.7 
55 years Positive tests 98 6,577 137 6,812 
 Positivity rate 9.8 6.5 9.2 6.5 
60 years Positive tests 153 10,198 210 10,561 
 Positivity rate 12.1 7.1 9.6 7.2 
65 years Positive tests 176 11,887 421 12,484 
 Positivity rate 15.7 9.4 11.7 9.5 
Total Positive tests 554 36,159 1,031 37,744 
 Positivity rate 12.1 7.4 9.7 7.5 
Notes 
1. Positive tests equal the number of FOBTs that returned a positive result. 
2. Positivity rate equals the number of participants with positive FOBT results as a percentage of the total number of participants with valid 
results. A valid result was either positive or negative; inconclusive results were excluded. 
3. NBCSP Aboriginal and Torres Strait Islander status was reported by the participant on the returned participant details form. Participants 
who did not indicate Aboriginal and Torres Strait Islander status were included in the ‘Not stated’ column. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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Table A2.7: FOBT positivity rates, by language spoken at home, 2013–14  
 Language other than English English Total 
Males 
50 years Positive tests 635 3,288 3,923 
 Positivity rate 7.8 7.0 7.1 
55 years Positive tests 527 2,857 3,384 
 Positivity rate 7.0 7.0 7.0 
60 years Positive tests 771 4,579 5,350 
 Positivity rate 8.1 7.9 7.9 
65 years Positive tests 820 5,883 6,703 
 Positivity rate 11.0 10.8 10.8 
Total Positive tests 2,753 16,607 19,360 
 Positivity rate 8.4 8.3 8.3 
Females 
50 years Positive tests 724 3,240 3,964 
 Positivity rate 6.9 6.1 6.3 
55 years Positive tests 601 2,827 3,428 
 Positivity rate 6.6 6.0 6.1 
60 years Positive tests 860 4,351 5,211 
 Positivity rate 7.4 6.4 6.6 
65 years Positive tests 778 5,003 5,781 
 Positivity rate 9.4 8.2 8.3 
Total Positive tests 2,963 15,421 18,384 
 Positivity rate 7.5 6.7 6.9 
Persons 
50 years Positive tests 1,359 6,528 7,887 
 Positivity rate 7.3 6.5 6.7 
55 years Positive tests 1,128 5,684 6,812 
 Positivity rate 6.8 6.5 6.5 
60 years Positive tests 1,631 8,930 10,561 
 Positivity rate 7.7 7.1 7.2 
65 years Positive tests 1,598 10,886 12,484 
 Positivity rate 10.1 9.4 9.5 
Total Positive tests 5,716 32,028 37,744 
 Positivity rate 7.9 7.5 7.5 
Notes 
1. Positive tests equal the number of FOBTs that returned a positive result. 
2. Positivity rate equals the number of participants with positive FOBT results as a percentage of the total number of participants with valid 
results. A valid result was either positive or negative; inconclusive results were excluded. 
3. NBCSP preferred language spoken at home was reported by the participant on the returned participant details form. Participants who did not 
indicate preferred language spoken at home were assumed to speak English. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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Table A2.8: FOBT positivity rates, by disability status, 2013–14  
 
Severe or profound 
activity limitation 
No severe or profound 
activity limitation Not stated Total 
Males 
50 years Positive tests 240 3,435 248 3,923 
 Positivity rate 12.3 7.0 6.0 7.1 
55 years Positive tests 221 2,988 175 3,384 
 Positivity rate 11.5 7.0 5.0 7.0 
60 years Positive tests 403 4,655 292 5,350 
 Positivity rate 12.3 7.8 6.3 7.9 
65 years Positive tests 629 5,739 335 6,703 
 Positivity rate 15.9 10.6 8.1 10.8 
Total Positive tests 1,493 16,817 1,050 19,360 
 Positivity rate 13.4 8.2 6.4 8.3 
Females 
50 years Positive tests 258 3,544 162 3,964 
 Positivity rate 9.5 6.2 4.5 6.3 
55 years Positive tests 267 3,002 159 3,428 
 Positivity rate 9.8 6.0 5.2 6.1 
60 years Positive tests 442 4,556 213 5,211 
 Positivity rate 10.6 6.4 5.3 6.6 
65 years Positive tests 501 5,049 231 5,781 
 Positivity rate 12.6 8.1 6.8 8.3 
Total Positive tests 1,468 16,151 765 18,384 
 Positivity rate 10.8 6.7 5.4 6.9 
Persons 
50 years Positive tests 498 6,979 410 7,887 
 Positivity rate 10.7 6.6 5.3 6.7 
55 years Positive tests 488 5,990 334 6,812 
 Positivity rate 10.5 6.4 5.1 6.5 
60 years Positive tests 845 9,211 505 10,561 
 Positivity rate 11.4 7.0 5.8 7.2 
65 years Positive tests 1,130 10,788 566 12,484 
 Positivity rate 14.3 9.3 7.5 9.5 
Total Positive tests 2,961 32,968 1,815 37,744 
 Positivity rate 12.0 7.4 5.9 7.5 
Notes 
1. Positive tests equal the number of FOBTs that returned a positive result. 
2. Positivity rate equals the number of participants with positive FOBT results as a percentage of the total number of participants with valid 
results. A valid result was either positive or negative; inconclusive results were excluded. 
3. NBCSP disability status was reported by the participant on the participant details form. Participants who did not indicate disability status are 
included in the ‘Not stated’ column. 
4. A ‘profound’ activity limitation indicates that a person always needs assistance with self-care, movement and/or communications activities. 
A ‘severe’ activity limitation indicates that a person sometimes needs assistance with these activities.  
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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A3: Primary health-care practitioner (PHCP) and 
colonoscopy follow-up tables and figures 
Table A3.1: Crude PHCP follow-up after a positive FOBT result, by state and territory, 2013–14 
 NSW Vic Qld WA SA Tas ACT NT Australia 
Males 
50 years Number 727 486 409 234 235 57 24 8 2,180 
 Per cent 60.4 49.1 53.3 54.9 62.5 n.p. n.p. n.p. 55.6 
55 years Number 680 401 374 218 190 75 20 7 1,965 
 Per cent 64.2 48.7 57.5 64.3 58.6 70.1 n.p. n.p. 58.1 
60 years Number 1,033 702 616 373 323 101 52 19 3,219 
 Per cent 64.2 54.4 57.4 62.3 65.9 67.3 n.p. n.p. 60.2 
65 years Number 1,371 841 916 425 409 135 40 17 4,154 
 Per cent 64.8 52.6 65.4 65.3 66.2 67.8 n.p. n.p. 62.0 
Total Number 3,811 2,430 2,315 1,250 1,157 368 136 51 11,518 
 Per cent 63.6 51.7 59.5 62.0 64.0 67.6 48.2 40.2 59.5 
Females 
50 years Number 759 582 478 258 240 62 31 10 2,420 
 Per cent 63.9 53.8 62.5 63.5 67.6 n.p. n.p. n.p. 61.0 
55 years Number 719 474 392 223 195 68 38 10 2,119 
 Per cent 67.4 53.2 63.6 64.5 61.5 64.2 n.p. n.p. 61.8 
60 years Number 1,105 709 662 350 350 117 52 17 3,362 
 Per cent 68.6 56.5 65.7 65.8 66.8 73.6 n.p. n.p. 64.5 
65 years Number 1,246 843 744 371 403 128 50 11 3,796 
 Per cent 68.2 59.1 66.7 68.3 70.1 68.4 n.p. n.p. 65.7 
Total Number 3,829 2,608 2,276 1,202 1,188 375 171 48 11,697 
 Per cent 67.3 56.0 65.0 65.8 67.1 68.7 56.6 n.p. 63.6 
Persons 
50 years Number 1,486 1,068 887 492 475 119 55 18 4,600 
 Per cent 62.2 51.6 57.9 59.1 65.0 65.4 50.9 n.p. 58.3 
55 years Number 1,399 875 766 441 385 143 58 17 4,084 
 Per cent 65.8 51.1 60.5 64.4 60.1 67.1 50.0 n.p. 60.0 
60 years Number 2,138 1,411 1,278 723 673 218 104 36 6,581 
 Per cent 66.4 55.4 61.4 63.9 66.4 70.6 56.2 n.p. 62.3 
65 years Number 2,617 1,684 1,660 796 812 263 90 28 7,950 
 Per cent 66.4 55.7 66.0 66.7 68.1 68.1 51.4 n.p. 63.7 
Total Number 7,640 5,038 4,591 2,452 2,345 743 307 99 23,215 
 Per cent 65.4 53.9 62.1 63.8 65.5 68.2 52.6 45.4 61.5 
Notes 
1. Percentages equal the number of people having consulted a primary health-care practitioner (PHCP) after a positive FOBT result as a 
proportion of the total number of people with positive FOBT results.  
2. Reporting of PHCP follow-up is not mandatory; actual numbers of participant consultations may be underestimated. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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Table A3.2: Kaplan–Meier PHCP follow-up at 26 and 52 weeks after a positive FOBT, by state and 
territory, 2013–14 
  NSW Vic Qld WA SA Tas ACT NT Australia 
26 weeks          
PHCP follow-
up (per cent) 64.9 54.1 62.0 63.7 65.3 67.8 53.1 45.4 61.4 
95% 
confidence 
interval 64.0–65.8 53.0–55.1 60.9–63.1 62.2–65.2 63.7–66.8 65.0–70.6 49.0–57.1 38.7–52.0 60.9–61.8 
52 weeks          
PHCP follow-
up (per cent) 66.7 54.7 62.8 64.9 66.2 68.6 53.8 51.4 62.5 
95% 
confidence 
interval 65.8–67.5 53.6–55.7 61.7–63.9 63.4–66.5 64.7–67.8 65.9–71.4 49.6–58.0 38.8–64.1 62.0–62.9 
Note: PHCP follow-up rates equal the estimated Kaplan–Meier follow-up rate of people who consulted a PHCP as a proportion of the total number 
of people with positive FOBT results. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
 
 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A3.1a: PHCP follow-up rate after positive FOBT, using Kaplan–Meier estimates, Australia, 
2013–14 
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Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A3.1b: PHCP follow-up rate after positive FOBT, using Kaplan–Meier estimates, New South 
Wales, Victoria, Queensland and Western Australia, 2013–14 
 
 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A3.1c: PHCP follow-up rate after positive FOBT, using Kaplan–Meier estimates, South 
Australia, Tasmania, Australian Capital Territory and Northern Territory, 2013–14 
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Table A3.3: Crude PHCP follow-up after a positive FOBT result, by remoteness area, 2013–14  
 Remoteness area  
 Major cities Inner regional Outer regional Remote Very remote Unknown Total 
Males 
50 years Number 1,458 452 210 30 9 20 2,180 
 Per cent 54.0 61.3 57.2 n.p. n.p. n.p. 55.6 
55 years Number 1,245 445 210 29 14 21 1,965 
 Per cent 56.5 62.6 58.0 n.p. n.p. n.p. 58.1 
60 years Number 1,997 751 385 42 15 29 3,219 
 Per cent 58.5 63.4 63.8 n.p. n.p. n.p. 60.2 
65 years Number 2,492 1,012 543 51 19 36 4,154 
 Per cent 60.4 63.5 67.7 n.p. n.p. n.p. 62.0 
Total Number 7,192 2,661 1,349 153 57 106 11,518 
 Per cent 57.8 62.9 63.2 58.6 57.0 55.5 59.5 
Females 
50 years Number 1,637 497 229 33 7 17 2,420 
 Per cent 59.1 64.7 67.7 n.p. n.p. n.p. 61.0 
55 years Number 1,360 472 237 26 5 17 2,119 
 Per cent 60.3 64.2 66.7 n.p. n.p. n.p. 61.8 
60 years Number 2,125 792 373 34 9 29 3,362 
 Per cent 63.4 66.9 66.9 n.p. n.p. n.p. 64.5 
65 years Number 2,362 924 440 35 10 25 3,796 
 Per cent 64.5 66.9 70.9 n.p. n.p. n.p. 65.7 
Total Number 7,484 2,686 1,279 128 32 88 11,697 
 Per cent 62.2 66.0 68.3 67.0 n.p. 62.9 63.6 
Persons 
50 years Number 3,096 950 439 63 16 37 4,600 
 Per cent 56.6 63.0 62.2 61.1 n.p. n.p. 58.3 
55 years Number 2,606 918 448 55 19 38 4,084 
 Per cent 58.4 63.4 62.3 n.p. n.p. n.p. 60.0 
60 years Number 4,122 1,543 757 77 24 58 6,581 
 Per cent 60.9 65.1 65.3 63.8 n.p. n.p. 62.3 
65 years Number 4,854 1,936 984 86 29 61 7,950 
 Per cent 62.3 65.1 69.1 60.4 n.p. n.p. 63.7 
Total Number 14,677 5,347 2,628 281 89 194 23,215 
 Per cent 59.9 64.4 65.6 62.2 52.4 58.6 61.5 
Notes 
1. Percentages equal the number of people having consulted a PHCP after a positive FOBT result as a proportion of the total number of people 
with positive FOBT results.  
2. Reporting of PHCP follow-up is not mandatory; actual numbers of participant consultations may be underestimated. 
3. The residential postcodes of participants were mapped to remoteness areas in the 2011 Australian Statistical Geography Standard 
remoteness structure through a postal area correspondence. Those that could not be mapped were included in the ‘Unknown’ column. 
4. Discrepancies may occur between totals and sums of the component items due to rounding—see ‘Geographical classification’, Appendix C. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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Notes 
1. Remoteness areas left unshaded contain data that are not publishable due to small numbers, confidentiality or other concerns.  
2. Rate per remoteness area is an average of PHCP follow-up reported across that remoteness area. 
3. PHCP follow-up rates rounded to integers. 
4. Differences in PHCP follow-up rates across remoteness areas may involve differences in assessment form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A3.2a: PHCP follow-up, by remoteness area, New South Wales, 2013–14 
 
 
Notes 
1. Rate per remoteness area is an average of PHCP follow-up reported across that remoteness area. 
2. PHCP follow-up rates rounded to integers. 
3. Differences in PHCP follow-up rates across remoteness areas may involve differences in assessment form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A3.2b: PHCP follow-up, by remoteness area, Victoria, 2013–14 
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Notes 
1. Rate per remoteness area is an average of PHCP follow-up reported across that remoteness area. 
2. PHCP follow-up rates rounded to integers. 
3. Differences in PHCP follow-up rates across remoteness areas may involve differences in assessment form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A3.2c: PHCP follow-up, by remoteness area, Queensland, 2013–14 
 
 
Notes 
1. Rate per remoteness area is an average of PHCP follow-up reported across that remoteness area. 
2. PHCP follow-up rates rounded to integers. 
3. Differences in PHCP follow-up rates across remoteness areas may involve differences in assessment form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A3.2d: PHCP follow-up, by remoteness area, Western Australia, 2013–14 
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Notes 
1. Rate per remoteness area is an average of PHCP follow-up reported across that remoteness area. 
2. PHCP follow-up rates rounded to integers. 
3. Differences in PHCP follow-up rates across remoteness areas may involve differences in assessment form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A3.2e: PHCP follow-up, by remoteness area, South Australia, 2013–14 
 
 
Notes 
1. Rate per remoteness area is an average of PHCP follow-up reported across that remoteness area. 
2. PHCP follow-up rates rounded to integers. 
3. Differences in PHCP follow-up rates across remoteness areas may involve differences in assessment form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A3.2f: PHCP follow-up, by remoteness area, Tasmania, 2013–14 
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Notes 
1. Remoteness areas left unshaded contain data that are not publishable due to small numbers, confidentiality or other concerns.  
2. Rate per remoteness area is an average of PHCP follow-up reported across that remoteness area. 
3. PHCP follow-up rates rounded to integers. 
4. Differences in PHCP follow-up rates across remoteness areas may involve differences in assessment form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A3.2g: PHCP follow-up, by remoteness area, Australian Capital Territory, 2013–14 
 
 
Notes 
1. Remoteness areas left unshaded contain data that are not publishable due to small numbers, confidentiality or other concerns.  
2. Rate per remoteness area is an average of PHCP follow-up reported across that remoteness area. 
3. PHCP follow-up rates rounded to integers. 
4. Differences in PHCP follow-up rates across remoteness areas may involve differences in assessment form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A3.2h: PHCP follow-up, by remoteness area, Northern Territory, 2013–14 
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Table A3.4: Crude PHCP follow-up after a positive FOBT result, by socioeconomic status area, 2013–14  
 Socioeconomic status area  
 1 (lowest) 2 3 4 5 (highest) Unknown Total 
Males 
50 years Number 454 431 422 418 431 24 2,180 
 Per cent 57.4 58.0 55.7 52.4 54.8 n.p. 55.6 
55 years Number 386 449 428 331 345 26 1,965 
 Per cent 54.0 62.3 60.4 54.8 58.4 n.p. 58.1 
60 years Number 679 725 619 609 550 37 3,219 
 Per cent 60.2 63.3 60.0 57.8 59.3 n.p. 60.2 
65 years Number 970 904 833 737 664 46 4,154 
 Per cent 64.2 62.0 61.4 60.3 61.7 n.p. 62.0 
Total Number 2,489 2,509 2,302 2,095 1,990 133 11,518 
 Per cent 60.0 61.7 59.7 56.9 58.9 56.6 59.5 
Females 
50 years Number 467 463 467 516 487 20 2,420 
 Per cent 63.3 60.6 62.3 60.4 59.2 n.p. 61.0 
55 years Number 441 437 411 409 400 21 2,119 
 Per cent 60.7 62.7 63.1 61.7 60.8 n.p. 61.8 
60 years Number 672 756 654 592 645 43 3,362 
 Per cent 62.3 67.6 65.3 61.0 65.7 n.p. 64.5 
65 years Number 816 853 764 667 659 37 3,796 
 Per cent 64.3 67.3 66.0 64.4 66.1 n.p. 65.7 
Total Number 2,396 2,509 2,296 2,184 2,191 121 11,697 
 Per cent 62.9 65.2 64.5 62.0 63.4 64.7 63.6 
Persons 
50 years Number 921 894 889 934 918 44 4,600 
 Per cent 60.2 59.3 59.0 56.5 57.1 n.p. 58.3 
55 years Number 827 886 839 740 745 47 4,084 
 Per cent 57.4 62.5 61.7 58.4 59.6 n.p. 60.0 
60 years Number 1,351 1,481 1,273 1,201 1,195 80 6,581 
 Per cent 61.3 65.4 62.6 59.3 62.6 62.5 62.3 
65 years Number 1,786 1,757 1,597 1,404 1,323 83 7,950 
 Per cent 64.2 64.5 63.5 62.2 63.8 61.9 63.7 
Total Number 4,885 5,018 4,598 4,279 4,181 254 23,215 
 Per cent 61.4 63.4 62.0 59.4 61.1 60.2 61.5 
Notes  
1. Percentages equal the number of people having consulted a PHCP after a positive FOBT result as a proportion of the total number of people 
with positive FOBT results.  
2. Reporting of PHCP follow-up is not mandatory; actual numbers of participant consultations may be underestimated. 
3. A participant’s socioeconomic status area was classified by mapping their residential postcode (through a postal area) to the ABS IRSD for 
2011. Those that could not be mapped were included in the ‘Unknown’ column. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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Table A3.5: Crude PHCP follow-up after a positive FOBT result, by Aboriginal and Torres Strait 
Islander status, 2013–14  
 Indigenous Non-Indigenous Not stated Total 
Males 
50 years Number 43 2,099 38 2,180 
 Per cent n.p. 56.9 23.9 55.6 
55 years Number 32 1,915 18 1,965 
 Per cent n.p. 58.9 n.p. 58.1 
60 years Number 54 3,127 38 3,219 
 Per cent n.p. 61.0 27.7 60.2 
65 years Number 59 4,017 78 4,154 
 Per cent n.p. 63.3 29.0 62.0 
Total Number 188 11,158 172 11,518 
 Per cent 62.0 60.6 27.0 59.5 
Females 
50 years Number 30 2,365 25 2,420 
 Per cent n.p. 62.1 24.0 61.0 
55 years Number 19 2,073 27 2,119 
 Per cent n.p. 62.4 n.p. 61.8 
60 years Number 45 3,292 25 3,362 
 Per cent n.p. 64.9 n.p. 64.5 
65 years Number 60 3,677 59 3,796 
 Per cent n.p. 66.4 38.8 65.7 
Total Number 154 11,407 136 11,697 
 Per cent 61.4 64.3 34.6 63.6 
Persons 
50 years Number 73 4,464 63 4,600 
 Per cent 57.5 59.5 24.0 58.3 
55 years Number 51 3,988 45 4,084 
 Per cent n.p. 60.6 32.8 60.0 
60 years Number 99 6,419 63 6,581 
 Per cent 64.7 62.9 30.0 62.3 
65 years Number 119 7,694 137 7,950 
 Per cent 67.6 64.7 32.5 63.7 
Total Number 342 22,565 308 23,215 
 Per cent 61.7 62.4 29.9 61.5 
Notes  
1. Percentages equal the number of people having consulted a PHCP after a positive FOBT result as a proportion of the total number of 
people with positive FOBT results.  
2. Reporting of PHCP follow-up is not mandatory; actual numbers of participant consultations may be underestimated. 
3. NBCSP Aboriginal and Torres Strait Islander status was reported by the participant on the returned participant details form. Participants 
who did not indicate Aboriginal and Torres Strait Islander status were included in the ‘Not stated’ column. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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Table A3.6: Crude PHCP follow-up after a positive FOBT result, by language spoken at home, 
2013–14  
 Language other than English English Total 
Males 
50 years Number 342 1,838 2,180 
 Per cent 53.9 55.9 55.6 
55 years Number 306 1,659 1,965 
 Per cent 58.1 58.1 58.1 
60 years Number 454 2,765 3,219 
 Per cent 58.9 60.4 60.2 
65 years Number 470 3,684 4,154 
 Per cent 57.3 62.6 62.0 
Total Number 1,572 9,946 11,518 
 Per cent 57.1 59.9 59.5 
Females 
50 years Number 413 2,007 2,420 
 Per cent 57.0 61.9 61.0 
55 years Number 343 1,776 2,119 
 Per cent 57.1 62.8 61.8 
60 years Number 558 2,804 3,362 
 Per cent 64.9 64.4 64.5 
65 years Number 479 3,317 3,796 
 Per cent 61.6 66.3 65.7 
Total Number 1,793 9,904 11,697 
 Per cent 60.5 64.2 63.6 
Persons 
50 years Number 755 3,845 4,600 
 Per cent 55.6 58.9 58.3 
55 years Number 649 3,435 4,084 
 Per cent 57.5 60.4 60.0 
60 years Number 1,012 5,569 6,581 
 Per cent 62.0 62.4 62.3 
65 years Number 949 7,001 7,950 
 Per cent 59.4 64.3 63.7 
Total Number 3,365 19,850 23,215 
 Per cent 58.9 62.0 61.5 
Notes 
1. Percentages equal the number of people having consulted a PHCP after a positive FOBT result as a proportion of the total number of 
people with positive FOBT results.  
2. Reporting of PHCP follow-up is not mandatory; actual numbers of participant consultations may be underestimated. 
3. NBCSP preferred language spoken at home was reported by the participant on the returned participant details form. Participants who did not 
indicate preferred language spoken at home were assumed to speak English. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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Table A3.7: Crude PHCP follow-up after a positive FOBT result, by disability status, 2013–14 
 
Severe or profound  
activity limitation 
No severe or profound 
activity limitation Not stated Total 
Males 
50 years Number 136 1,998 46 2,180 
 Per cent 56.7 58.2 18.5 55.6 
55 years Number 126 1,795 44 1,965 
 Per cent 57.0 60.1 25.1 58.1 
60 years Number 243 2,883 93 3,219 
 Per cent 60.3 61.9 31.8 60.2 
65 years Number 382 3,688 84 4,154 
 Per cent 60.7 64.3 25.1 62.0 
Total Number 887 10,364 267 11,518 
 Per cent 59.4 61.6 25.4 59.5 
Females 
50 years Number 149 2,236 35 2,420 
 Per cent 57.8 63.1 21.6 61.0 
55 years Number 154 1,920 45 2,119 
 Per cent 57.7 64.0 28.3 61.8 
60 years Number 276 2,997 89 3,362 
 Per cent 62.4 65.8 41.8 64.5 
65 years Number 319 3,405 72 3,796 
 Per cent 63.7 67.4 31.2 65.7 
Total Number 898 10,558 241 11,697 
 Per cent 61.2 65.4 31.5 63.6 
Persons 
50 years Number 285 4,234 81 4,600 
 Per cent 57.2 60.7 19.8 58.3 
55 years Number 280 3,715 89 4,084 
 Per cent 57.4 62.0 26.6 60.0 
60 years Number 519 5,880 182 6,581 
 Per cent 61.4 63.8 36.0 62.3 
65 years Number 701 7,093 156 7,950 
 Per cent 62.0 65.7 27.6 63.7 
Total Number 1,785 20,922 508 23,215 
 Per cent 60.3 63.5 28.0 61.5 
Notes  
1. Percentages equal the number of people having consulted a PHCP after a positive FOBT result as a proportion of the total number of 
people with positive FOBT results.  
2. Reporting of PHCP follow-up is not mandatory; actual numbers of participant consultations may be underestimated. 
3. NBCSP disability status was reported by the participant on the participant details form. Participants who did not indicate disability status are 
included in the ‘Not stated’ column. 
4. A ‘profound’ activity limitation indicates that a person always needs assistance with self-care, movement and/or communications activities. 
A ‘severe’ activity limitation indicates that a person sometimes needs assistance with these activities.  
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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Table A3.8: Symptoms reported to PHCPs after a positive FOBT result, 2013–14 
 
No 
symptoms 
Recent 
onset rectal 
bleeding 
 ≤6 months 
Longer- 
standing 
rectal 
bleeding  
>6 months 
Significant 
change in 
bowel 
habits 
Iron 
deficiency 
anaemia 
Abdominal 
pain 
All 
participants 
reporting 
symptom 
status 
Males 
50 years Number 1,631 146 166 49 14 44 2,016 
 Per cent 80.9 7.2 8.2 2.4 0.7 2.2  
55 years Number 1,478 119 122 36 9 53 1,794 
 Per cent 82.4 6.6 6.8 2.0 0.5 3.0  
60 years Number 2,467 190 173 70 34 57 2,943 
 Per cent 83.8 6.5 5.9 2.4 1.2 1.9  
65 years Number 3,228 201 228 104 40 83 3,822 
 Per cent 84.5 5.3 6.0 2.7 1.0 2.2  
Total Number 8,804 656 689 259 97 237 10,575 
 Per cent 83.3 6.2 6.5 2.4 0.9 2.2  
Females 
50 years Number 1,796 134 152 77 58 102 2,254 
 Per cent 79.7 5.9 6.7 3.4 2.6 4.5  
55 years Number 1,585 113 101 100 24 87 1,944 
 Per cent 81.5 5.8 5.2 5.1 1.2 4.5  
60 years Number 2,510 190 164 116 36 128 3,076 
 Per cent 81.6 6.2 5.3 3.8 1.2 4.2  
65 years Number 2,856 206 176 141 51 166 3,486 
 Per cent 81.9 5.9 5.0 4.0 1.5 4.8  
Total Number 8,747 643 593 434 169 483 10,760 
 Per cent 81.3 6.0 5.5 4.0 1.6 4.5  
Persons 
50 years Number 3,427 280 318 126 72 146 4,270 
 Per cent 80.3 6.6 7.4 3.0 1.7 3.4  
55 years Number 3,063 232 223 136 33 140 3,738 
 Per cent 81.9 6.2 6.0 3.6 0.9 3.7  
60 years Number 4,977 380 337 186 70 185 6,019 
 Per cent 82.7 6.3 5.6 3.1 1.2 3.1  
65 years Number 6,084 407 404 245 91 249 7,308 
 Per cent 83.3 5.6 5.5 3.4 1.2 3.4  
Total Number 17,551 1,299 1,282 693 266 720 21,335 
 Per cent 82.3 6.1 6.0 3.2 1.2 3.4  
Notes 
1. Percentages equal the number of people reporting specific symptoms after a positive FOBT as a proportion of the total number of people 
who reported any symptoms. 
2. Only participants who had a symptom status (including ‘no symptoms’) recorded in the assessment form question 2 were included in this 
analysis. There were 1,124 participants with missing data for this question excluded from the analysis. 
3. Percentages can add to more than 100, as respondents may have reported more than 1 symptom.  
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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Table A3.9: Referrals made by PHCPs after a positive FOBT result and subsequent consultation, 
2013–14 
 Colonoscopy 
Double 
contrast 
barium 
enema Sigmoidoscopy 
CT 
colonography Other  
No 
referral 
All 
PHCP 
visits 
Males 
50 years Number 2,058 1 — 2 26 93 2,180 
 Per cent 94.4 — — 0.1 1.2 4.3  
55 years Number 1,832 1 2 2 30 98 1,965 
 Per cent 93.2 0.1 0.1 0.1 1.5 5.0  
60 years Number 2,974 2 2 3 55 183 3,219 
 Per cent 92.4 0.1 0.1 0.1 1.7 5.7  
65 years Number 3,810 2 6 6 77 253 4,154 
 Per cent 91.7 — 0.1 0.1 1.9 6.1  
Total Number 10,674 6 10 13 188 627 11,518 
 Per cent 92.7 0.1 0.1 0.1 1.6 5.4  
Females 
50 years Number 2,230 1 1 1 79 108 2,420 
 Per cent 92.1 — — — 3.3 4.5  
55 years Number 1,957 1 2 3 53 103 2,119 
 Per cent 92.4 — 0.1 0.1 2.5 4.9  
60 years Number 3,082 4 1 3 82 190 3,362 
 Per cent 91.7 0.1 — 0.1 2.4 5.7  
65 years Number 3,452 2 3 7 91 241 3,796 
 Per cent 90.9 0.1 0.1 0.2 2.4 6.3  
Total Number 10,721 8 7 14 305 642 11,697 
 Per cent 91.7 0.1 0.1 0.1 2.6 5.5  
Persons 
50 years Number 4,288 2 1 3 105 201 4,600 
 Per cent 93.2 — — 0.1 2.3 4.4  
55 years Number 3,789 2 4 5 83 201 4,084 
 Per cent 92.8 — 0.1 0.1 2.0 4.9  
60 years Number 6,056 6 3 6 137 373 6,581 
 Per cent 92.0 0.1 — 0.1 2.1 5.7  
65 years Number 7,262 4 9 13 168 494 7,950 
 Per cent 91.3 0.1 0.1 0.2 2.1 6.2  
Total Number 21,395 14 17 27 493 1,269 23,215 
 Per cent 92.2 0.1 0.1 0.1 2.1 5.5  
Notes 
1. Percentages equal the number of people consulting a PHCP after a positive FOBT who received/did not receive referral for either 
colonoscopy or other examination as a proportion of the total number of follow-up consultations after a positive FOBT. 
2. Referrals may sum to more than all follow-up PHCP visits, as more than 1 referral may be given to a person. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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Table A3.10: PHCP referrals for colonoscopy or other examination after a positive FOBT result, by 
geographical location, 2013–14  
 
Colonoscopy 
 
Other 
 
No referral  
All 
PHCP 
visits 
Number Per cent  Number Per cent  Number Per cent  Number 
Major 
cities 
Males 6,642 92.4  142 2.0  408 5.7  7,192 
Females 6,853 91.6  204 2.7  427 5.7  7,484 
Persons 13,495 92.0  346 2.4  835 5.7  14,677 
Inner 
regional 
Males 2,487 93.4  47 1.8  127 4.8  2,661 
Females 2,482 92.4  75 2.8  128 4.8  2,686 
Persons 4,969 92.9  122 2.3  256 4.8  5,347 
Outer 
regional 
Males 1,257 93.1  21 1.6  71 5.3  1,349 
Females 1,161 90.8  42 3.3  76 6.0  1,279 
Persons 2,417 92.0  63 2.4  148 5.6  2,628 
Remote Males 141 92.2  3 2.2  9 5.6  153 
Females 116 90.1  7 5.1  6 4.8  128 
Persons 256 91.2  10 3.5  15 5.2  281 
Very 
remote 
Males 52 n.p.  3 n.p.  2 n.p.  57 
Females 30 n.p.  — n.p.  1 n.p.  32 
Persons 82 n.p.  3 n.p.  3 n.p.  89 
Unknown Males 96 n.p.  — —  10 n.p.  71 
Females 79 n.p.  6 n.p.  3 n.p.  88 
Persons 175 90.2  6 3.1  13 6.7  194 
Notes  
1. Percentages equal the number of people consulting a PHCP after a positive FOBT who received/did not receive referral for either 
colonoscopy or other examination as a proportion of the total number of follow-up consultations after a positive FOBT. 
2. The residential postcodes of participants were mapped to remoteness areas in the 2011 Australian Statistical Geography Standard 
remoteness structure through a postal area correspondence. Those that could not be mapped were included in the ‘Unknown’ row. 
3. Discrepancies may occur between totals and sums of the component items due to rounding—see ‘Geographical classification’, Appendix C. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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Table A3.11: Reason for non-referrals for colonoscopy by PHCPs, 2013–14 
Bowel cancer 
 previously 
 diagnosed 
Limited life 
expectancy 
Recent 
colonoscopy 
(<18 months) 
Patient 
declines 
colonoscopy 
Significant 
comorbidity 
Other 
medical 
condition(s) 
All 
non-referred 
participants 
Males 
50 years Number 3 2 48 40 3 44 122 
 Per cent 2.5 1.6 39.3 32.8 2.5 36.1  
55 years Number — 2 55 44 8 40 133 
 Per cent — 1.5 41.4 33.1 6.0 30.1  
60 years Number 4 4 102 87 11 61 245 
 Per cent 1.6 1.6 41.6 35.5 4.5 24.9  
65 years Number 7 16 168 93 23 80 344 
 Per cent 2.0 4.7 48.8 27.0 6.7 23.3  
Total Number 14 24 373 264 45 225 844 
 Per cent 1.7 2.8 44.2 31.3 5.3 26.7  
Females 
50 years Number — 1 65 60 11 75 190 
 Per cent — 0.5 34.2 31.6 5.8 39.5  
55 years Number 2 1 68 53 7 53 162 
 Per cent 1.2 0.6 42.0 32.7 4.3 32.7  
60 years Number 1 5 120 102 19 67 280 
 Per cent 0.4 1.8 42.9 36.4 6.8 23.9  
65 years Number 2 3 172 94 19 89 344 
 Per cent 0.6 0.9 50.0 27.3 5.5 25.9  
Total Number 5 10 425 309 56 284 976 
 Per cent 0.5 1.0 43.5 31.7 5.7 29.1  
Persons 
50 years Number 3 3 113 100 14 119 312 
 Per cent 1.0 1.0 36.2 32.1 4.5 38.1  
55 years Number 2 3 123 97 15 93 295 
 Per cent 0.7 1.0 41.7 32.9 5.1 31.5  
60 years Number 5 9 222 189 30 128 525 
 Per cent 1.0 1.7 42.3 36.0 5.7 24.4  
65 years Number 9 19 340 187 42 169 688 
 Per cent 1.3 2.8 49.4 27.2 6.1 24.6  
Total Number 19 34 798 573 101 509 1,820 
 Per cent 1.0 1.9 43.8 31.5 5.5 28.0  
Notes 
1. Percentages equal the number of consultations for each reason (after a positive FOBT) that did not refer for colonoscopy as a proportion of 
the total number of positive FOBT consultations that did not refer for colonoscopy. 
2. A participant may have multiple reasons for non-referral for colonoscopy indicated. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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Table A3.12: Crude colonoscopy follow-up after a positive FOBT result, by state and territory,  
2013–14  
 NSW Vic Qld WA SA Tas ACT NT Australia 
Males 
50 years Number 707 641 553 238 253 71 27 3 2,493 
 Per cent 58.8 64.8 72.0 55.9 67.3 n.p. n.p. n.p. 63.5 
55 years Number 619 537 451 196 227 85 31 9 2,155 
 Per cent 58.4 65.2 69.3 57.8 70.1 79.4 n.p. n.p. 63.7 
60 years Number 1,028 869 793 363 348 105 64 15 3,585 
 Per cent 63.9 67.3 73.8 60.6 71.0 70.0 n.p. n.p. 67.0 
65 years Number 1,397 1,112 1,087 385 448 162 63 14 4,668 
 Per cent 66.1 69.5 77.6 59.1 72.5 81.4 n.p. n.p. 69.6 
Total Number 3,751 3,159 2,884 1,182 1,276 423 185 41 12,901 
 Per cent 62.6 67.2 74.1 58.7 70.6 77.8 65.6 32.3 66.6 
Females 
50 years Number 743 724 583 236 245 74 42 5 2,652 
 Per cent 62.6 66.9 76.2 58.1 69.0 n.p. n.p. n.p. 66.9 
55 years Number 646 599 434 227 221 73 49 5 2,254 
 Per cent 60.6 67.2 70.5 65.6 69.7 68.9 n.p. n.p. 65.8 
60 years Number 1,035 903 762 351 377 127 70 11 3,636 
 Per cent 64.3 72.0 75.7 66.0 71.9 79.9 n.p. n.p. 69.8 
65 years Number 1,206 1,004 876 365 408 150 61 5 4,075 
 Per cent 66.0 70.4 78.6 67.2 71.0 80.2 n.p. n.p. 70.5 
Total Number 3,630 3,230 2,655 1,179 1,251 424 222 26 12,617 
 Per cent 63.8 69.4 75.8 64.5 70.6 77.7 73.5 n.p. 68.6 
Persons 
50 years Number 1,450 1,365 1,136 474 498 145 69 8 5,145 
 Per cent 60.7 65.9 74.1 57.0 68.1 79.7 63.9 n.p. 65.2 
55 years Number 1,265 1,136 885 423 448 158 80 14 4,409 
 Per cent 59.5 66.3 69.9 61.8 69.9 74.2 69.0 n.p. 64.7 
60 years Number 2,063 1,772 1,555 714 725 232 134 26 7,221 
 Per cent 64.1 69.6 74.7 63.1 71.5 75.1 72.4 n.p. 68.4 
65 years Number 2,603 2,116 1,963 750 856 312 124 19 8,743 
 Per cent 66.0 70.0 78.0 62.8 71.8 80.8 70.9 n.p. 70.0 
Total Number 7,381 6,389 5,539 2,361 2,527 847 407 67 25,518 
 Per cent 63.2 68.3 74.9 61.5 70.6 77.7 69.7 30.7 67.6 
Notes 
1. Percentages of colonoscopies performed equal the number of people who have had a colonoscopy recorded after a positive FOBT as a 
proportion of the total number of people with positive FOBT results. 
2. Record of a colonoscopy as part of the NBCSP is identified from colonoscopy report forms, histopathology report forms and/or Medicare claims. 
3. As progression through the pathway to the colonoscopy stage may take some time, some participants may not have had sufficient time to have 
had a colonoscopy. Additionally, reporting of colonoscopy follow-up is not mandatory. Therefore, actual numbers of participant colonoscopies 
may be underestimated. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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Table A3.13: Kaplan–Meier estimated colonoscopy follow-up per 100 people with positive FOBTs 
at 26 and 52 weeks since positive FOBT, by state and territory, 2013–14 
  NSW Vic Qld WA SA Tas ACT NT Australia 
26 weeks          
Colonoscopy 
follow-up  
(per cent) 61.9 67.8 74.9 61.1 68.7 76.8 68.9 32.7 66.8 
95% 
confidence 
interval 61.0–62.8 66.9–68.8 73.9–75.9 59.5–62.6 67.1–70.2 74.2–79.3 65.0–72.8 26.0–39.4 66.3–67.3 
52 weeks          
Colonoscopy 
follow-up  
(per cent) 66.9 70.4 80.4 64.8 75.3 80.9 74.1 32.7 71.2 
95% 
confidence 
interval 65.9–67.8 69.4–71.4 79.3–81.5 63.2–66.5 73.7–76.9 78.4–83.5 70.1–78.0 26.0–39.4 70.7–71.7 
(a) The crude rate was substituted as the estimated Kaplan–Meier rate was lower than the actual crude rate. 
Note: Colonoscopy follow-up rates equal the estimated Kaplan–Meier follow-up rate of people who have had a colonoscopy as a proportion of the 
total number of people with positive FOBT results, including people who suspended or opted off the program. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
 
 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A3.3a: Colonoscopy follow-up after a positive FOBT, using Kaplan–Meier estimates, 
Australia, 2013–14 
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Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A3.3b: Colonoscopy follow-up after a positive FOBT using Kaplan–Meier estimates,  
New South Wales, Victoria, Queensland and Western Australia, 2013–14 
 
 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A3.3c: Colonoscopy follow-up after a positive FOBT using Kaplan–Meier estimates,  
South Australia, Tasmania, Australian Capital Territory and Northern Territory, 2013–14 
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Table A3.14: Crude colonoscopy follow-up after a positive FOBT result, by remoteness area,  
2013–14  
 Remoteness area  
 Major cities Inner regional Outer regional Remote Very remote Unknown Total 
Males 
50 years Number 1,787 450 202 24 11 19 2,493 
 Per cent 66.2 60.9 54.9 n.p. n.p. n.p. 63.5 
55 years Number 1,478 424 198 20 9 25 2,155 
 Per cent 67.0 59.6 54.5 n.p. n.p. n.p. 63.7 
60 years Number 2,407 738 370 37 9 24 3,585 
 Per cent 70.6 62.3 61.4 n.p. n.p. n.p. 67.0 
65 years Number 2,986 1,076 512 38 16 40 4,668 
 Per cent 72.3 67.5 63.8 n.p. n.p. n.p. 69.6 
Total Number 8,658 2,688 1,282 120 45 108 12,901 
 Per cent 69.6 63.6 60.0 46.0 45.1 56.5 66.6 
Females 
50 years Number 1,933 481 200 20 7 12 2,652 
 Per cent 69.8 62.5 59.1 n.p. n.p. n.p. 66.9 
55 years Number 1,562 442 207 24 5 14 2,254 
 Per cent 69.2 60.1 58.3 n.p. n.p. n.p. 65.8 
60 years Number 2,450 794 328 29 8 26 3,636 
 Per cent 73.1 67.1 59.0 n.p. n.p. n.p. 69.8 
65 years Number 2,673 938 401 30 11 22 4,075 
 Per cent 73.0 67.9 64.5 n.p. n.p. n.p. 70.5 
Total Number 8,617 2,655 1,136 103 31 74 12,617 
 Per cent 71.6 65.2 60.7 54.0 n.p. 52.9 68.6 
Persons 
50 years Number 3,720 930 402 45 18 31 5,145 
 Per cent 68.0 61.7 56.9 43.3 n.p. n.p. 65.2 
55 years Number 3,040 867 405 44 14 39 4,409 
 Per cent 68.1 59.9 56.4 n.p. n.p. n.p. 64.7 
60 years Number 4,857 1,532 699 66 18 50 7,221 
 Per cent 71.8 64.7 60.2 55.0 n.p. n.p. 68.4 
65 years Number 5,659 2,014 913 68 27 62 8,743 
 Per cent 72.6 67.7 64.1 47.9 n.p. n.p. 70.0 
Total Number 17,275 5,343 2,418 223 76 182 25,518 
 Per cent 70.6 64.4 60.3 49.4 45.1 55.0 67.6 
Notes 
1. Percentages of colonoscopies performed equal the number of people who have had a colonoscopy recorded after a positive FOBT as a proportion of the 
total number of people with positive FOBT results.  
2. Reporting of colonoscopy follow-up is not mandatory. Therefore, actual numbers of participant colonoscopies may be underestimated. 
3. The residential postcodes of participants were mapped to remoteness areas in the 2011 Australian Statistical Geography Standard remoteness structure 
through a postal area correspondence. Those that could not be mapped were included in the ‘Unknown’ column. 
4. Discrepancies may occur between totals and sums of the component items due to rounding—see ‘Geographical classification’, Appendix C. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
 National Bowel Cancer Screening Program: monitoring report 2013–14 95 
 
Notes 
1. Rate per remoteness area is an average of colonoscopy follow-up reported across that remoteness area. 
2. Colonoscopy follow-up rates rounded to integers. 
3. Differences in colonoscopy follow-up rates across remoteness areas may involve differences in form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A3.4a: Colonoscopy follow-up, by remoteness area, New South Wales, 2013–14 
 
 
Notes 
1. Rate per remoteness area is an average of colonoscopy follow-up reported across that remoteness area. 
2. Colonoscopy follow-up rates rounded to integers. 
3. Differences in colonoscopy follow-up rates across remoteness areas may involve differences in form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A3.4b: Colonoscopy follow-up, by remoteness area, Victoria, 2013–14 
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Notes 
1. Rate per remoteness area is an average of colonoscopy follow-up reported across that remoteness area. 
2. Colonoscopy follow-up rates rounded to integers. 
3. Differences in colonoscopy follow-up rates across remoteness areas may involve differences in form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A3.4c: Colonoscopy follow-up, by remoteness area, Queensland, 2013–14 
 
 
Notes 
1. Rate per remoteness area is an average of colonoscopy follow-up reported across that remoteness area. 
2. Colonoscopy follow-up rates rounded to integers. 
3. Differences in colonoscopy follow-up rates across remoteness areas may involve differences in form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A3.4d: Colonoscopy follow-up, by remoteness area, Western Australia, 2013–14 
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Notes 
1. Rate per remoteness area is an average of colonoscopy follow-up reported across that remoteness area. 
2. Colonoscopy follow-up rates rounded to integers. 
3. Differences in colonoscopy follow-up rates across remoteness areas may involve differences in form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A3.4e: Colonoscopy follow-up, by remoteness area, South Australia, 2013–14 
 
 
Notes 
1. Rate per remoteness area is an average of colonoscopy follow-up reported across that remoteness area. 
2. Colonoscopy follow-up rates rounded to integers. 
3. Differences in colonoscopy follow-up rates across remoteness areas may involve differences in form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A3.4f: Colonoscopy follow-up, by remoteness area, Tasmania, 2013–14 
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Notes 
1. Remoteness areas left unshaded contain data that are not publishable due to small numbers, confidentiality or other concerns.  
2. Rate per remoteness area is an average of colonoscopy follow-up reported across that remoteness area. 
3. Colonoscopy follow-up rates rounded to integers. 
4. Differences in colonoscopy follow-up rates across remoteness areas may involve differences in form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A3.4g: Colonoscopy follow-up, by remoteness area, Australian Capital Territory, 2013–14 
 
 
Notes 
1. Remoteness areas left unshaded contain data that are not publishable due to small numbers, confidentiality or other concerns.  
2. Rate per remoteness area is an average of colonoscopy follow-up reported across that remoteness area. 
3. Colonoscopy follow-up rates rounded to integers. 
4. Differences in colonoscopy follow-up rates across remoteness areas may involve differences in form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A3.4h: Colonoscopy follow-up, by remoteness area, Northern Territory, 2013–14 
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Table A3.15: Crude colonoscopy follow-up after a positive FOBT result, by socioeconomic status 
area, 2013–14  
 Socioeconomic status area  
 1 (lowest) 2 3 4 5 (highest) Unknown Total 
Males 
50 years Number 448 467 464 524 568 22 2,493 
 Per cent 56.6 62.9 61.3 65.7 72.2 n.p. 63.5 
55 years Number 418 417 456 422 414 28 2,155 
 Per cent 58.5 57.8 64.3 69.9 70.1 n.p. 63.7 
60 years Number 690 741 708 735 681 30 3,585 
 Per cent 61.2 64.7 68.7 69.7 73.5 n.p. 67.0 
65 years Number 978 945 968 915 808 54 4,668 
 Per cent 64.7 64.8 71.4 74.8 75.1 n.p. 69.6 
Total Number 2,534 2,570 2,596 2,596 2,471 134 12,901 
 Per cent 61.1 63.2 67.4 70.6 73.1 57.0 66.6 
Females 
50 years Number 453 467 512 602 602 16 2,652 
 Per cent 61.4 61.1 68.3 70.5 73.2 n.p. 66.9 
55 years Number 407 444 433 470 480 20 2,254 
 Per cent 56.1 63.7 66.5 70.9 72.9 n.p. 65.8 
60 years Number 646 742 733 712 765 38 3,636 
 Per cent 59.9 66.4 73.2 73.3 78.0 n.p. 69.8 
65 years Number 799 877 819 755 791 34 4,075 
 Per cent 63.0 69.2 70.8 72.9 79.3 n.p. 70.5 
Total Number 2,305 2,530 2,497 2,539 2,638 108 12,617 
 Per cent 60.5 65.8 70.2 72.1 76.3 57.8 68.6 
Persons 
50 years Number 901 934 976 1,126 1,170 38 5,145 
 Per cent 58.9 62.0 64.8 68.2 72.7 n.p. 65.2 
55 years Number 825 861 889 892 894 48 4,409 
 Per cent 57.3 60.7 65.4 70.4 71.6 n.p. 64.7 
60 years Number 1,336 1,483 1,441 1,447 1,446 68 7,221 
 Per cent 60.6 65.5 70.9 71.5 75.8 53.1 68.4 
65 years Number 1,777 1,822 1,787 1,670 1,599 88 8,743 
 Per cent 63.9 66.9 71.1 74.0 77.1 65.7 70.0 
Total Number 4,839 5,100 5,093 5,135 5,109 242 25,518 
 Per cent 60.8 64.5 68.7 71.3 74.7 57.3 67.6 
Notes 
1. Percentages of colonoscopies performed equal the number of people who have had a colonoscopy recorded after a positive FOBT as a 
proportion of the total number of people with positive FOBT results.  
2. Reporting of colonoscopy follow-up is not mandatory. Therefore, actual numbers of participant colonoscopies may be underestimated.  
3. A participant’s socioeconomic status area was classified by mapping their residential postcode (through a postal area) to the ABS IRSD for 
2011. Those that could not be mapped were included in the ‘Unknown’ column. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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Table A3.16: Crude colonoscopy follow-up after a positive FOBT result, by Aboriginal and Torres 
Strait Islander status, 2013–14  
 Indigenous Non-Indigenous Not stated Total 
Males 
50 years Number 35 2,385 73 2,493 
 Per cent n.p. 64.6 45.9 63.5 
55 years Number 31 2,092 32 2,155 
 Per cent n.p. 64.3 n.p. 63.7 
60 years Number 50 3,462 73 3,585 
 Per cent n.p. 67.5 53.3 67.0 
65 years Number 53 4,466 149 4,668 
 Per cent n.p. 70.4 55.4 69.6 
Total Number 169 12,405 327 12,901 
 Per cent 55.8 67.3 51.3 66.6 
Females 
50 years Number 35 2,554 63 2,652 
 Per cent n.p. 67.1 60.6 66.9 
55 years Number 21 2,200 33 2,254 
 Per cent n.p. 66.2 n.p. 65.8 
60 years Number 43 3,550 43 3,636 
 Per cent n.p. 70.0 n.p. 69.8 
65 years Number 45 3,945 85 4,075 
 Per cent n.p. 71.2 55.9 70.5 
Total Number 144 12,249 224 12,617 
 Per cent 57.4 69.0 57.0 68.6 
Persons 
50 years Number 70 4,939 136 5,145 
 Per cent 55.1 65.9 51.7 65.2 
55 years Number 52 4,292 65 4,409 
 Per cent n.p. 65.3 47.4 64.7 
60 years Number 93 7,012 116 7,221 
 Per cent 60.8 68.8 55.2 68.4 
65 years Number 98 8,411 234 8,743 
 Per cent 55.7 70.8 55.6 70.0 
Total Number 313 24,654 551 25,518 
 Per cent 56.5 68.2 53.4 67.6 
Notes 
1. Percentages of colonoscopies performed equal the number of people who have had a colonoscopy recorded after a positive FOBT as a 
proportion of the total number of people with positive FOBT results.  
2. Reporting of colonoscopy follow-up is not mandatory. Therefore, actual numbers of participant colonoscopies may be underestimated. 
3. NBCSP Aboriginal and Torres Strait Islander status was reported by the participant on the returned participant details form. Participants 
who did not indicate Aboriginal and Torres Strait Islander status were included in the ‘Not stated’ column. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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Table A3.17: Crude colonoscopy follow-up after a positive FOBT result, by language spoken at 
home, 2013–14  
 Language other than English English Total 
Males 
50 years Number 387 2,106 2,493 
 Per cent 60.9 64.1 63.5 
55 years Number 316 1,839 2,155 
 Per cent 60.0 64.4 63.7 
60 years Number 491 3,094 3,585 
 Per cent 63.7 67.6 67.0 
65 years Number 532 4,136 4,668 
 Per cent 64.9 70.3 69.6 
Total Number 1,726 11,175 12,901 
 Per cent 62.7 67.3 66.6 
Females 
50 years Number 458 2,194 2,652 
 Per cent 63.3 67.7 66.9 
55 years Number 381 1,873 2,254 
 Per cent 63.4 66.3 65.8 
60 years Number 564 3,072 3,636 
 Per cent 65.6 70.6 69.8 
65 years Number 507 3,568 4,075 
 Per cent 65.2 71.3 70.5 
Total Number 1,910 10,707 12,617 
 Per cent 64.5 69.4 68.6 
Persons 
50 years Number 845 4,300 5,145 
 Per cent 62.2 65.9 65.2 
55 years Number 697 3,712 4,409 
 Per cent 61.8 65.3 64.7 
60 years Number 1,055 6,166 7,221 
 Per cent 64.7 69.0 68.4 
65 years Number 1,039 7,704 8,743 
 Per cent 65.0 70.8 70.0 
Total Number 3,636 21,882 25,518 
 Per cent 63.6 68.3 67.6 
Notes 
1. Percentages of colonoscopies performed equal the number of people who have had a colonoscopy recorded after a positive FOBT as 
a proportion of the total number of people with positive FOBT results.  
2. Reporting of colonoscopy follow-up is not mandatory. Therefore, actual numbers of participant colonoscopies may be underestimated. 
3. NBCSP preferred language spoken at home was reported by the participant on the returned participant details form. Participants who did not 
indicate preferred language spoken at home were assumed to speak English. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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Table A3.18: Crude colonoscopy follow-up after a positive FOBT result, by disability status,  
2013–14  
 
Severe or profound 
activity limitation 
No severe or profound 
activity limitation Not stated Total 
Males 
50 years Number 126 2,267 100 2,493 
 Per cent 52.5 66.0 40.3 63.5 
55 years Number 111 1,966 78 2,155 
 Per cent 50.2 65.8 44.6 63.7 
60 years Number 224 3,207 154 3,585 
 Per cent 55.6 68.9 52.7 67.0 
65 years Number 366 4,117 185 4,668 
 Per cent 58.2 71.7 55.2 69.6 
Total Number 827 11,557 517 12,901 
 Per cent 55.4 68.7 49.2 66.6 
Females 
50 years Number 147 2,417 88 2,652 
 Per cent 57.0 68.2 54.3 66.9 
55 years Number 160 2,020 74 2,254 
 Per cent 59.9 67.3 46.5 65.8 
60 years Number 254 3,263 119 3,636 
 Per cent 57.5 71.6 55.9 69.8 
65 years Number 277 3,672 126 4,075 
 Per cent 55.3 72.7 54.5 70.5 
Total Number 838 11,372 407 12,617 
 Per cent 57.1 70.4 53.2 68.6 
Persons 
50 years Number 273 4,684 188 5,145 
 Per cent 54.8 67.1 45.9 65.2 
55 years Number 271 3,986 152 4,409 
 Per cent 55.5 66.5 45.5 64.7 
60 years Number 478 6,470 273 7,221 
 Per cent 56.6 70.2 54.1 68.4 
65 years Number 643 7,789 311 8,743 
 Per cent 56.9 72.2 54.9 70.0 
Total Number 1,665 22,929 924 25,518 
 Per cent 56.2 69.5 50.9 67.6 
Notes 
1. Percentages of colonoscopies performed equal the number of people who have had a colonoscopy recorded after a positive FOBT as a 
proportion of the total number of people with positive FOBT results.  
2. Reporting of colonoscopy follow-up is not mandatory. Therefore, actual numbers of participant colonoscopies may be underestimated. 
3. NBCSP disability status was reported by the participant on the participant details form. Participants who did not indicate disability status are 
included in the ‘Not stated’ column. 
4. A ‘profound’ activity limitation indicates that a person always needs assistance with self-care, movement and/or communications activities. 
A ‘severe’ activity limitation indicates that a person sometimes needs assistance with these activities.  
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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A4: Bowel abnormality detection tables 
Table A4.1: Colonoscopy outcomes (excludes histopathology), 2013–14 
 Colonoscopy outcome  
 
Suspected 
cancer 
Polyp(s) 
≥10 mm 
Polyp(s) 
<10 mm 
Other 
diagnoses(a) 
No 
abnormality 
Outcome not 
specified 
All 
colonoscopy 
report forms 
Males 
  50 years Number 75 310 651 386 352 6 1,780 
 Per cent 4.2 17.4 36.6 21.7 19.8 0.3  
55 years Number 73 316 561 279 257 2 1,488 
 Per cent 4.9 21.2 37.7 18.8 17.3 0.1  
60 years Number 152 542 980 509 390 8 2,581 
 Per cent 5.9 21.0 38.0 19.7 15.1 0.3  
65 years Number 283 797 1,286 597 415 16 3,394 
 Per cent 8.3 23.5 37.9 17.6 12.2 0.5  
Total Number 583 1,965 3,478 1,771 1,414 32 9,243 
 Per cent 6.3 21.3 37.6 19.2 15.3 0.3  
Females 
 50 years Number 58 196 549 453 608 7 1,871 
 Per cent 3.1 10.5 29.3 24.2 32.5 0.4  
55 years Number 46 165 495 410 460 6 1,582 
 Per cent 2.9 10.4 31.3 25.9 29.1 0.4  
60 years Number 102 309 855 717 625 9 2,617 
 Per cent 3.9 11.8 32.7 27.4 23.9 0.3  
65 years Number 168 406 1,025 769 597 10 2,975 
 Per cent 5.6 13.6 34.5 25.8 20.1 0.3  
Total Number 374 1,076 2,924 2,349 2,290 32 9,045 
 Per cent 4.1 11.9 32.3 26.0 25.3 0.4  
Persons 
50 years Number 133 506 1,200 839 960 13 3,651 
 Per cent 3.6 13.9 32.9 23.0 26.3 0.4  
55 years Number 119 481 1,056 689 717 8 3,070 
 Per cent 3.9 15.7 34.4 22.4 23.4 0.3  
60 years Number 254 851 1,835 1,226 1,015 17 5,198 
 Per cent 4.9 16.4 35.3 23.6 19.5 0.3  
65 years Number 451 1,203 2,311 1,366 1,012 26 6,369 
 Per cent 7.1 18.9 36.3 21.4 15.9 0.4  
Total Number 957 3,041 6,402 4,120 3,704 64 18,288 
 Per cent 5.2 16.6 35.0 22.5 20.3 0.3  
(a) Other diagnoses include haemorrhoids, diverticular disease and inflammatory bowel disease. 
Note: Only colonoscopies with an associated colonoscopy report form were included in this analysis; colonoscopies identified from histopathology 
report forms or Medicare claims only were not included.  
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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Table A4.2: Overall diagnostic outcomes (including histopathology), by state and territory, 2013–14 
State/ 
territory  
Invitations 
issued(a) 
Number 
screened(b) 
Total 
positive 
FOBT 
FOBT positive 
Colonoscopy 
recorded(c) 
No  
cancer or 
adenoma(d) 
Polyps 
awaiting 
histo-
pathology(e) 
Confirmed 
diminutive 
adenoma(f) 
Confirmed 
small 
adenoma(f) 
Confirmed 
advanced 
adenoma(f) 
Suspected 
cancer(g)  
Confirmed 
cancer(h) 
NSW Number 477,356 158,527 11,679 4,890 2,485 1,229 518 5 435 156 62 
 Per cent     50.8 25.1 10.6 0.1 8.9 3.2 1.3 
Vic Number 341,694 126,503 9,355 4,823 2,514 1,546 245 65 274 144 35 
 Per cent     52.1 32.1 5.1 1.3 5.7 3.0 0.7 
Qld Number 282,790 100,408 7,397 4,538 1,825 1,522 318 81 611 145 36 
 Per cent     40.2 33.5 7.0 1.8 13.5 3.2 0.8 
WA Number 138,922 53,263 3,842 1,500 583 739 47 8 61 61 1 
 Per cent     38.9 49.3 3.1 0.5 4.1 4.1 0.1 
SA Number 107,255 45,551 3,579 1,898 942 538 129 51 175 55 8 
 Per cent     49.6 28.3 6.8 2.7 9.2 2.9 0.4 
Tas Number 33,531 13,750 1,090 656 339 127 29 29 106 24 2 
 Per cent     51.7 19.4 4.4 4.4 16.2 3.7 0.3 
ACT  Number 23,157 8,837 584 325 128 118 36 — 29 10 4 
 Per cent     39.4 36.3 11.1 — 8.9 3.1 1.2 
NT Number 10,850 2,897 218 39 23 8 3 — — 4 1 
 Per cent     n.p. n.p. n.p. — — n.p. n.p. 
Australia Number 1,415,555 509,736 37,744 18,669 8,839 5,827 1,325 239 1,691 599 149 
 Per cent         47.3 31.2 7.1 1.3 9.1 3.2 0.8 
(a) ‘Invitations issued’ equals the number of eligible people who were issued an invitation to screen in the NBCSP. 
(b) ‘Number screened’ equals the number of people who completed an FOBT kit and had results forwarded to the Register. 
(c) ‘Colonoscopy recorded’ includes colonoscopies recorded via the colonoscopy report and/or histopathology report forms. It does not include colonoscopies identified through Medicare claims. 
(d) No cancers were suspected at colonoscopy or confirmed non-cancerous by histopathology; no polyps identified at colonoscopy, or polyps confirmed as non-adenomatous at histopathology. 
(e) Polyps detected at colonoscopy and sent to histopathology for analysis. No histopathology report form received by Register. 
(f) Confirmed adenoma figures were based on a combination of the colonoscopy and histopathology report forms for a person received by the Register.  
(g) Cancer suspected at colonoscopy but not yet confirmed by histopathology.  
(h) Cancer confirmed by histopathology.  
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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Table A4.3: Overall diagnostic outcomes (including histopathology), by age and sex, 2013–14 
  
Invitations 
issued(a) 
Number 
screened(b) 
Total 
positive 
FOBT 
FOBT positive 
Colonoscopy 
recorded(c) 
No  
cancer or 
adenoma(d) 
Polyps awaiting 
histopathology(e) 
Confirmed 
diminutive 
adenoma(f) 
Confirmed 
small 
adenoma(f) 
Confirmed 
advanced 
adenoma(f) 
Suspected 
cancer(g)  
Confirmed 
cancer(h) 
Males  
50 years Number 221,518 56,295 3,923 1,821 835 611 125 21 166 55 8 
 Per cent     45.9 33.6 6.9 1.2 9.1 3.0 0.4 
55 years Number 147,334 49,093 3,384 1,531 622 544 114 27 163 49 12 
 Per cent     40.6 35.5 7.4 1.8 10.6 3.2 0.8 
60 years Number 173,409 68,548 5,350 2,628 1,047 927 209 35 298 91 21 
 Per cent     39.8 35.3 8.0 1.3 11.3 3.5 0.8 
65 years Number 163,971 63,056 6,703 3,485 1,195 1,261 311 53 443 166 56 
 Per cent     34.3 36.2 8.9 1.5 12.7 4.8 1.6 
Total Number 706,232 236,992 19,360 9,465 3,699 3,343 759 136 1,070 361 97 
 Per cent     39.1 35.3 8.0 1.4 11.3 3.8 1.0 
Females  
50 years Number 220,119 64,604 3,964 1,907 1,163 473 96 22 112 34 7 
 Per cent     61.0 24.8 5.0 1.2 5.9 1.8 0.4 
55 years Number 147,866 56,966 3,428 1,609 965 413 85 17 92 31 6 
 Per cent     60.0 25.7 5.3 1.1 5.7 1.9 0.4 
60 years Number 175,506 80,438 5,211 2,665 1,486 716 186 23 174 62 18 
 Per cent     55.8 26.9 7.0 0.9 6.5 2.3 0.7 
65 years Number 165,832 70,736 5,781 3,023 1,526 882 199 41 243 111 21 
 Per cent     50.5 29.2 6.6 1.4 8.0 3.7 0.7 
Total Number 709,323 272,744 18,384 9,204 5,140 2,484 566 103 621 238 52 
 Per cent         55.8 27.0 6.1 1.1 6.7 2.6 0.6 
(continued) 
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Table A4.3 (continued): Overall diagnostic outcomes (including histopathology), by age and sex, 2013–14 
  
Invitations 
issued(a) 
Number 
screened(b) 
Total 
positive 
FOBT 
FOBT positive 
Colonoscopy 
recorded(c) 
No  
cancer or 
adenoma(d) 
Polyps awaiting 
histopathology(e) 
Confirmed 
diminutive 
adenoma(f) 
Confirmed 
small 
adenoma(f) 
Confirmed 
advanced 
adenoma(f) 
Suspected 
cancer(g)  
Confirmed 
cancer(h) 
Persons  
50 years Number 441,637 120,899 7,887 3,728 1,998 1,084 221 43 278 89 15 
 Per cent     53.6 29.1 5.9 1.2 7.5 2.4 0.4 
55 years Number 295,200 106,059 6,812 3,140 1,587 957 199 44 255 80 18 
 Per cent     50.5 30.5 6.3 1.4 8.1 2.5 0.6 
60 years Number 348,915 148,986 10,561 5,293 2,533 1,643 395 58 472 153 39 
 Per cent     47.9 31.0 7.5 1.1 8.9 2.9 0.7 
65 years Number 329,803 133,792 12,484 6,508 2,721 2,143 510 94 686 277 77 
 Per cent     41.8 32.9 7.8 1.4 10.5 4.3 1.2 
Total Number 1,415,555 509,736 37,744 18,669 8,839 5,827 1,325 239 1,691 599 149 
 Per cent         47.3 31.2 7.1 1.3 9.1 3.2 0.8 
(a) ‘Invitations issued’ equals the number of eligible people who were issued an invitation to screen in the NBCSP. 
(b) ‘Number screened’ equals the number of people who completed an FOBT kit and had results forwarded to the Register. 
(c) ‘Colonoscopy recorded’ includes colonoscopies recorded via the colonoscopy report and/or histopathology report forms. It does not include colonoscopies identified through Medicare claims. 
(d) No cancers were suspected at colonoscopy or confirmed non-cancerous by histopathology; no polyps identified at colonoscopy, or polyps confirmed as non-adenomatous at histopathology. 
(e) Polyps detected at colonoscopy and sent to histopathology for analysis. No histopathology report form received by Register. 
(f) Confirmed adenoma figures were based on a combination of the colonoscopy and histopathology report forms for a person received by the Register.  
(g) Cancer suspected at colonoscopy but not yet confirmed by histopathology.  
(h) Cancer confirmed by histopathology. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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A5: Adverse event tables 
Table A5.1: Adverse outcomes after investigation of positive FOBT by colonoscopy, 2013–14 
  Adverse outcomes  
Unplanned 
hospital 
admission 
within 30 days 
 
Colonoscopies Bleeding 
Infection/ 
sepsis Perforation 
Reaction to 
sedation/ 
anaesthesia Death Other 
Delayed 
discharge 
Surgery 
required 
Males Number 12,901 29 — — 7 — 16 13 14 1 
 Per cent  0.2 — — 0.1 — 0.1 0.1 0.1 — 
Females Number 12,617 12 — 2 1 — 8 7 9 1 
 Per cent  0.1 — — — — 0.1 0.1 0.1 — 
Persons Number 25,518 41 — 2 8 — 24 20 23 2 
 Per cent  0.2 — — — — 0.1 0.1 0.1 0.0 
Notes 
1. All participants known to have had a colonoscopy are included, including those only recorded through Medicare claim or histopathology data. 
2. A colonoscopy may have more than 1 adverse event. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
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A6: Additional NBCSP outcome data 
Overall outcomes (August 2006–June 2014) 
Overall data on invitees, and their progression through the pathway, have been applied to 
the Population based screening framework (APHDPCSS 2008) stages (Figure A6.1). 
 
Recruitment
6,988,058 invitations sent
Screening
2,548,035 participants returned 
an FOBT for screening
(36.5%)
Assessment
187,953 positive FOBTs
(7.5%)(a)
Diagnosis(b)
137,820 recorded 
colonoscopies
(73.3%)
Recorded colonoscopy outcomes
No cancer or adenoma   79,125 (57.4%)
Polyp awaiting histopathology results   33,476 (24.3%)
Diminutive adenoma     6,441   (4.7%)
Small adenoma     2,495   (1.8%)
Advanced adenoma   12,294   (8.9%)
Suspected cancer     2,801   (2.0%)
Confirmed cancer     1,188   (0.9%)
 
(a) Based on the 2,513,632 participants who returned a valid FOBT. 
(b) The number of recorded colonoscopies includes those identified through a Medicare claim, which may not have had associated outcome 
data available for analysis. 
Notes 
1. Invitees aged 50, 55, 60 and 65 were included; other aged invitees (for example, pilot invitees from phase 1) were excluded. 
2. Adenoma classifications are described in Appendix B. 
3. Figure is not to scale. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2014. 
Figure A6.1: Overall NBCSP outcomes for invitees aged 50, 55, 60 and 65, August 2006–June 2014  
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Figure A6.1 in this report has been updated to take into account invitees who have received a 
second invitation—something the previous monitoring report did not. The current overall 
screening rate of 36.5% is lower than the 45.4% rate achieved in the pilot program, while the 
overall crude colonoscopy follow-up (diagnosis) rate of 73.3% is higher than that achieved in 
the pilot program (55.0%) (DoHA 2005).  
Since the inception of the NBCSP in 2006, 3,989 participants have been diagnosed with a 
suspected or confirmed cancer and 12,294 more have been diagnosed with advanced 
adenomas. Additionally, 8,936 participants have been diagnosed with earlier-stage 
adenomas. 
While the NBCSP only follows participants up to the point of definite diagnosis, and 
outcomes of treatment for these participants are unknown, it would be expected that the 
earlier treatment the NBCSP afforded these participants should improve their treatment 
outcomes. This may eventually be shown as reductions in bowel cancer incidence and 
mortality in the coming years.  
Lastly, an increase in the rate of return of colonoscopy and histopathology report forms, 
would improve monitoring of the NBCSP and its invitees. 
Updated outcomes for 2012–13 invitees 
The previous monitoring report, National Bowel Cancer Screening Program monitoring report: 
July 2012–June 2013 (AIHW 2014e), presented national statistics on key program activity, 
performance and outcome indicators for people invited from 1 July 2012 to 30 June 2013. The 
report used outcome data up until 31 December 2013, and those results are shown in the 
comparison table provided after the summary of this report (Table 1).  
For many participants invited late in the period reported, limited follow-up data were 
available. The latest program data, to 31 December 2014, provide an extra 12 months of 
participation and documented follow-up outcomes for this cohort. Table A6.1 provides a 
comparison of the initial and updated statistics for these people invited from 1 July 2012 to 
30 June 2013.  
The changes reflected in the final column show slight increases in participation rates, as well 
as increases in outcome data related to additional follow-up form return. It is important to 
note, however, that while the values in this table are based on a larger amount of outcome 
data and may be considered final, follow-up information remains incomplete due to an 
unknown number of follow-up outcome forms—particularly those relating to 
histopathology—never being returned to the NBCSP Register. 
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Table A6.1: Initially reported and final performance measure outcomes, people aged 50, 55 and 65, 
2012–13  
 Initial(a) Final(b) 
Performance measure Percentage of those invited to participate 
Overall participation rate 33.4 34.1 
 50 years 27.4 28.2 
 55 years 33.2 33.8 
 65 years 41.6 42.3 
 Percentage of those who screened 
FOBT positivity rate 7.5 7.5 
 Percentage of those with a positive screen 
PHCP follow-up rate 58.0 59.6 
Colonoscopy follow-up rate 70.4 75.1 
 Percentage of colonoscopy outcomes 
Suspected/confirmed cancers 3.2 3.3 
Advanced adenomas 5.7 6.9 
Small or diminutive adenomas 3.9 5.7 
Polyps awaiting histopathology 41.2 37.2 
No abnormality 46.0 46.9 
(a) Initial values relate to those known for the 2012–13 invitees using data as reported in the previous monitoring report (AIHW 2014e).  
(b) Final values relate to those known for the 2012–13 invitees using data as at 31 December 2014.  
Notes 
1. Participation is the percentage of eligible invitees who returned a completed FOBT kit, regardless of whether they later suspended 
their participation or opted off. 
2. FOBT positivity equals the percentage of valid FOBT results that were positive, with valid results being either positive or negative; 
inconclusive results were excluded. 
3. PHCP follow-up rate equals the percentage of people with a positive FOBT result who then consulted a PHCP and had an assessment 
form returned to the NBCSP Register.  
4. Colonoscopy follow-up rate equals the percentage of people with a positive FOBT result who then had a colonoscopy recorded in the 
register.  
5. Colonoscopy outcomes relate to the most accurate outcome data available for recorded colonoscopies. 
Source: National Bowel Cancer Screening Program Register. 
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Appendix B: National Bowel Cancer 
Screening Program (NBCSP) information 
NBCSP resources 
 
Note: This figure does not reflect the target population cohorts from 1 January 2015. 
© Commonwealth of Australia 2014.  
Source: Health (2015a). Reproduced with permission of the copyright owner. 
Figure B.1: The NBCSP participant’s screening pathway  
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NBCSP definitions 
Target population 
The NBCSP has been phased in gradually to ensure demand for services such as colonoscopy 
can be met. Table B.1 outlines the start dates of each phase, and the target age groups. 
Table B.1: NBCSP phases and target populations 
Phase Start date End date Target ages 
1 7 August 2006 30 June 2008 55 and 65 
2 1 July 2008 30 June 2011(a) 50, 55 and 65 
2(b) 1 July 2011 30 June 2013 50, 55 and 65 
3 1 July 2013 Ongoing 50, 55, 60 and 65 
4 1 January 2015  50, 55, 60, 65, 70 and 74 
4 1 January 2016  50, 55, 60, 64, 65, 70, 72 and 74 
4 1 January 2017  50, 54, 55, 58, 60, 64, 68, 70, 72 and 74 
4 1 January 2018  50, 54, 58, 60, 62, 64, 66, 68, 70, 72 and 74 
4 1 January 2019  50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72 and 74 
(a) Eligible birthdates, and thus invitations, ended on 31 December 2010. 
(b) Ongoing NBCSP funding commenced. 
Note: The eligible population for all Phase 2 and 3 start dates incorporates all those turning the target ages from 1 January of that  
year, onwards. 
Eligible population 
The eligible population invited included those in the target population, as defined above, 
who were registered as an Australian citizen or migrant in the Medicare enrolment file, or 
were registered with a Department of Veterans’ Affairs gold card. Invitees who were outside 
the target ages or had a current address outside Australia were excluded from this report. 
People who chose to opt off or suspend participation were included in the eligible 
population.  
Polyps 
Colorectal (bowel) polyps are small growths of colon tissue that protrude into the colonic or 
rectal lumen. They are usually asymptomatic, but sometimes cause visible rectal bleeding 
and, rarely, other symptoms. Polyps may occur individually but it is common for a person to 
have multiple polyps. They occur more commonly in later life, and hereditary and dietary 
(lifestyle) factors may play a part. Polyps may become cancerous and are generally defined 
as 2 main types: 
• hyperplastic—a type of polyp that has a low risk, if any, of developing into a cancer; 
however, people with multiple hyperplastic polyps are associated with an increased risk 
of bowel cancer 
• adenoma (adenomatous)—a polyp that has a higher chance of becoming cancerous, as it 
contains molecular characteristics that are common with adenocarcinoma (see ‘Adenoma 
classifications’ below). 
 National Bowel Cancer Screening Program: monitoring report 2013–14 113 
Polyp number, size and microscopic features may also predict the likelihood of a polyp 
becoming cancerous, with larger and flatter (non-stalked) polyps having the higher risk. 
During a colonoscopy, polyps are removed, thus lowering the risk of bowel cancer 
developing in the person. 
Adenoma classifications 
An adenoma (adenomatous polyp) is a benign tumour that arises from epithelial cells. All 
adenomas have malignant potential. Adenomas in the rectum or colon have a higher chance 
of developing into cancer (adenocarcinoma) than adenomas in most other organs.  
Although nearly all cancers in the colon (adenocarcinomas) arise from adenomas, only a 
small minority of adenomas (1 in 20 or fewer) progress to cancer (Ahnen & Macrae 2008). 
While most small tubular adenomas have a low risk of progressing to cancer, the risk is 
much higher in advanced adenomas.  
Adenoma classifications were derived from information reported by colonoscopists and 
histopathologists, and were classified from highest risk (advanced) to lowest risk 
(diminutive), as listed below. Where a person had multiple adenomas, they were classified 
according to the adenoma having the highest risk. 
Advanced adenoma 
If any of the indicators of higher risk were present, the adenoma was classified as advanced: 
• adenoma multiplicity—3 or more adenomas present at examination, regardless of 
histopathology or size 
• adenoma size—a size of 10 millimetres or greater. The measurement is subject to certain 
problems with accuracy. Where colonoscopy and pathology reports differ in their 
recording of size, the larger size was used. 
• high-grade dysplasia 
• significant villous change or serrated—adenomas recorded as serrated, tubulovillous or 
villous on pathology reports. 
Non-advanced adenomas 
Small adenoma 
A tubular or mixed adenoma between 5 millimetres and 9 millimetres. 
Diminutive adenoma 
A tubular or mixed adenoma smaller than 5 millimetres, or with no size recorded.  
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Appendix C: Data sources and 
classifications 
Data sources 
Multiple data sources were analysed to produce this report. These are summarised in 
Table C.1. All data used in this report were based on calendar years. 
Table C.1: Data sources for information presented in this report 
Measure Data source 
1 Participation National Bowel Cancer Screening Program Register 
2 FOBT outcomes National Bowel Cancer Screening Program Register 
3 Follow up of positive FOBT results National Bowel Cancer Screening Program Register 
4 Bowel abnormality detection National Bowel Cancer Screening Program Register 
5 Adverse events National Bowel Cancer Screening Program Register 
6 Incidence of bowel cancer (ICD-10 C18–20) Australian Cancer Database (ACD), Australian Institute of Health and 
Welfare (AIHW) 
7 Mortality from bowel cancer (ICD-9 153,  
154.0–154.1, ICD-10 C18–20) 
National Mortality Database (NMD), AIHW 
8 Expenditure AIHW Health Expenditure Database; Medicare Australia statistics 
Population data Australian June 2001 standard population; Estimated resident 
populations, Australian Bureau of Statistics (ABS); 2011 Census of 
Population and Housing, ABS 
National Bowel Cancer Screening Program (NBCSP) Register data 
This report uses NBCSP Register data to present statistics on the progression of eligible 
participants through the screening pathway, for those invited into the NBCSP from 
1 July 2013 to 30 June 2014. It covers measures of participation, faecal occult blood test 
(FOBT) results, and follow-up investigations and outcomes. Analyses are presented by age, 
sex, state and territory, geographical region, socioeconomic status, Indigenous status, 
language spoken at home, and disability status. 
Data Quality Statement: NBCSP screening data: 2013–14 
Summary of key issues 
• The NBCSP is managed by the Department of Health in partnership with state and 
territory governments. The NBCSP is monitored annually by the Australian Institute of 
Health and Welfare (AIHW). Results are compiled and reported at the national level by 
the AIHW in an annual NBCSP monitoring report.  
• NBCSP data depend on the return of data forms from participants, general practitioners, 
colonoscopists and pathologists to the NBCSP Register. The register is maintained by the 
Department of Human Services. Data from the register are provided to the AIHW 
6-monthly as de-identified unit record data.  
• Analysis of remoteness and socioeconomic status are based on postcode of residential 
address of NBCSP invitees at the time of screening. Correspondences for these 
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disaggregations may be unavoidably older than the year(s) of screening data being 
reported, potentially leading to inaccuracies.  
• Aboriginal and Torres Strait Islander status, preferred language spoken at home and 
disability status are self-reported by participating individuals.  
• Exclusion of people screened outside the NBCSP will result in an underestimation of 
population screening rates in the target ages.  
• Data return for later stages in the NBCSP screening pathway (GP, colonoscopy and 
pathology follow-up, as required) is not mandatory. Further, not all people who received 
a positive (abnormal) screening result may have had time to complete follow-up steps at 
the time of reporting. These factors may result in under-reporting of outcome data.  
• Data may be suppressed for confidentiality and reliability reasons (for example, if the 
denominator is less than 100, or the rate could not be sensibly estimated). 
Description 
The NBCSP is managed by the Department of Health in partnership with state and territory 
governments. The NBCSP started in 2006 and uses national invitation and screening analysis 
processes. A ‘usual care’ model is then used for follow-up functions for those with a positive 
(abnormal) screening result; that is, these people are encouraged to see their doctor to 
discuss the test result and seek further diagnostic testing (such as colonoscopy) as required. 
Data from these follow-up functions are returned to the national NBCSP Register via 
non-mandatory form return. 
Currently, people who are registered as Australian citizens or migrants in the Medicare 
enrolment file, or are registered with a Department of Veterans’ Affairs gold card, receive a 
screening invitation at, or around, their 50th, 55th, 60th and 65th birthdays. From January 
2015, program expansion to implement a biennial screening interval for those aged 50–74 
will start. It is due to be completed by 2020. 
NBCSP data depend on the return of data forms from participants, general practitioners, 
colonoscopists and pathologists to the NBCSP Register. The register is maintained by the 
Department of Human Services. Data from the register are provided to the AIHW 6-monthly 
as de-identified unit record data.  
The NBCSP is monitored annually by the AIHW. Results are compiled and reported at the 
national level by the AIHW in an annual NBCSP monitoring report. 
Institutional environment 
The AIHW is a major national agency set up by the Australian Government under the 
Australian Institute of Health and Welfare Act 1987 to provide reliable, regular and relevant 
information and statistics on Australia’s health and welfare. It is an independent corporate 
Commonwealth entity established in 1987, governed by a management Board, and 
accountable to the Australian Parliament through the Health portfolio. 
The AIHW aims to improve the health and wellbeing of Australians through better health 
and welfare information and statistics. It collects and reports information on a wide range of 
topics and issues, ranging from health and welfare expenditure, hospitals, disease and 
injury, and mental health, to ageing, homelessness, disability and child protection. 
The AIHW also plays a role in developing and maintaining national metadata standards. 
This work contributes to improving the quality and consistency of national health and 
welfare statistics. The AIHW works closely with governments and non-government 
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organisations to achieve greater adherence to these standards in administrative data 
collections to promote national consistency and comparability of data and reporting. 
The Australian Institute of Health and Welfare Act 1987, in conjunction with compliance to the 
Privacy Act 1988 (Cwlth), ensures that the data collections managed by the AIHW are kept 
securely and under the strictest conditions with respect to privacy and confidentiality. 
For further information see the AIHW website, <www.aihw.gov.au>. 
Under agreement with the Department of Health and AIHW, the Department of Human 
Services supply a de-identified snapshot of all NBCSP activity to the AIHW at 6-month 
intervals. The AIHW has been receiving these data, for reporting purposes, since 2006. 
Relevance 
NBCSP screening data are highly relevant for monitoring trends and outcomes from NBCSP 
screening participation. It is important to note that additional bowel cancer screening is 
undertaken outside of the NBCSP. Data on people screened outside the program are not 
routinely collected; therefore, the level of underestimation of overall bowel cancer screening 
in Australia is unknown.  
Socioeconomic status Index of Relative Socio-economic Disadvantage (IRSD) rankings are 
calculated by postal area (POA) using a population-based method at the Australia-wide 
level. These ranked socioeconomic status POAs are then allocated to their relevant 
jurisdiction, meaning quintiles should contain similar socioeconomic groups across 
jurisdictions. 
Timeliness 
The data discussed in this data quality statement are for the period July 2013–June 2014 , and 
will first be made publically available in June 2015. 
A snapshot of all NBCSP activity is made available to the AIHW regularly at 6-month 
intervals. However, as there is a time lag between issuing invitations and confirmed 
diagnosis of bowel cancer, the monitoring reports are based on outcomes of a cohort of 
people sent invitations in a given period—this is usually cut off about 6 months before the 
date of the data supply to allow for sufficient follow-up data for analysis. 
Therefore, the reportable NBCSP data held at the AIHW at any given time is about 6 months 
behind the current date. 
Accuracy 
Self-reporting of Aboriginal and Torres Strait Islander, language spoken at home and 
disability status within the program means the accuracy of these data are dependent on 
correct, and complete, information from participants. 
IRSD rankings are measured only at the time of the Australian Census of Population and 
Housing and are not available for about 18 months from the census date. Consequently, 
socioeconomic status for a geographical area may be up to 6 years out of date and not an 
accurate representation of the status of residents at the time the data are analysed.  
An Australian Bureau of Statistics POA to remoteness correspondence and a POA to 
socioeconomic status correspondence are used to allocate persons screened to remoteness 
and socioeconomic status areas based on their postcode of residence. POAs are defined to 
match Australia Post postcodes as closely as possible, but for various reasons, they do not 
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match identically. Socioeconomic status is calculated using a population-based method at the 
Australia-wide level. 
The remoteness (and socioeconomic status) to POA correspondences are based on postal 
areas, boundaries and classifications as at the year of the last Australian census, which may 
have been up to 5 years earlier, and boundaries, socioeconomic status and remoteness 
regions may have changed over time, creating inaccuracies. New postal areas defined since 
the previous census will not have valid remoteness or socioeconomic status correspondence 
data available as they will not match the old postal areas. 
NBCSP outcome data are via non-mandatory form return from GP visits, colonoscopies, 
histopathology, adverse events and surgical resection. The level of form return is unknown; 
therefore, there is an unknown amount of missing outcome data. This needs to be taken into 
consideration when reviewing NBCSP outcome analyses.  
The data used in NBCSP monitoring reports allow for 6 months of follow-up time 
post-invitation. However, this may not be enough time for all people who had a positive 
screening result to have completed the screening pathway and had outcomes returned to the 
NBCSP Register. This may also result in some under-reporting of outcome data.  
Some data cells have been suppressed for confidentiality and reliability reasons (for example, 
if the denominator is less than 100, or the rate could not be sensibly estimated). 
Coherence 
NBCSP screening data are reported and published annually by the AIHW. Any changes in 
reporting practices over time will be clearly noted within the monitoring reports; none have 
occurred to date. In future, the addition of extra screening ages and biennial rescreening are 
expected to affect results in most areas of the screening pathway. Further, the 
implementation of reporting using new performance indicators will start in 2016. 
Interpretability 
While the concept of participation in the NBCSP is easy to interpret, the NBCSP screening 
pathway and other concepts and statistical calculations are more complex and may be 
confusing to some users. All concepts are explained within the body of the reports 
presenting these data, along with footnotes to provide further details and caveats. The 
appendixes provide additional detail on the data sources and classifications, and on the 
statistical methods used. 
Accessibility 
The NBCSP annual monitoring reports, and any supplementary data, are available via the 
AIHW website where they can be downloaded free of charge. Users can request data not 
available online or in reports via the Cancer and Screening Unit of the AIHW on 02 6244 1000 
or via email to <screening@aihw.gov.au>. Requests that take longer than half an hour to 
compile are charged for on a cost-recovery basis. General enquiries about AIHW 
publications can be made to the Digital and Media Communications Unit on 02 6244 1000 or 
via email to <info@aihw.gov.au>. 
General enquiries about AIHW publications can be made to the Digital and Media 
Communications Unit on 02 6244 1000 or via email to <info@aihw.gov.au>. 
This Data Quality Statement can be found on AIHW website at 
<http://meteor.aihw.gov.au/content/index.phtml/itemId/608831>. 
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AIHW Australian Cancer Database 
All forms of cancer, except basal and squamous cell carcinomas of the skin, are notifiable 
diseases in each Australian state and territory. This means there is legislation in each 
jurisdiction that requires hospitals, pathology laboratories and various other institutions to 
report all cases of cancer to their central cancer registry. An agreed subset of the data 
collected by these cancer registries is supplied annually to the AIHW, where the data are 
compiled into the Australian Cancer Database (ACD). The ACD currently contains data on 
all cases of cancer diagnosed from 1982 to 2009 for all states and territories, and for 2010 and 
2011 for all except NSW and the ACT. 
The 2010 and 2011 incidence data for NSW and the ACT were not available for inclusion in 
the 2011 version of the ACD. The development of the new NSW Cancer Registries system 
has resulted in a delay in processing incidence data for 2010 onwards and therefore the most 
recent NSW data available for inclusion in the ACD are for 2009 (though their 2009 death-
certificate-only cases were also not available and have been estimated as well). Full details 
about this situation are given at: <http://www.cancerinstitute.org.au/data-and-
statistics/accessing-our-data/availability-of-nsw-central-cancer-registry-data>. As the 
coding of ACT cancer notifications is contracted to the NSW Cancer Registry, the most recent 
data available for the ACT are also for 2009.  
The 2010 and 2011 incidence data for NSW and the ACT were estimated by the AIHW. These 
estimates were combined with the actual data supplied by the other 6 state and territory 
cancer registries to form the 2011 ACD. The detailed methodology by which data for NSW 
and the ACT were estimated for 2010 and 2011 is available in Appendix F of Cancer in 
Australia: an overview 2014 (AIHW 2014f). 
Cancer reporting and registration is a dynamic process, and records in the state and territory 
cancer registries may be modified if new information is received. As a result, the number of 
cancer cases reported by the AIHW for any particular year may change slightly over time 
and may not always align with state and territory reporting for that same year. 
Data have been analysed using the year of diagnosis of cancer. This is a more accurate 
reflection of incidence during a particular year than the year of registration of cancer. 
The Data Quality Statement for the ACD 2011 can be found on the AIHW website at 
<http://meteor.aihw.gov.au/content/index.phtml/itemId/586979>. 
AIHW National Mortality Database 
The AIHW National Mortality Database (NMD) contains information provided by the 
Registries of Births, Deaths and Marriages and the National Coronial Information System, 
and coded by the ABS, for deaths from 1964 to 2012. Registration of deaths is the 
responsibility of the state and territory registrars of births, deaths and marriages. These data 
are then collated and coded by the ABS and are maintained at the AIHW in the NMD. 
In the NMD, the year of occurrence of the death, and the year in which the death was 
registered, are both provided. For the purposes of this report, actual mortality data are 
shown based on the year of occurrence of the death, except for the most recent year (2012), 
where the number of people whose death was registered is used. Previous investigation has 
shown that the year of death and its registration coincide for the most part. However, in 
some instances, deaths at the end of each calendar year may not be registered until the 
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following year. Thus, year-of-death information for the latest available year is generally an 
underestimate of the actual number of deaths that occurred in that year. 
In this report, deaths registered in 2010 and earlier are based on the final version of cause-of-
death data; deaths registered in 2011 and 2012 are based on revised and preliminary 
versions, respectively, and are subject to further revision by the ABS. 
A statement on data quality relating to the AIHW NMD is available at the following ABS 
website: Quality declaration summary, Causes of death, 2012, ABS cat. no. 3303.0 
<http://www.abs.gov.au/AUSSTATS/abs@.nsf/Latestproducts/3303.0Quality%20Declarat
ion02012?opendocument&tabname=Notes&prodno=3303.0&issue=2012&num=&view=>. 
All states and territories have provision for the identification of Aboriginal and Torres Strait 
Islander deaths on their death registration forms. However, the coverage of deaths identified 
as Indigenous varies across states and territories and over time. While the identification of 
Indigenous deaths is incomplete in all state and territory registration systems, the ABS and 
AIHW assessed the adequacy of identification for analysis and: 
• Western Australia, South Australia and the Northern Territory were found to have had 
adequate identification from 1991 onwards,  
• Queensland was added as having adequate identification from 1998 onwards, and 
• New South Wales was also deemed as having adequate identification from 2001 
onwards (meaning 5 jurisdictions can be reported from 2001 onwards).  
Data for Aboriginal and Torres Strait Islander deaths, state and territory and geographical 
location have been combined for the 5 years from 2008–2012 due to the small number of 
deaths from bowel cancer in some categories each year.  
AIHW Disease Expenditure Database 
The AIHW Disease Expenditure Database contains estimates of expenditure by disease 
category, age group and sex for each of the following areas of expenditure: admitted patient 
hospital services, out-of-hospital medical services, prescription pharmaceuticals, 
optometrical and dental services, community mental health services and public health cancer 
screening. 
For more information on the AIHW Disease Expenditure Database, see Health system 
expenditures on cancer and other neoplasms in Australia: 2008–09 (AIHW 2013a). 
The Data Quality Statement for the Disease Expenditure Database can be found on the 
AIHW website at <http://meteor.aihw.gov.au/content/index.phtml/itemId/512599>. 
ABS Population data 
To derive their estimates of the resident populations, the ABS uses the 5-yearly Census of 
Population and Housing data and adjusts it as follows: 
• All respondents in the Census are placed in their state or territory, Statistical Local Area 
(SLA) and postcode of usual residence; overseas visitors are excluded. 
• An adjustment is made for persons missed in the Census. 
• Australians temporarily overseas on Census night are added to the usual residence 
Census count. 
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Estimated resident populations are then updated each year from the Census data, using 
indicators of population change such as births, deaths and net migration. More information 
is available from the ABS website at <www.abs.gov.au>. 
The ABS estimated (mid-year) resident population data were used to calculate incidence and 
mortality rates in this report. These data were sourced from ABS Australian demographic 
statistics (ABS cat. no. 3101.0). 
Classifications 
Geographical classification 
The ability to access and provide a wide range of services is influenced by the distance 
between clients and providers, be it for the clients to travel to the service providers or for the 
providers to travel to deliver services close to a person’s home. The geographical location of 
areas is therefore an important concept in planning and analysing the provision of services.  
Geographical location was classified according to the ABS Australian Statistical Geography 
Standard (ASGS) 2011 Remoteness Structure, which groups geographical areas into 6 
categories. These categories, called Remoteness Areas, are based on ASGS Statistical Area 
level 1 units and defined using the Accessibility/Remoteness Index for Australia (ARIA). 
ARIA is a measure of the remoteness of a location from the services provided by large towns 
or cities. Accessibility is judged purely on distance to one of the metropolitan centres. A 
higher ARIA score denotes a more remote location. The 6 Remoteness Areas are listed in 
Table C.2; the sixth, Migratory, is not used in this publication. The category Major cities 
includes Australia’s capital cities, with the exceptions of Hobart and Darwin, which are 
classified as Inner regional. Further information is available on the ABS website at 
<http://www.abs.gov.au/websitedbs/D3310114.nsf/home/geography>. 
Table C.2: Remoteness Areas of the Australian Statistical Geography Standard 2011 
Region  Collection districts (CDs) within region 
Major cities of Australia  CDs with an average ARIA index value of 0 to 0.2 
Inner regional Australia  CDs with an average ARIA index value greater than 0.2 and less than or equal to 2.4 
Outer regional Australia CDs with an average ARIA index value greater than 2.4 and less than or equal to 5.92 
Remote Australia  CDs with an average ARIA index value greater than 5.92 and less than or equal to 10.53 
Very remote Australia  CDs with an average ARIA index value greater than 10.53 
Migratory  Areas composed of offshore, shipping and migratory CDs 
Residential address postcodes of participants were mapped to 2011 ASGS Remoteness Areas, 
ranging from Major cities to Very remote areas. As some postcodes can span different 
Remoteness Areas, a weighting for each Remoteness Area is attributed to the postcode. This 
can result in non-integer counts for remoteness classifications. For example, the Northern 
Territory postal area 0822 is classified as 69.3% Very remote, 15.9% Remote and 14.8% Outer 
regional. Participants with postcode 0822 have their counts apportioned accordingly. 
Tables in this report based on geographical location were rounded to integer values. Where 
figures were rounded, discrepancies may occur between totals and sums of the component 
items. Participants whose postcode was not available in the remoteness correspondence were 
included in an ‘Unknown’ column in the relevant tables. 
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Socioeconomic classification 
A person’s health, and their ability to access and provide a wide range of services, is also 
influenced by the relative socioeconomic advantage and disadvantage of the area in which 
they live. 
Socioeconomic classifications were based on the 2011 ABS Index of Relative Socio-economic 
Disadvantage (IRSD). Geographical areas are assigned a score based on attributes such as 
low income, low educational attainment, high unemployment and jobs in relatively 
unskilled occupations. It does not refer to the socioeconomic situation of a particular 
individual, but instead refers to the area in which a person lives. A low score on this index 
means an area has more low-income families, people with little training and high 
unemployment, and may be considered disadvantaged relative to other areas with higher 
scores. However, such an area is also likely to contain some people who are relatively 
advantaged. When area-level indexes are used as proxy measures of individual-level 
socioeconomic advantage and disadvantage, many people are likely to be misclassified. 
Geographical areas may be excluded where no score is determined due to low populations 
or high levels of non-response in the underlying census.  
In this report, socioeconomic status of a participant’s area of residence was classified using 
the participant’s residential postcode according to the IRSD for 2011. Socioeconomic status 
(based on IRSD rankings) were calculated with a postal area (POA) correspondence 
(previously called a concordance) using a population-based method at the Australia-wide 
level. Five socioeconomic groups, based on the level of the index, were used for analysis, 
where group 1 represents the most disadvantaged fifth of the population and group 5 the 
least disadvantaged. Participants whose postcode was not available in the socioeconomic 
status correspondence were included in an ‘Unknown’ column in the relevant tables. 
Caution should always be taken when analysing the results of data that have been converted 
using correspondences, and the potential limitations of the data taken into account. 
NBCSP classifications 
See Appendix B for classifications specific to the NBCSP. 
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Appendix D: Statistical methods 
Comparisons and tests of statistical significance 
This report includes statistical tests of the significance of comparisons of rates between 
population groups. Any statistical comparison applied to one variable must take account of 
any other potentially relevant variables. For example, any comparison of participation by 
state and territory must also take account of differences in the distribution of age and sex 
between the states and territories. These other variables are known as confounding variables. 
Crude rates 
In contrast to age-specific, age-standardised, or Kaplan-Meier rates (below), a crude rate is 
simply defined as the number of events over a specified period of time (for example, a year) 
divided by the total population. The crude rate (for participation, attendance and follow-up) 
is the proportion of people who have proceeded to a key point on the screening pathway (at 
the date of the data extraction) out of those eligible to proceed to that point. For example, the 
crude participation rate is the proportion of the eligible people invited to participate in  
2013–14 who return a completed faecal occult blood test (FOBT) kit by 31 December 2014. 
The crude colonoscopy follow-up is the proportion of people invited in 2013–14 with a 
positive FOBT result who proceeded to colonoscopy by 31 December 2014.  
The crude proportions will generally underestimate the true proportions of the population 
who participated in the National Bowel Cancer Screening Program (NBCSP). This is because, 
at any point in time, there are members of the population who are eligible to proceed to the 
next point on the screening pathway, but who have not yet had time to do so. For example, a 
person who has just received an invitation to screen may intend to participate in screening 
but may not have had time to do so. They will be counted in the denominator of the crude 
participation but not in the numerator. Similarly, there is a time lag between when a person 
with a positive FOBT result is referred for a colonoscopy and when they can actually have 
the colonoscopy. A colonoscopy follow-up calculated during this lag includes them in the 
denominator but not in the numerator. 
Age-specific rates 
Age-specific rates were calculated by dividing the number of cases occurring in each 
specified age group by the corresponding population in the same age group, expressed as 
per 100,000 persons.  
Age-standardised rates  
Rates are adjusted for age to help comparisons between populations that have different age 
structures—for example, between youthful and ageing communities. Two different methods 
are commonly used to adjust for age. In this publication, direct standardisation was used, in 
which age-specific rates were multiplied against a constant population (the Australian 2001 
population). This effectively removes the influence of age structure on the summary rate, 
and is described as the age-standardised rate. The method used for this calculation 
comprises 3 steps:  
• Calculate the age-specific rate for each age group. 
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• Calculate the expected number of cases in each 5-year age group by multiplying the 
age-specific rates by the corresponding standard population, and dividing by 100,000, 
giving the expected number of cases. 
• Calculate the age-standardised rate by summing the expected number of cases in each 
age group, and dividing this sum by the total of the standard population used in the 
calculation and multiplying by 100,000. 
The results of age standardisation depend directly on the constant population chosen. Care 
must be taken when comparing the reported age-standardised rates between countries 
because different constant populations may have been used in each case. 
Confidence intervals 
Confidence intervals are a range determined by variability in data, within which there is a 
specified (usually 95%) chance that the true value of a calculated parameter lies.  
This report uses data that are based on administrative data sets that contain ‘complete 
counts’, not sample survey data. While confidence intervals could be used to describe 
variability that is due to non-sample errors in the data, practically it is not easy to do so 
accurately. Therefore, as the size of this error is difficult to determine, and to avoid providing 
confidence intervals that could be misleading, the AIHW instead recommends caution be 
exercised when interpreting small differences between rates. This is especially true where 
counts are small, and rates based on small counts will be noted (see ‘Small counts’ below).  
In this report, 95% confidence intervals are only used in ‘Section 2, Chapter 3 Follow-up of 
positive FOBT results’ to determine if a statistically significant difference exists between 
compared Kaplan–Meier estimates. Where the confidence intervals do not overlap, the 
difference between values is greater than that which could be explained by chance and is 
regarded as statistically significant.  
Kaplan–Meier estimates of participation and follow-up 
Kaplan–Meier estimates are statistical methods that calculate a modelled rate based on the 
time it takes each individual invited for screening to move between points on the screening 
pathway. For example, participation is calculated by following each invited person and, for 
those who respond (by returning a completed FOBT kit), recording the time (in weeks) it 
took them to do so. This allows the calculation of an overall response rate over time from the 
date of invitation, calculated as if all invitations sent throughout a particular period were 
sent on the same date. Such Kaplan–Meier estimates represent valid estimates of the true 
FOBT participation. The Bowel Cancer Screening Pilot Program used Kaplan–Meier 
estimates of participation, attendance and follow-up. The use of Kaplan–Meier estimates in 
the NBCSP was endorsed by the Implementation Advisory Group, and allows direct 
comparison of participation, attendance and follow-up rates with the Bowel Cancer 
Screening Pilot Program.  
In principle, the Kaplan–Meier estimate gives a result only at a specific point in time. The 
estimate is likely to grow for later points in time. However, inspection of these estimates 
shows that they reach a plateau, after which they have only a negligible increase.  
Kaplan–Meier estimates in this report were calculated at 26 weeks and 52 weeks for 
participation, and PHCP and colonoscopy follow-up.  
The Kaplan–Meier estimates require that classifying variables be known for the population. 
For the purposes of this report, they can be calculated for participation classified by age, sex 
 124 National Bowel Cancer Screening Program: monitoring report 2013–14 
and jurisdiction. However, they cannot be used for participation classified by Aboriginal and 
Torres Strait Islander status, language group or disability status, which are not known for all 
the invited population. These variables are only known for those participants who identify 
themselves as a member of these groups on their returned participant details form. 
Therefore, the Kaplan–Meier estimates cannot be applied for these sub-groups. 
Aboriginal and Torres Strait Islander status, language group status and disability status will 
be known for all people completing FOBT kits (at least to the extent that people self-identify 
as members of these groups). Hence, in principle, Kaplan–Meier estimates can be calculated 
for these groups for participation at subsequent points on the screening pathway. In practice, 
these calculations depend on sufficient numbers of people identifying as group members to 
allow the calculation of reliable estimates. 
Confidentiality and reliability of data 
The AIHW operates under a strict privacy regime which has its basis in section 29 of the 
Australian Institute of Health and Welfare Act 1987 (AIHW Act) and the Privacy Act 1988 
(Privacy Act). 
Section 29 of the AIHW Act requires that confidentiality of data relating to persons (living 
and deceased) and organisations be maintained. The Privacy Act governs confidentiality of 
information about living individuals. 
As well as the protection offered by AIHW Act and the Privacy Act, personal information 
held by the AIHW is covered by a range of other Commonwealth, state and territory 
legislation. 
The AIHW is committed to reporting that maximises the value of information released for 
users while being statistically reliable and meeting legislative requirements described above. 
To ensure the confidentiality of its data, the AIHW has a range of policies, protocols and 
processes in place—the AIHW Policy on reporting to manage confidentiality and reliability 
(AIHW Confidentiality Policy) is one important example, as it deals with how data should be 
reported to ensure confidentiality. 
AIHW Confidentiality Policy, a summary 
The AIHW Confidentiality Policy contains 7 guidelines to assist those working with data to 
apply it to their outputs. 
Guideline 1 
It is AIHW policy that, if the data being considered have already been released publicly at 
the granularity AIHW intends to release, further confidentialisation is not required. 
Guideline 2 
Cells in tables where the value of the cell is the same as a row/column/wafer total (that is, 
all other cells in the row, column or wafer are zero) generally lead to disclosure of an 
additional attribute. It is AIHW policy that these cells need to be confidentialised unless the 
attribute that would be disclosed is deemed to be non-sensitive in the context of the data 
being published.  
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Guideline 3 
It is AIHW policy that data on organisations must be confidentialised if 1 organisation 
contributes more than 85% of the total, or 2 organisations more than 90%, unless the attribute 
that would be disclosed is deemed to be non-sensitive in the context of the data being 
published or the organisation(s) have given consent to release.  
Guideline 4 
It is AIHW policy that guidelines 2 and 3 need to be applied so as to ensure that attribute 
confidentiality is maintained within tables and across tables within the same release. That is, 
when assessing whether a cell needs to be confidentialised, consideration needs to be given 
to whether there are other cells in that table, or other tables in the release, which may require 
consequential confidentialisation. 
Guideline 5 
Rates, averages and other statistics based on denominators of less than 100 are usually not 
reliable and it is AIHW policy that they should generally not be reported.  
Guideline 6 
It is AIHW policy that if data suppliers or clients require additional suppression rules be 
applied to an AIHW release in order to manage confidentiality or reliability, then these 
should be applied. Where such additional rules are applied they should be described in the 
release, and it should be noted that this approach is required by the data supplier. 
Guideline 7 
It is AIHW policy that, if a client wishes to be provided with data output (for example, 
tables) at a more detailed level than any of the above guidelines would allow, then they may 
apply to be provided output against which some or all of the above guidelines are not 
applied. Provision of this more detailed output would be subject to the client signing a 
confidentiality undertaking and agreeing that any publication of information (including in 
online data cubes) based on output released to them will comply with this policy. 
Jurisdictional bowel cancer incidence data 
Further to the AIHW Confidentiality Policy guideline 6, tables specifically showing bowel 
cancer incidence by state and territory had counts fewer than 5 suppressed. Incidence rates 
based on fewer than 5 cases were also suppressed. Suppressed values are marked with ‘n.p.’ 
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Glossary 
adenoma: See Appendix B for details. 
age standardisation: A method of removing the influence of age when comparing 
populations with different age structures. This is usually necessary because the rates of many 
diseases vary strongly (usually increasing) with age. The age structures of the different 
populations are converted to the same ‘standard’ structure, then the disease rates that would 
have occurred with that structure are calculated and compared (AIHW 2014c). 
asymptomatic: Without symptoms. 
benign: Non-cancerous tumours that may grow larger but do not spread to other parts of the 
body. Not malignant. 
bowel cancer: Comprises cancer of the colon and cancer of the rectum. It is also known as 
colorectal cancer. 
cancer death: A death where the underlying cause of death is indicated as cancer. Persons 
with cancer who die of other causes are not counted in the mortality statistics in this 
publication. 
cancer (malignant neoplasm): A large range of diseases whose common feature is that some 
of the body’s cells become defective, begin to multiply out of control, can invade and 
damage the area around them, and can also spread to other parts of the body to cause further 
damage. 
confidence interval: A range determined by variability in data, within which there is a 
specified (usually 95%) chance that the true value of a calculated parameter lies. 
colonoscopy: A procedure to examine the bowel using a special scope (colonoscope) usually 
carried out in a hospital or day clinic. 
colonoscopy follow-up rate: The proportion of people with a positive FOBT who 
subsequently had a colonoscopy. 
colorectal cancer: See bowel cancer. 
crude rate: See Appendix D for details. 
CT colonography: A procedure that produces computed tomography (CT) pictures of the 
bowel by X-raying from many different angles. 
double contrast barium enema: A type of bowel X-ray in which barium sulphate and air are 
added into the bowel to assist in detecting abnormal growths. 
eligible population: For this report the eligible population comprised people invited to 
participate in screening in 2013–14, who were Australians registered as Australian citizens or 
migrants in the Medicare enrolment file, or are registered with a Department of Veterans’ 
Affairs gold card, who turned 50, 55, 60 and 65 from 1 January 2013 to 30 June 2014, even if 
they had opted off or suspended their participation in the program. 
epithelium: The tissue lining the outer layer of the body, the digestive tract, and other 
hollow organs and structures. 
false negative: A screening test result that incorrectly indicates a person does not have a 
marker for the condition being tested when they do have the condition. Not all screening 
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tests are completely accurate, so false negative results cannot be discounted. Further, with an 
FOBT test for bowel cancer, if a polyp, adenoma or cancer is not bleeding at the time of the 
test, it may be missed by the screening test. 
false positive: A screening test result that incorrectly indicates that a person has the 
condition being tested when they do not have the condition. As FOBT tests detect blood in 
stool (which may be caused by a number of conditions), a false positive finding regarding 
bowel cancer may still detect other non-bowel cancer conditions, or precancerous polyps or 
adenomas. 
FOBT: Faecal occult blood test. A test used to detect tiny traces of blood in a person’s faeces 
that may be a sign of bowel cancer. The immunochemical FOBT is a central part of 
Australia’s National Bowel Cancer Screening Program (NBCSP). 
Pathologists categorise completed NBCSP FOBTs into 1 of 3 groups:  
1. correctly completed  
2. incorrectly completed  
3. unsatisfactory.  
Participants are provided with specific instructions on how to complete the FOBT. Any tests 
not completed according to these instructions are classified as incorrectly completed. 
Unsatisfactory tests refer to those tests that could not be processed due to a problem with the 
kit (for example, an expired kit, or a completed kit that has taken more than 2 weeks in 
transit to arrive for testing). Participants with FOBTs that are not correctly completed are 
requested to complete another FOBT. (See Appendix B for details of the participant screening 
pathway.) 
FOBT result: FOBT results are classified by pathologists into 1 of 3 groups: 
1. positive (blood is detected in at least 1 of 2 samples)  
2. negative (blood is not detected)  
3. inconclusive (the participant is asked to complete another kit). 
histopathology: The microscopic study of the structure and composition of tissues and 
associated disease. 
incidence: The number of new cases (of an illness or event, and so on) occurring during a 
given period. Compare with prevalence (AIHW 2014c). 
Indigenous: A person of Aboriginal and/or Torres Strait Islander descent who identifies as 
Aboriginal and/or Torres Strait Islander. 
International Statistical Classification of Diseases and Related Health Problems: The 
World Health Organization’s internationally accepted classification of death and disease. The 
tenth revision (ICD-10) is currently in use. 
invitee: A person who has been invited to participate in the National Bowel Cancer 
Screening Program. 
lymph node: A mass of lymphatic tissue, often bean-shaped, that produces adaptive 
immune system cells and through which lymph filters. These nodes are located throughout 
the body. 
malignant: Abnormal changes consistent with cancer. 
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metastasis: The process by which cancerous cells are transferred from one part of the body to 
another to form a secondary cancer; for example, via the lymphatic system or the 
bloodstream. 
morbidity: Ill health in an individual, or the level of ill health in a population or group. 
mortality: Death. For this publication specifically, see cancer death. 
neoplasm: An abnormal (‘neo’, new) growth of tissue. Can be benign (not a cancer) or 
malignant (a cancer). Same as tumour (AIHW 2014c). 
opt off: Invitees who do not wish to participate in the National Bowel Cancer Screening 
Program now or in the future may opt off the program. Invitees will not be contacted again. 
Invitees may elect to opt back on at a later date. 
participant: A person who has agreed to participate in the National Bowel Cancer Screening 
Program by returning a completed FOBT kit and participant details form. 
polyp: See Appendix B for details. 
polypectomy: the removal of a polyp. 
positive predictive value: Proportion of people with a positive FOBT screen who have 
adenomas or cancer detected at colonoscopy and confirmed by histopathology. 
positivity rate: Number of positive FOBT results as a percentage of the total number of valid 
FOBT results. 
prevalence: The number or proportion (of cases, instances, and so forth) in a population at a 
given time. Compare with incidence (AIHW 2014c). 
primary health-care practitioner (PHCP): Classified by the Department of Human Services 
(DHS) as a general practitioner or other primary health-care provider. This may include 
remote health clinics or specialists providing general practitioner services. 
primary health-care practitioner follow-up rate: The proportion of people who were sent a 
positive FOBT result and who subsequently visit a primary health-care practitioner. 
prognosis: The likely outcome of an illness. 
radiation therapy: The treatment of disease with any type of radiation, most commonly with 
ionising radiation, such as X-rays, beta rays and gamma rays. 
screening: Repeated testing, at regular intervals, of apparently well people to detect a 
medical condition at an earlier stage than would otherwise be the case. Screening tests are 
not diagnostic (for example, see false positive, false negative and positive predictive value); 
therefore, people who receive a positive screening result require further assessment and 
diagnosis to determine whether or not they have the disease or risk marker being screened.  
sigmoidoscopy: Inspection of last portion of the bowel through either a rigid or flexible 
hollow tube. 
significant difference: Rates are referred to as significantly different if their difference is 
calculated as  statistically significant. That is, the confidence intervals of the rates do not 
overlap. See ‘Confidence intervals’ in Appendix D for more information. 
socioeconomic status: See Appendix C for details. 
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suspend: Invitees who would like to participate in the National Bowel Cancer Screening 
Program but are unable to do so at this time. Invitees will be contacted once the nominated 
suspension period has elapsed. 
target population: See Table B.1 (in Appendix B). 
tumour: See neoplasm. 
underlying cause of death: The condition, disease or injury initiating the sequence of events 
leading directly to death; that is, the primary, or main, cause. 
valid results: Only FOBT results that are either positive or negative are classified as valid 
results. Inconclusive results are excluded. 
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